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ABSTRACT 
Angiotensin-converting enzyme (ACE) inhibitors are some of the most commonly prescribed 
medications for hypertension. They are cited in many papers as the treatment most often 
recommended by guidelines and favoured over other antihypertensive drugs as first-line 
agents especially when other high-risk conditions are present, such as diabetic nephropathy. 
The development of captopril (CPT) was amongst the earliest successes of the revolutionary 
concept of structure-based drug design. Due to its relatively poor pharmacokinetic profile or 
short half-life of about 1 hour, the formulation of sustained-release microcapsule dosage form 
is useful to improve patient compliance and to achieve predictable and optimized therapeutic 
plasma concentrations.  
 
Currently, CPT is mainly administered in tablet form. One of the difficulties of CPT 
formulation has been reported to be its instability in aqueous solutions. CPT is characterized 
by a lack of a strong chromophore and, therefore, not able to absorb at the more useful UV–
Vis region of the spectrum. For this reason, an accurate, simple, reproducible, and sensitive 
HPLC-ECD method was developed and validated for the determination of CPT in dosage 
forms. The method was successfully applied for the determination of CPT in commercial and 
developed formulations. 
 
Possible drug-excipient and excipient-excipient interactions were investigated prior to 
formulating CPT microcapsules because successful formulation of a stable and effective solid 
dosage form depends on careful selection of excipients.  Nuclear magnetic resonance 
spectroscopy, Fourier transform infra-red spectroscopy (FT-IR), differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA) were used for the identification 
and purity testing of CPT and excipients. The studies revealed no thermal changes during 
stress testing of binary and whole mixtures which indicate absence of solid state interactions. 
There were no shifts, appearance and disappearance in the endothermic or exothermic peaks 
and on the change of other associated enthalpy values on thermal curves obtained with DSC 
method. Characteristic peaks for common functional groups in the FT-IR were present in all 
the mixtures indicating the absence of incompatibility. The techniques used in this study can 
be said to have been efficient in the characterization and evaluation of the drug and 
excipients. 
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The technique of microencapsulation by oil-in-oil was used to prepare CPT microcapsules. 
The effects of polymer molecular weight, homogenizing speed on the particle size, flow 
properties, morphology, surface properties and release characteristics of the prepared CPT 
microcapsules were examined. In order to decrease the complexity of the analysis and reduce 
cost response surface methodology using best polynomial equations was successfully used to 
quantify the effect of the formulation variables and develop an optimized formulation thereby 
minimizing the number of experimental trials. 
 
There was a burst effect during the first stage of dissolution. Scanning electron microscopy 
(SEM) results indicated that the initial burst effect observed in drug release could be 
attributed to dissolution of CPT crystals present at the surface or embedded in the superficial 
layer of the matrix. During the preparation of microcapsules, the drug might have been 
trapped near the surface of the microcapsules and or might have diffused quickly through the 
porous surface. The release kinetics of CPT from most formulations followed Fickian 
diffusion mechanism. SEM photographs showed that diffusion took place through pores at 
the surface of the microcapsules. The Kopcha model diffusion and erosion terms showed 
predominance of diffusion relative to swelling or erosion throughout the entire test period. 
Drug release mechanism was also confirmed by Makoid-Banakar and Korsmeyer-Peppas 
models exponents which further support diffusion release mechanism in most formulations. 
The models postulate that the total of drug release is a summation of a couple of mechanisms; 
burst release, relaxation induced controlled-release and diffusional release.  
 
Inspection of the 2D contour and 3D response surfaces allowed the determination of the 
geometrical nature of the surfaces and further providing results about the interaction of the 
different variables used in central composite design (CCD). The wide variation indicated that 
the factor combinations resulted in different drug release rates. Lagrange, canonical and 
mathematical modelling were used to determine the nature of the stationery point of the 
models. This represented the optimal variables or stationery points where there is interaction 
in the experimental space. It is difficult to understand the shape of a fitted response by mere 
inspection of the algebraic polynomial when there are many independent variables in the 
model. Canonical and Lagrange analyses facilitated the interpretation of the surface plots 
after a mathematical transformation of the original variables into new variables. In 
conclusion, these results suggest the potential application of Eudragit® / Methocel® 
microcapsules as suitable sustained-release drug delivery system for CPT.  
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STUDY OBJECTIVES 
Hypertension is recognised as a major contributor to the disease burden globally that is as 
prevalent in many developing countries, as in the developed world. The capacity for the 
management of hypertension varies considerably from country to country, but in general the 
majority of diagnosed hypertensives are inadequately controlled throughout the world (1).  
 
The renin–angiotensin–aldosterone system (RAAS) plays an important role in the 
pathogenesis of a variety of clinical conditions, including atherosclerosis, hypertension, left 
ventricular hypertrophy, myocardial infarction and heart failure. Inhibition of the RAAS with 
angiotensin converting enzyme (ACE) inhibitors has been shown to be effective in lowering 
blood pressure and reducing cardiovascular mortality and morbidity in many at-risk patient 
populations. A number of studies have shown that captopril (CPT) is effective in reducing the 
rate of renal disease progression in patients with diabetic nephropathy. The importance of 
diabetic nephropathy as a major cardiovascular risk factor has been established by a number 
of large epidemiologic and interventional studies (2). 
CPT is one of the most commonly prescribed ACE inhibitors and is a World Health 
Organization (WHO) listed drug that is indicated for the treatment of several cardiovascular 
diseases. It is available in 12.5, 25 and 50 mg tablets. The recommended dose of CPT is 25-
150 mg two or three times daily. The maximum permitted daily dose is 450 mg. CPT should 
be taken on an empty stomach one hour before or two hours after meals since absorption of 
CPT is reduced when taken with food.  CPT has a short biological half-life and is therefore 
suitable for formulation as a sustained-release product in order to reduce the frequency of 
administration of doses and to improve patient adherence. 
The objectives of this study were therefore: 
1. To develop and validate a suitable high performance liquid chromatographic method 
with electrochemical detection (HPLC-ECD) for the analysis of CPT.  
2. To use spectroscopic and thermo-analytical techniques to evaluate the compatibility 
of CPT with Eudragit® RS, Methocel® K100M, Methocel® K15M, microcrystalline 
cellulose (MCC) and citric acid. 
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3. To use response surface methodology (RSM) to investigate pharmaceutical excipients 
and compositions for the manufacture of CPT microcapsules using a solvent 
evaporation technique. 
4. To use mathematical flow models to study the flow properties of the microcapsules 
and to evaluate their surface morphology using scanning electron microscopy (SEM). 
5. To study the dissolution kinetics and release mechanisms of CPT from microcapsules 
using mathematical models. 
6. To analyze fitted response surface plots of observed responses using Canonical and 
Lagrange techniques to establish the optimal formulations from formulation studies. 
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CHAPTER 1 
CAPTOPRIL, AN ANGIOTENSION CONVERTING ENZYME INHIBITOR  
 
1.1. INTRODUCTION 
Hypertension is a risk factor in the development of cardiovascular disease and is responsible 
for more deaths worldwide than any other cardiovascular disease (1, 2). The angiotensin I 
(AI) converting enzyme is a causal factor for hypertension and facilitates the production of 
angiotensin II (AII) that causes vasoconstriction and degradation of the vasodilating 
compound, bradykinin. Therefore, inhibition of angiotensin converting enzyme (ACE) is 
considered an important therapeutic approach in the control of hypertension. With the 
development of a model structure of ACE, specific inhibitors that bind to the active site of the 
enzyme active have been developed (3). Despite the fact that synthetic inhibitors of the ACE 
are remarkably effective as antihypertensive drugs, they often cause adverse and unwanted 
side effects (1).  
 
In the 1960s, Vane was actively investigating the cause(s) of hypertension and Ferreira, a 
member of the research team, had an extract of the bradykinin potentiating factor (BPF) 
isolated from the venom of the Brazilian viper Bothrops jararaca. Ferreira had already 
established that BPF potentiated the activity of bradykinin through inhibition of the enzyme 
that deactivated it. The BPF was tested on ACESQ 881 and found to be a potent inhibitor 
thereof, precipitating a strong interest in the use of the ACE inhibitor for the management of     
hypertension (4). 
 
In order to elucidate the properties of other ACE molecules, other peptide analogs were used 
(5-7).  There are two forms of ACE in humans, the ubiquitous somatic ACE and the sperm-
specific germinal ACE, both encoded by the same gene through transcription from alternative 
promoters (8).  
 
The crystal structures of the ACE were determined using a multiple isomorphous replacement 
technique at a resolution of 2.4 Å. ACE is 615 amino acids long and is structurally comprised 
of 21 ά-helices and three antiparallel β-strands (Figure 1.1).  
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Captopril (CPT) is a competitive inhibitor of the ACE, and binds to human ACE with an 
enzyme affinity (Kis) of 1.4 which mimics the two carboxy-terminal residues of the enzyme 
substrate (9, 10). The sulfhydryl functional group of CPT replaces the zinc-binding water 
molecule and directly interacts with the zinc ion in a distorted tetrahedral geometry as shown 
in Figure 1.1 b. The carboxy-end of the proline moiety is held in place by three highly 
conserved residues viz., Gln-265, Lys-495 and Tyr-504, through ionic and hydrogen bonding. 
The residues prevent sliding of the substrate from the catalytic site in the large internal 
channel of the enzyme. Locking mechanisms of this type may slip when the negative charge 
of the carboxy terminus is masked by amidation. For most substrates the ACE cleaves the 
carboxy-terminal dipeptide and can hydrolyze three amino acids from substance P and 
luteinizing releasing hormone where the carboxy-termini are also modified by amidation 
(11). The sulfhydryl functional group and the terminal proline moieties of CPT are connected 
by a peptide bond. The position of the carbonyl oxygen of the peptide bond is locked by three 
hydrogen bonds of significant strength with residues His-337, His-497 and Tyr-507 (11).  
 
 
Figure 1.1 (a, b). Schematic representation of the structure of the ACE zinc ion and the bound CPT are shown 
in green and red, respectively (11). 
 
The ACE has a large internal channel encompassing throughout the protein molecule and this 
highly unusual substrate-binding channel is comprised of two chambers, similar to a peanut 
shell. The zinc ion which is critical for catalysis is located in a narrow bottleneck that 
connects the two chambers.  
 
a b
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The ACE plays a critical role in cardiovascular functioning and cleaves the carboxy terminal 
His-Leu dipeptide from AI to produce a potent vasopressor octapeptide, AII (Figure 1.2). 
ACE inhibitors are a first line of therapy for the treatment of hypertension, heart failure, 
myocardial infarction and diabetic nephropathy (11). Interestingly, the ACE inhibitors were 
developed without any knowledge of the molecular structure of human ACE, and rather on 
the basis of an assumed mechanistic homology of the enzyme with carboxypeptidase A      
(11-13).  
 
CPT is routinely used in the management of hypertension and is commercially available as 
immediate release tablets ranging in dose from 12.5-50 mg (14). The acceptance of CPT 
inspired the development of a new generation of ACE inhibiting molecules as the ACE was a 
well-validated therapeutic target. 
 
Angiotensinogen 
 
                                                            RENIN 
 
Angiotensin I 
 
                                                                
 
 
  Angiotensin II 
 
                             
 
                                                            
 
 
 
 
 
 
 
Figure 1.2. Site of action of ACE inhibitors (A) and receptor blockers (B) (adapted from 16). 
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CPT has been widely used for the treatment of hypertension and congestive heart failure and 
has a short elimination half-life following oral administration. Consequently, CPT may be a 
suitable candidate for inclusion in sustained release dosage forms. The development of a once 
daily CPT formulation for oral administration would be a significant advantage in the 
promotion of patient adherence. Furthermore, the added advantage of a minimization of si
effects and reduced fluctuations in blood levels on long term therapy may well result in better 
therapeutic outcomes (7). Attempts have been made to design long acting technologies for the 
delivery of CPT and have taken the form of sustained or controll
Current hypertension guidelines differ in their recommendations for first line 
antihypertension therapy. In a study done in Canada, it was observed that prescribing ACE 
inhibitors as first line therapy in patients without card
recommended (17). In South Africa, ACE inhibitors have proved to be effective blood 
lowering agents with an excellent tolerability profile. ACE inhibitors available in South 
Africa have been classified by means of the syst
method (18). In general, there are three classes of ACE inhibitors (Figure 1.
chemical composition, namely, sulfhydryl
dicarboxylate-containing inhibitors e
inhibitors exemplified by fosinopril.
Figure 1.3. Classification of ACE inhibitors
 
CPT and fosinopril are the lone representatives of their respective chemical sub
classifications whereas the majority of the inhibitors contain the dicarboxylate functionality. 
All of these compounds effectively block the conversion of AI to AII and have s
therapeutic and physiological effects to each other. The compounds differ primarily in their 
potency and pharmacokinetic profiles. 
sulfhydryl-containing
ed release dosage forms (15).
iovascular morbidity could not be 
em Objectified Judgement Analysis (SOJA) 
-containing inhibitors exemplified by CPT, 
xemplified by enalapril and phosphonate
 
 
 
dicarboxylate-containing phosphonate
ACE-INHIBITORS
 
de 
 
3) based on their 
-containing 
 
-
imilar 
-containing
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1.2. PHYSICOCHEMICAL PROPERTIES OF CAPTOPRIL  
1.2.1. Description 
Captopril is known as 1-[3-mercapto-2-(S)-methyl-1-oxopropyl]-S (L) proline (19, 20) and is 
a crystalline powder that occurs as white crystals. The crystalline powder has a slight 
sulfurous odour. It contains not less than 98.0% and not more than 102.0% of CPT calculated 
on an anhydrous basis (20).  
 
The chemical structure of CPT (21) is depicted in Figure 1.4.  
 
 
 
 
 
Figure 1.4. Chemical structure of CPT [C9H15NO3S] (MW = 217.3) 
 
Despite the fact that CPT has two stereogenic centres, the molecule was developed and is 
marketed as a single enantiomer, as only one of the four possible isomers can bind with the 
active site of ACE (20). 
 
1.2.2.  Solubility 
CPT has an aqueous solubility of 160 mg/ml at 25 ºC (22) and solubility versus temperature 
is linear up to 40 °C, above which CPT shows extraordinarily high water solubility. CPT is 
freely soluble at >100 mg/ml in methanol, ethanol, isopropanol, chloroform, or methylene 
chloride but its solubility in oils is less than 1 mg/ml at 25 °C (22). 
 
1.2.3.  Storage 
CPT should be stored at room temperature in tightly closed containers and protected from 
light, moisture and heat (23).  
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1.2.4.  pKa 
CPT is a weakly acidic compound, whereas all other ACE inhibitors are amphoteric in nature. 
The carboxylic acid functional group attached to the pyrolle ring is a common structural 
feature of ACE inhibitors. CPT has a pKa in the range of 2.5-3.5 and is ionized at 
physiological pH. The pKa and ionization of the secondary amine present in the 
dicarboxylate chain depends on the adjacent functional group and whether it is in the product 
or active form (24). 
 
1.2.5.  Melting range 
CPT melts over a 1-3 ºC temperature range at between 106-109 ºC (25). 
 
1.2.6. Optical rotation 
The optical rotation of CPT in ethanol was   = -127.8 ˚. The R, S isomer rotates 
approximately + 5 ˚ (22). 
 
1.2.7. Ultraviolet absorption spectrum 
A solution of CPT in methanol, water, 0.1 M sodium hydroxide and 0.1 M hydrochloric acid 
yield two wavelengths of maximum absorption, which occur at around 200 nm (due to the 
thiol functional group)  and 225 nm (due to weak sulfhydryl absorption) (22).   
 
1.2.8. Polymorphism 
An unstable, low (86˚ C) melting and stable, high (106˚ C) melting form of CPT have been 
observed) (22). 
 
1.3. SYNTHETIC PATHWAY 
1.3.1. Synthetic Procedure 
Chirumamilla et al (26) have used chiral intermediates in the synthesis of CPT. These 
intermediates were obtained by resolution of racemic compounds or by chemical, biocatalytic 
methods and or by asymmetric synthesis by biochemical process (26). The synthesis of CPT 
with 3-acetylthio-2-methylpropanoic acid as the starting material was first reported by 
Cushman et al (27) and the resultant overall yield was approximately 12%. More recently, a 
simple synthetic procedure for CPT has been reported (28). The resultant yield from this  
synthesis was approximately 26%, however, the conversion of methacrylic acid to the 
optically active starting material, R-3-hydroxy-2-methylpropanoic acid, using a microbial 
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oxidative transformation, was poor (29, 30). A more convenient synthetic procedure for CPT 
using methacrylic acid as a starting material is shown in Figure 1.5 (31).   
OH
O
R
O
X *
Ι
 ΙΙ; X = Cl, R = OH, R,S
ΙΙΙ; X = Br, R = OH, R,S
ΙV; X = Cl, R = Cl, R,S
  V; X = Br, R = OH, RS HN
O
OH(L)
HS O
N OH
O
(D)
X O
N OH
O
(L)
*
 VΙa; X = Cl, R,S
 VΙb; X = Cl, R
VΙIa; X = Br, R,S
VΙIb; X = Br, R
VΙΙΙ
NH4SH
HX
(L)
      
Figure1.5. Synthesis of CPT (31) 
In order to develop a more reliable synthetic procedure for CPT with, methacrylic acid as the 
starting material, Groszkowski et al added a hydrogen halide (32). The carboxlic acids II and 
III were converted to their corresponding acyl halides IV and V in nearly 95% yields, using 
N, N-dimethylformamide as the catalyst (33). To avoid protection of the carboxylic acid 
function of L-proline with IV or V, a procedure defined by Hongo et al was used with a 
resultant 90% yield (34). N-(R, S-3-Halogeno-2-methylpropanoyl)-L-proline (VIa or VIIa) 
was then separated into optically pure diastereoisomers using dicyclohexylamine. The 
treatment of the halides of VIb or VIIb with methanolic ammonium hydrosulfide produced a 
28% overall yield of CPT. This synthetic procedure is an improvement over that reported by 
Cushman et al (27) and is more convenient than the method reported by Shimazaki et al (28) 
which also involves a fermentation step.  
1.3.2.  Structure Activity Relationships 
ACE is a stereoselective drug target and the currently approved ACE inhibitors act as either 
di- or tripeptide substrate analogs. Consequently, their stereochemistry must be consistent 
with the L-amino acids present in their natural substrates. This criterion was established early 
in the development of ACE inhibitors when compounds with carboxyl-terminal D-amino 
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acids were discovered to be very poor inhibitors of the enzyme (35, 36) and this was 
subsequently confirmed by Patchett et al (37) and a 100- to 1000-fold loss in inhibitor 
activity whenever the configuration of the carboxylate was altered (35). 
 
CPT was introduced as a useful and popular orally active antihypertensive agent, and the 
proof of principle demonstrating that a peptidomimetic inhibitor of the rennin-angiotensin-
aldosterone system would be an excellent way to control hypertension, is a remarkable 
milestone in drug discovery. In order to enhance therapy, ACE inhibitors can be combined 
with diuretics to produce a synergistic control of blood pressure (38). 
 
1.3.3.  Stereospecificity 
CPT has two chiral centres, one associated with the proline moeity and the other associated 
with the 3-mercapto-2-methylpropionic acid side chain. Accordingly, there are three other 
possible stereoisomers of which S-captopril is biologically active and R-captopril, 1-[3-
mercapto-2(S)-methyl-1-oxopropyl]-R (D)-proline possesses no inhibiting activity for the 
ACE (39).   
 
Some commonly used drugs used in human medicine are chiral in nature and are sold as 
racemic mixtures (40). CPT is manufactured and commercially available as an S, S 
stereoisomer (40).  
 
1.4. STABILITY 
1.4.1. Solid state stability 
No significant decomposition of CPT was observed in bulk samples when stored at 5 ˚C,     
33 ˚C and 50 ˚C for up to 6 months or when exposed to 900 foot-candles in a light box for   
30 days, when compared to samples stored at -20˚C samples and which were used as the 
control (22). 
 
1.4.2. Solution stability 
CPT undergoes a first order free radical oxidation in aqueous solution to yield captopril 
disulfide (41). CPT is stable at pH 1.2 and as the pH increases the stability decreases (42, 43). 
CPT oxidation may be reduced by addition of chelating agents and antioxidants to solution or 
by use of nitrogen or low oxygen headspace in containers (44).  
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1.5. CLINICAL PHARMACOLOGY 
CPT reduces blood pressure in human patients with low, normal, and high renin levels that 
present with essential hypertension and in patients with renovascular hypertension and 
hypertension associated with chronic renal failure. In hypertensive patients with high plasma 
renin activity, CPT exerts most of its pharmacological effects through inhibition of ACE. The 
exact mechanism by which CPT reduces high blood pressure associated with low or normal 
plasma renin-angiotensin (PRA) is not known, but it is clear that CPT does not act on an 
overactive PRA system in these cases. The antihypertensive effect of CPT is enhanced when 
it is given in combination with a diuretic or following salt depletion (45).  
 
The sulfhydryl functional group in the CPT is essential for the excellent inhibitory activity of 
ACE, but is however also the reason for the two most common side effects; skin rashes and 
taste disturbances such as a metallic aftertaste or loss of taste. These side effects usually 
subside after a reduction in the dose or discontinuation of CPT use. The side effects are 
similar to those observed for  penicillamine that is used to treat Wilson’s disease and 
rheumatoid arthritis and where a sulfhydryl functional group is present (46, 47). 
 
1.5.1.  Interactions 
It had been established that the simultaneous administration of CPT with commonly used 
non-steroidal anti-inflammatory drugs (NSAID) such as diclofenac sodium, flurbiprofen, 
mefenamic acid, meloxicam and tiaprofenic may alter the antihypertensive effect of CPT. In 
order to establish the kinetic and thermodynamic behavior of CPT in the presence of 
NSAID's, studies were performed in buffers of pH 4.0, 7.4 and 9.0 at 37 ˚C and at higher 
temperatures. The studies revealed that most of the NSAID bind to CPT, forming charge-
transfer complexes that are likely to decrease the availability of CPT and therefore concurrent 
administration of NSAID with CPT should be avoided (48).  
 
The effects of CPT on serum digoxin concentrations were studied in patients with severe 
congestive heart failure. Serum digoxin concentrations were measured prior to and following 
administration of CPT for 1 week in patients on chronic digoxin therapy. Each patient that 
was taking 0.25 mg of digoxin four times a day orally was administered 12.5 mg of CPT 
three times a day for 7 days, also orally. The peak serum concentration of digoxin (Cmax) 
prior to and following CPT administration were 1.7 ng/ml and 2.7 ng/ml, the time to peak 
(tmax) was 2.4 h and 1.3 h, and the area under the 24 h digoxin concentration-time curve 
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(AUC0-24h) was 30.0 ng. h/ml and 41.7 ng. h/ml on days 0 and 7 respectively. It is clear that 
CPT causes an increase in the peak serum concentration and the area under the digoxin 
concentration-time curve and the time to peak is reduced. However, no patients developed or 
showed evidence of digoxin toxicity. The concomitant administration of CPT and digoxin 
increases serum digoxin concentrations in patients with severe congestive heart failure (49). 
In this study, there was evidence of a direct pharmacokinetic captopril-digoxin interaction. 
 
H2-receptor antagonists block gastric acid secretions and some cardiovascular effects of 
histamine presence. In view of this fact, the simultaneous administration of CPT and           
H2-receptor antagonists may alter the antihypertensive effect of CPT, and combination 
therapy should be avoided. However, in healthy subjects, cimetidine administration did not 
affect the pharmacokinetic parameters of unchanged CPT or the inhibition of plasma ACE 
activity (50).  
 
In other studies, in vitro availability studies of CPT in the presence of commonly used H2-
receptor antagonists such as cimetidine, ranitidine and famotidine was performed in buffers 
of pH 4.0, 7.4 and 9.0 at 37 ˚C. These studies clearly indicate that most of the H2-receptor 
antagonists bound to CPT, forming charge-transfer complexes. As a result, the availability of 
CPT was affected by the concurrent administration of H2-receptor antagonists and co-
administration of the drugs should be avoided (51). 
 
The administration of an aluminium/magnesium containing antacid reduced the bioavalability 
of unchanged CPT by approximately 45 % in healthy individuals; therefore co-administration 
should be avoided (52). 
 
1.5.2.  Precautions 
1.5.2.1. Pregnancy 
The widespread availability and use of ACE inhibitors has resulted in numerous reports on 
their effect during pregnancy (53-57). The administration of CPT during pregnancy in 
experimental animals is associated with an increase in the number of stillbirths and a high 
incidence of intrauterine death (53, 54). CPT use during pregnancy is therefore opposed, as 
adverse toxic effects on the foetus have been reported (55). Intrauterine growth retardation, 
respiratory and circulatory abnormalities and patent ductus arterious have been reported in 
children whose mothers were treated with CPT whilst they were pregnant (56, 57). The 
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mechanism underlying the toxic effects of CPT on the foetus has not yet been elucidated; 
however, a decreased maternal and foetal placental blood flow appears to be an important 
consideration (58, 59). CPT-induced foetal toxicity may be explained by a decrease in AII 
levels leading to a reduction in uterine blood flow (60) and consequently foetal oxygen 
deprivation (58). Similarly, the toxic effect of CPT may also be a consequence of the 
decreased formation of AII on the foetal side of the placental circulation. It has been 
concluded that the toxic effects of CPT may be due to a reduction of foetal placental blood 
flow via a potentiation of the vasoconstrictor effect of endogenous bradykinin, an effect 
likely to be mediated via the release of prostanoids (61).  
 
Although the deleterious effects of ACE inhibitors on foetal development may be dependent 
on the stage of pregnancy in which CPT is used, the foetal effects of their use during the first 
trimester of pregnancy remains controversial. In a survey of Michigan Medicaid recipients, 
there was no association between the use of ACE inhibitors during the first trimester of 
pregnancy and congenital foetal defects (62). The absence of firm evidence for a teratogenic 
effect of ACE inhibitors has prompted some investigators to state that it would not be 
appropriate to terminate pregnancy due to CPT exposure early in pregnancy (63). The 
adverse foetal effects may be a consequence of the pharmacologic effect of ACE inhibitors 
and not a result of any dysmorphogenic or genetic effect. However, there are several reports 
of malformed foetuses in mothers who have used ACE inhibitors during the first trimester of 
pregnancy. The foetal effects noted include phocomelia, death, omphalocele, congenital heart 
defects, hypertrichosis, growth retardation, respiratory failure, renal failure, and 
intraventricular hemorrhage (64-66). The interpretation of these observations and the role of 
early first trimester ACE inhibitor administration is confounded by the fact that use of such 
drugs often occurs throughout pregnancy and was not limited to use in the first trimester.  
Furthermore, virtually all mothers were taking other medications in addition to the ACE 
inhibitors during their pregnancy. 
 
The use of ACE inhibitors during the second or third trimesters of pregnancy is believed to 
have adverse effects on the foetus (67). The most commonly reported adverse effects of ACE 
inhibitors taken during these stages of pregnancy include intrauterine growth retardation, 
neonatal hypotension, renal failure, oligohydramnios and patent ductus arteriosus (64-67). 
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1.5.2.2. Paediatric patients 
Preterm infants with renovascular hypertension and treated with CPT, developed significant 
trilineage bone marrow suppression (68). CPT-associated pancytopenia is a rare complication 
that was thought to be dose-related and caused by accumulation of the drug through defective 
renal tubular excretion. However, it appears that the combination of renal artery stenosis and 
renal tubular dysfunction of premature infants may have caused pancytopenia. CPT should be 
used with caution in premature and newborn infants that have underlying renal or 
renovascular disease, even if overt renal dysfunction is not evident. The monitoring of 
creatinine clearance or free serum CPT levels may help establish the degree of accumulation 
of CPT before the manifestation of pancytopenia (68). 
 
The safety and efficacy of CPT therapy in children with severe and refractory hypertension 
has been evaluated in a collaborative international study which enrolled a group of 73 
patients, 15 years of age or younger. Most patients had hypertension associated with renal 
disease or vascular abnormalities. CPT was administered for periods of less than 3 months to 
more than 1 year. A significant decrease in both systolic and diastolic blood pressures was 
produced by the administration of CPT, usually in conjunction with other antihypertensive 
agents (most commonly diuretics and/or beta-blockers). CPT was demonstrated to be an 
effective and safe drug for the treatment of children with severe hypertension (68). 
 
1.5.2.3. Geriatric patients 
The safety and efficacy of CPT in geriatric patients with mild to moderate hypertension was 
examined in an eight-week multicenter study that included 99 patients. Following a placebo 
period, patients were treated with 25 mg of CPT twice daily. Patients who were uncontrolled 
after two weeks of active therapy were randomly selected to receive either 25 mg CPT and 15 
mg hydrochlorothiazide or 50 mg of CPT twice daily. The average decrease in blood pressure 
on completion of study completion was 16.9/11.9 mmHg for the diastolic and systolic 
pressures respectively. At the conclusion of the trial, 75.8% of patients had responded 
positively to CPT. Furthermore, the CPT was well tolerated and believed to be a good 
therapeutic alternative for treating hypertension in the elderly population (69). 
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1.5.2.4. Smoking 
A study was conducted to assess whether an interaction exists between the renin-angiotensin 
system and the sympathetic nervous system at the level of the adrenal medulla in human 
subjects that smoked. Thirteen habitual smoking volunteers were studied in a randomized, 
single-dose, double-blind, cross-over fashion using 50 mg CPT versus placebo followed by 
smoking of two high nicotine content cigarettes within 15 min of the dose. Blood samples 
were withdrawn before, during and after smoking. It was found that the increase in the 
concentration of plasma adrenaline during cigarette smoking was modest. There was no 
difference in the adrenaline levels in all subjects. Thus, the adrenaline response to cigarette 
smoking was not reduced by acute blockade of the production of AII. A significant increase 
in heart rate and blood pressure was found in the subjects. The plasma renin concentration 
increased significantly during CPT treatment, whereas it decreased throughout the study 
period in the placebo phase. Plasma AII concentrations decreased in both the CPT and 
placebo groups throughout the study period, but this effect was more pronounced during CPT 
treatment. In conclusion, cigarette smoking-induced activation of the sympathetic nervous 
system was not affected by acute ACE-inhibition with CPT. This is an indication that AII 
does not facilitate smoking-induced activation of sympathoadrenal activity in humans (70).  
 
1.5.2.5. Lactation 
In a study of 12 normotensive lactating women who were given 100 mg of CPT three times 
daily, for 7 doses, the mean Cmax for CPT in breast milk was 4.7 ± 0.7 µg/ml. The mean area 
under the curve (AUC0-8hr) for CPT in blood was 1067.2 ng•hr /ml, while that for milk was 
22.9 ng•hr /ml (71). Therefore, the concentration of CPT in milk was 1% of that found in the 
blood, and the peak milk concentration occurred much later than the time-to-peak blood 
concentration of CPT. The area under the milk concentration versus time curve was about 3% 
of that under the blood curve. Based on these findings, the American Academy of Paediatrics 
suggests that CPT is suitable for use in patients who wish to breast feed (71). 
 
 In another study (72), thorough investigation of CPT in human plasma and breast milk 
demonstrated a delayed excretion of CPT in the milk, with levels in the range of 0.6% of the 
maternal plasma levels. This study suggested selective restriction of the passage of CPT from 
blood into milk and "safe" levels for breast-feeding despite a relatively high daily dose of 300 
mg per day. 
Page | 14 
 
1.5.2.6. Food 
The presence of food in the GI tract has been reported to reduce the absorption of CPT by 
approximately 30 to 40%. Although more recent investigations suggest that food is unlikely 
to significantly alter the effects of CPT, it is advisable to administer the drug one hour before 
or two hours after meals. Food does not appear to alter the absorption of most of the other 
angiotensin converting enzyme inhibitors (73).   
 
1.5.2.7. Renal impairment 
The major route of elimination of CPT is via urinary excretion and it would be expected that 
the diminished renal function that is often associated with severe hypertension and congestive 
heart failure would prolong the elimination half-life of CPT (74-76). The inhibition of ACE 
activity by CPT has been shown to be prolonged in patients with renal dysfunction as 
compared to that observed in healthy subjects (77). Therefore there is a need to reduce the 
dose of CPT when treating patients with renal failure (78).   
 
1.5.2.8. Adverse effects 
CPT generally is well tolerated, and side effects are usually mild and transient. A dry, 
persistent cough has been reported commonly with the use of CPT. Coughing resolves after 
discontinuing the drug. Other side effects include abdominal pain, constipation, diarrhea, 
rash, dizziness, fatigue, headache, loss of taste, loss of appetite and numbness or tingling in 
the hands or feet. CPT may cause kidney failure and increased levels of potassium in the 
blood. Serious but fortunately very rare side effects are liver failure and angioedema (1-3).  
 
1.6. CLINICAL PHARMACOKINETICS 
1.6.1.  Absorption 
CPT is rapidly absorbed and blood levels of the drug are detected 15 minutes after oral 
dosing (22). These findings are similar to those in reports that suggest that the onset of 
antihypertensive activity occurs as soon as 15 minutes after a single dose of CPT to 
hypertensive patients.  CPT has a relatively short half-life in plasma with estimates in humans 
ranging from 1.6 to 1.9 h (22). Approximately 70% of an ingested oral dose is absorbed in 
healthy fasting human subjects, and an absolute bioavailability of 60% has been reported 
when compared to an IV dose (16).   
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Kripalani et al (79) reported the possibility that CPT may exhibit complex nonlinear 
pharmacokinetics, yet this phenomenon has not been reported by other authors (14, 20, 21). A 
single-dose pharmacokinetic study of CPT given in either a 25 or 50 mg dose to a group of 12 
volunteers was undertaken. CPT has been shown to be rapidly absorbed and a Cmax was 
observed 0.5-1.0 h following oral administration. Doubling the dose from 25 to 50 mg 
resulted in a C max50/C max25 of 1.914 suggesting that CPT does not exhibit dose dependent or 
non-linear kinetics. After reaching peak concentration, blood levels of CPT declined rapidly 
and were generally undetectable at 6-8 h post-dose (80).  
 
1.6.2.  Distribution 
CPT readily binds to serum albumin and other plasma proteins (81). The drug also forms 
mixed disulphides with endogenous thiol-containing compounds such as cysteine and 
glutathione in addition to forming a disulphide dimer of the parent compound. These 
components in blood and urine are measured collectively as total CPT. Since the formation of 
these inactive disulphides is reversible, the total amount of CPT may serve as a reservoir of 
the pharmacologically active moiety and thus contribute to a duration of action that is longer 
than that predicted by the blood concentration of unchanged CPT. To measure free or 
unchanged concentrations of  CPT, a chemical stabiliser must be added to biological samples 
to prevent the formation of disulphides of CPT, ex vivo. Following IV administration of CPT 
intravenously to healthy subjects, the total body clearance of CPT and steady-state volume of 
distribution was about 0.7 L/h/kg and 0.8 L/kg respectively. In healthy subjects, peak blood 
concentrations are reached about 45 to 60 minutes after oral administration. The 
bioavailability of CPT is altered neither in patients of different ages nor those who are taking 
concomitant medications including diuretics, procainamide, allopurinol, cimetidine or 
digoxin (81, 82).  
 
1.6.3.  Metabolism 
CPT is mainly eliminated by metabolism and its bioavailability is 65 %. Methylation is one 
of the major metabolic routes of CPT and the variability may contribute to the modulation of 
the intracellular concentration of CPT (83-85). The liver is the primary site of captopril 
methylation, whereas the intestine plays only a minor role. The kidney may also contribute to 
the excretion of CPT (84, 86). The methyltransferase enzyme in human red blood cells (RBC) 
has been implicated in the S-methylation of CPT (83). The rate of methylation of CPT ranged 
over one order of magnitude in the liver and kidney. In the human liver, the mean rate of CPT 
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methylation was greater in women than in men, whereas in the kidney no differences in 
metabolism based on the sex of the volunteers was observed, and the mean rate of 
methylation for all cases was 47 ± 23 pmol/min/mg (83). 
 
1.6.4.  Excretion 
The concentration of CPT in blood and urine of healthy subjects and patients with chronic 
renal failure following oral administration of 50 mg were determined by high-performance 
liquid chromatography.The maximum blood concentration of free CPT in healthy subjects 
was observed within 1 hour of administration and was not detectable 6 hours after dosing and 
41% of administered CPT was excreted in the urine as free CPT and metabolic products  
within 2 hours of dosing and 58% was excreted within 6 hours. In patients with chronic renal 
failure, an average serum creatinine of 5.1 mg/dl was observed and the absorption rate 
constant (ka), Cmax and AUC were not significantly different from those observed in normal 
subjects. However, the elimination rate constant (ke) and biological half-life (t1/2) revealed 
that the elimination of CPT from the plasma would be delayed. The cumulative amount of 
drug excreted in the urine as CPT and metabolic products were decreased at 2, 4, and 6 hours 
in patients with chronic renal failure. Consequently, impaired renal function is an important 
factor in the retention of CPT in the blood (87).   
 
The elimination half-life of unchanged CPT was approximately 2 hours. The primary route of 
elimination of CPT is via the kidney. The renal clearance of unchanged CPT exceeds the 
glomerular filtration rate, due to active tubular secretion of the drug (81, 82).  
 
1.7. CONCLUSIONS 
CPT is an orally effective AI converting enzyme inhibitor and is used for the treatment of 
hypertension and congestive heart failure. CPT has a relatively short elimination half-life in 
plasma. It is considered a drug of choice in antihypertensive therapy due to its effectiveness 
and low toxicity. It is usually prescribed to patients who are chronically ill and require long-
term therapy. The development of a once or twice daily oral formulation of CPT would be a 
significant advantage for the promotion of patient adherence, and in addition, the side effects 
of the drug would be minimized as a result of reduction of concentration fluctuations in the 
blood on long term therapy (7, 19). More particularly, some of the challenges would be to 
formulate a dosage form that may improve the taste, odour of CPT and enhance its release. 
An approach to use CPT loaded microcapsules which will maintain a constant therapeutic 
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concentration and reduce the number of times the drug must be taken will be prepared using a 
range of polymers.  
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CHAPTER 2 
CHARACTERIZATION OF CAPTOPRIL USING NMR SPECTROSCOPY 
 
2.1. INTRODUCTION 
Half a century ago, nuclear magnetic resonance (NMR) spectroscopy was first introduced as 
an analytical tool for structure elucidation of small organic molecules (88). Since then, NMR 
spectroscopy has evolved at a tremendous pace and the technique has subsequently been 
applied in the fields of inorganic chemistry, structural biology and medicine (88). Recent 
improvements in sensitivity (88) have ensured that NMR spectroscopy has become an 
important technique in structural-based drug design and drug discovery, and it has shown its 
potential for playing a greater role in the pharmaceutical industry (88, 89). Whilst the 
reproducibility of NMR spectroscopic methods is undoubtedly very high, the European 
Pharmacopoeia limits the use of NMR to the identification of drugs and reagents (88). 
 
NMR is being increasingly applied to study the properties and quality control of drugs (90).  
To date, no data have been published on the analysis of CPT Active Pharmaceutical 
Ingredient (API) by physical methods such as NMR. NMR offers high speed analysis and is 
sufficiently informative to judge both the structural and quality attributes of the substance 
undergoing analysis (91). During the last years, NMR spectroscopy and NMR imaging 
(magnetic resonance imaging, MRI) have been used to monitor drug delivery system 
performance in vitro and in vivo. However, the high installation and running costs of 
superconducting magnet technology limits the application range and prevents the further 
spread of this technology (92).  
 
Advanced NMR spectrometers with proton resonance frequencies of 300 MHz and higher 
have been used in analytical practice to study low density lipoproteins (LDL) (93), 
carbohydrates (94-96), enalapril (97), lisinopril (98), ramipril (99), quinapril (100), 
perindopril (101) and benazepril (102-105). This has also been used in analytical procedures 
to study angiotensin II receptor antagonists such as valsartan (106), losartan (107), 
irebesartan (108), telmisartan (109), candesartan (110) and eprosartan (111). 
 
The first and most obvious advantage of NMR at higher magnetic fields is the greater 
potential for intrinsic separation of resulting resonances. The chemical shift that occurs 
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following application of the magnetic field is unaffected by changes in spectrometer magnetic 
field-strength (B0) and the resonant frequencies of nuclei; hence, their observed differences in 
hertz change linearly with changes of B0. Moreover, homonuclear scalar couplings remain 
constant with B0 and therefore complex multiplets overlap less with neighbouring resonances 
at higher field-strengths. This allows fine-structures to be interpreted relatively easily (96).  
 
One of the most important criteria in the assessment of drug quality and quality assurance is 
the determination of API content in bulk drug substances and in pharmaceutical dosage 
forms. Conventional methods of analysis such as gravimetric and volumetric techniques are 
the more common analytical tools recommended by different Pharmacopeia’s and Drug 
Standard suppliers. In spite of the simplicity, specificity and accuracy of the modern 
advanced instrumental analysis, techniques such as spectrophotometric (IR, UV, and NMR), 
chromatographic methods (TLC, GC and HPLC) and others are used for analysis of drugs 
(112). In fact, apart from UV analysis, there are only a few examples of use of other 
instrumental techniques reported in monographs in the different Pharmacopoeias. It seems 
that official compendia are reluctant to adopt more of these techniques (112), which may well 
be a consequence of the lack of such instrumental facilities in some parts of the world (112).  
It must be noted that NMR is more specific (113) than other techniques such as UV 
spectrophotometry. For example, several different compounds may have the same or similar 
λmax value as CPT, which could result in an incorrect decision when using UV method 
described in most pharmacopoeias. When compounds have similar 1H spectra due to their 
related structures, it is usually impossible to distinguish them, and as such 2D NMR should 
be used, because it permits better separation of peaks.  
 
Since the development of high resolution NMR spectrophotometers in the 1950s, NMR 
spectra have been a major means of studying both newly synthesized molecules and natural 
products. Since drugs in clinical use are synthetic or natural products, NMR spectroscopy has 
been mainly applied to the elucidation and confirmation of their chemical structures. NMR 
methods have also been applied to quantitative analysis of compounds in order to determine 
the impurity profile of these materials (114-115), to characterize the composition of drug 
products and to investigate metabolites of drugs in biological fluids (116-118). The 
application of solid state measurements can provide information about polymorphism of drug 
powders (119-120) and the conformation of drugs in tablets. 
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2.1.1. The instrument 
 NMR is a spectroscopic technique that relies on the evaluation of the magnetic properties of 
an atomic nucleus. When placed in a strong magnetic field, certain nuclei resonate at 
characteristic frequencies in the radio frequency range of the electromagnetic spectrum (121).  
 
NMR is essentially an absorption phenomenon, similar to that observed in UV and IR 
techniques. However, the energy of NMR is from radio frequency radiation by nuclei 
exposed to the mass field. A magnet is the core of an NMR instrument and should create a 
static, stable and homogeneous magnetic field when in use. The magnet consists of a closed 
loop (‘solenoid’) of conducting Nb/Ti alloy wire immersed in a bath of liquid helium (b.p. 
4K). A large current flows around the loop, creating a strong continuous field with no 
external power supply. The helium container is insulated with a vacuum jacket and is cooled 
further by the use of liquid nitrogen (b.p. 77K). The probe is a coil of wire positioned around 
the sample that alternately transmits and receives radio frequency signals. A computer directs 
the transmitter to send a high power, short duration pulse of radio frequency to the probe coil. 
Immediately after, the generation of the pulse weak signals called free induction decay (FID) 
received by the probe coil are amplified, converted to an audio frequency and sampled at 
regular intervals of time by the analog digital converter (ADC) to produce a digital FID 
signal. The computer determines the timing and intensity of the output pulse by the 
transmitter and receiver and processes the digital information supplied by the ADC. The 
computer performs Fourier transformation of the signals to produce and plot NMR (121, 
122).  
 
Organic compounds are basically composed of the elements hydrogen and carbon, and in 
some cases phosphorus, nitrogen and oxygen. Additionally halogens such as fluorine, 
chlorine, bromine and iodine or metal atoms may be present. Each of the aforementioned 
elements has an isotopic nucleus which can be detected by NMR in appropriately designed 
experiments. The low natural abundance of 15N and 17O in nature prevents NMR being 
routinely applied to these elements without the use of labelled reference substances, but 1H-, 
13C-, 19F- and 31P NMR spectroscopy have become routine techniques for daily analytical 
work (123). Modern NMR spectrometers are available with field strengths up to 18.8 Tesla or 
a proton resonance frequency of 800 MHz (124), and at times 900 MHz (125-126). Routine 
analysis is made at proton frequencies of between 300 and 500 MHz (127).  
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2.1.2. Spectra 
Fundamentally, NMR spectra can be generated using either continuous wave or Fourier 
transform acquisition (126-128). Continuous wave NMR spectra are generated along similar 
principles to those recorded using optical spectrometers. A sample is placed into a strong 
magnetic field and the frequency of the sample is slowly scanned. In Fourier Transform 
NMR (FT-NMR), the magnitude of the energy changes is small. This means that the 
sensitivity is a major limitation. These instruments are not usually available (129). The 
frequency at which an NMR signal appears depends mainly on the magnetic field strength. 
The chemical environment in which an active nucleus is located can lead to a small shift in 
the resonance frequency and is referred to as the ‘Chemical Shift'. The presence of different 
functional groups finds their expression in this ‘Chemical Shift’. The result is that an 
intensity-/frequency-diagram or NMR spectrum is generated. In 1H NMR spectroscopy the 
presence of each H-atom leads to the generation of at least one signal and since most 
molecules of analytical interest contain more than one H-atom, the resultant spectra are 
generally more complex than conventional chromatograms. What is crucial to interpreting the 
information contained in NMR spectra is the spectral dispersion which is a linear function of 
the applied magnetic field strength. The homonuclear spin coupling of protons leads to a low 
dispersion in 1H NMR spectroscopy. In 1H NMR spectra of complex mixtures, it is often not 
possible to detect single components, but the sum of functional groups in the mixture can be 
determined. In 13C NMR spectra, the dispersion is much higher.  
Even though NMR spectroscopy is mainly a technique used for structural analysis, it has 
many applications as a quantitative analytical tool (126-130). The most attractive feature of 
NMR spectroscopy is that in a given solution and under appropriate conditions, the molar 
response factor is exactly the same for all resonating. This allows an analyst to perform 
quantitative analyses without the need for analytical standard of the analyst through the use of 
simple and well characterized primary standards, as used for volumetric analysis. 
Quantitative analysis using NMR is normally achieved by evaluation of the ratio of the 
integral of a signal generated by a test compound and the integral of a signal produced by a 
primary standard of that same compound. Furthermore, under quantitative conditions, 
matching integrals of signals with the structural formula of a compound are indicative of the 
purity of that material (130).  
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The European Pharmacopoeia promoted the use of NMR spectroscopy for the identification 
of drugs and reagents, and in some cases NMR spectra replace the use of IR spectroscopy. 
Thus, the 1H NMR spectra are used in the same manner as IR spectra, which can be described 
as a sort of pattern recognition. An increasing number of reagents, adenine, butoxycaine and 
aesculin have been identified by 1H and 13C-NMR spectra in the USP Pharmacopoeia (123). 
NMR spectroscopy, being a primary ratio method of measurement, is highly suitable to 
evaluate the quality of drugs. NMR spectroscopy can be used for the identification of a drug 
substance, the identification and quantification of impurities arising from the synthesis 
pathway and degradation or residual solvents, as well as the determination of the content in 
the assay (131).  
Following the discovery of an active pharmaceutical ingredient (API) with potential for 
therapeutic use, it is vital to completely characterize the solid-state form of the bulk API and 
of any formulated product containing that API. The solid-state form of an API - in particular 
the crystalline, amorphous or solvate nature - can have a dramatic effect on the dissolution 
rate, solubility, bioavailability, physical stability and potential for interaction with excipients 
of that compound. Formulation and processing of an API has been shown to impact some of 
these physical properties (132).  
There are many analytical techniques that can be used to identify the solid-state form of an 
API. Traditional techniques used for solid-state analysis include differential scanning 
calorimetry (DSC) (132), Fourier Transform Infrared Spectroscopy (FT-IR) (133), Raman 
Spectroscopy (134), and Powder X-ray Diffraction (PXRD) (135). While there are many 
advantages to using these methods, one most notable disadvantage is that many of the 
techniques cannot be easily used to characterize the individual components contained in a 
formulated product. NMR can provide information about both the API and a formulated 
product. Although NMR is currently not widely used due to its expense and lack of 
availability, its use to characterize pharmaceutical products is becoming more prevalent since 
information can be obtained from NMR spectra about an API and/or the drug product in 
which the API is formulated. 
The motivation for using NMR spectroscopy to characterize pharmaceuticals can be readily 
ascertained by highlighting areas in which NMR can provide unique information about a 
particular system. Such areas include the following:  
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a. NMR is a non-destructive and non-invasive technique that can be applied to the 
analysis of an API or drug product (136),  
b. Quantization of solid-state forms of API and delivery systems is possible (137), 
c. Low levels of  API in a drug product can be investigated using isotopic labelling 
(138), 
d. The conformation and arrangement of molecules can be established (139), and 
e. The molecular dynamics of a system can be determined (140). 
The use of NMR is not currently widespread within the pharmaceutical industry due firstly to 
its expense (140-141). Secondly, lengthy analysis time and low throughput are barriers in the 
use of NMR, but the development of a multiple sample probe, as well as other advancements, 
are likely to increase the potential for use of this technique in the near future (140).  
NMR is particularly rich in the number and type of spectroscopic observables it can offer. 
Chemical shifts, J-couplings and dipolar couplings are but a few of the parameters that can be 
measured via NMR (135). However, for these NMR parameters to have some utility, they 
must be able to be applied to the structural elucidation of compounds. In this study, focus is 
mainly on the chemical shift and J-coupling. 
 
2.1.3. Chemical shifts 
Chemical shifts in NMR spectra are the cornerstone of the technique. These shifts provide 
positional information about individual NMR peaks, which in turn can be ascribed or 
assigned to individual atoms within the chemical structure of the compound under 
investigation. Unlike most other forms of spectroscopy, major spectroscopic values (chemical 
shifts) in NMR are reported using a relative rather than an absolute measure as chemical 
shifts are field dependent and are fundamentally an electronic phenomenon. As a result, all 
chemical shifts are measured in parts per million (ppm) as opposed to absolute frequencies in 
Hertz (Hz). These shifts arise primarily due to the geometry or distribution of electrons 
surrounding the nuclei that are monitored using NMR (142). 
  
The theoretical treatment of chemical shifts for simple systems comprised of a free atom with 
no orbital or spin angular momentum can be determined using Lamb’s formula (143) in 
Equation 2.1:  
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                                      Equation 2.1                                               
ρ (r)  = electron density from the nucleus, 
  r  = distance of the electron density from the nucleus,  
Bo  = strength of the magnetic field of the NMR, 
  c = speed of light, 
  m  = mass of light,  
m = mass of an electron, 
e  = charge (cgs).  
 
In essence, the chemical shift is proportional to the electrostatic potential energy of 
interaction between the nucleus and electrons (144).  
If the nucleus is in a molecule where the electrons are not free to move in circles around the 
direction of the applied magnetic field, a theoretical expression for the chemical shift, defined 
by Ramsey, is normally used (136, 145, 146).  
It is evident that there is an inverse relationship between the distance of an electron from a 
nucleus and the resultant chemical shift observed for that electron. When electrons are pushed 
away from the nucleus the chemical shift is small and the nucleus is said to be deshielded. In 
NMR, these changes are generally plotted in reverse so that shielded nuclei have low or 
upfield chemical shifts (around 1 ppm for H), and deshielded nuclei have high or downfield 
chemical shifts (around 8 ppm for H). Chemical shifts vary according to the characteristic 
electronic and nuclear structure of each element of a molecule. Chemical shifts provide 
detailed information about the covalent structure of atoms and molecules in a structure (142).  
Once a compound of interest is ready for NMR analysis, and suitable solution conditions 
have been determined, a series of 2 or 3D experiments are conducted. The outcome of such 
experiments is the collection of sufficiently detailed spectral data to assign every observed 
peak or resonance to all detectable atoms in a compound - a process called sequential 
assignment. Two types of 2D experiments are normally undertaken. Initially a Correlation 
spectroscopy (COSY) experiment is performed in order to allow individual carbons to be 
identified as a consequence of distinct chemical shifts. Following the COSY, Heteronuclear 
Multiple Quantum Coherence (HMQC) and Heteronuclear Multiple Bond Coherence 
(HMBC) experiments are performed to develop spectra that are almost identical to the COSY 
spectrum. All of these spectra are displayed using a software package called MestRe-C 
Version 4.3.6.0 or MestRe Nova (Mestrelab Research, Santiago de Compostela, Spain, 2006).   
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Once the sequential assignment is completed, it is possible to begin the structure elucidation 
process (147).   
2.1.4. J-coupling 
Nuclei that are subject to the same chemical environment are equivalent, and those exposed 
to different environments or having different chemical shifts are non-equivalent. Nuclei that 
are close to one another also exert an influence on the magnetic field of each other and which 
are depicted in NMR spectra if the nuclei are non-equivalent. If the distance between non-
equivalent nuclei is less than or equal to three bond lengths, this effect is clearly visible in 
NMR spectra and is referred to as spin-spin coupling or J-coupling. 
One of the primary goals of an analytical laboratory is to identify and characterize any 
impurities that may be present in bulk drug or formulated products. The nature of impurities 
that may be present is important to ensure that stable formulations and interactions with 
excipients can be respectively produced and identified. Furthermore, regulatory agencies 
require that impurities present at levels > 0.1% must be identified. Complex mixtures, 
especially those with low amounts of individual components, are a challenge to analytical 
chemists working in pharmaceutical research and development (148).  
CPT contains two asymmetric centres, one associated with the (S)-proline functionality and 
the other with the 3-mercapto-2-methylpropionic acid side chain. The compound is normally 
administered as enantiomerically pure, with both centres of dissymmetry being completely 
resolved. The physicochemical and analytical characteristics of CPT have been described by 
Kadin (149) and by Caplar et al (150). Many of the details in these published profiles are 
similar; however the ultraviolet absorption curves are substantially different. Kadin showed 
(149) UV spectrum with a single maximum around 200 nm and no other absorption bands at 
any other wavelength. This observation is in contrast to that reported by Caplar et al (150), in 
which the spectrum of CPT consisted of two maxima at wavelengths of 207 and 327 nm 
respectively. In addition, circular dichroism (CD) with band maxima at 225 and 242 nm was 
also reported (151).  
 
A distinguishing characteristic of CPT (Figure 1.3) is that it is a relatively simple chemical 
compound that is comprised of condensed, simple amino acids. A hydrogen bond can be 
presumed to exist between the hydrogen atom of the carboxylic acid and the carbonyl group, 
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and another hydrogen bond is presumed to exist between the hydrogen from a sulfhdryl group 
and a carbonyl group. 
The reactions of thiol compounds with molecular oxygen are well documented (152), and it is 
a challenge to resolve this difficulty as ambient oxygen pressure is always present. The 
reactions of oxygen with thiol compounds in aqueous solutions are most often described by 
Equations 2.2 and 2.3: 
                                     2 RSH + O2   → RSSR + H2O2                                                          Equation 2.2 
                                   4 RSH + O2   → 2 RSSR + H2O                                    Equation 2.3 
The products of such reactions are disulfides and hydrogen peroxide or water (114). 
However, it is known that the oxidation of thiol compounds can produce products containing 
a sulfur atom in different oxidation states depending on the reaction conditions. Under mild 
conditions (pH 7-9), thiol compounds are oxidised to produce disulfides (153), whereas at pH 
12, these compounds are transformed predominantly into sulfinic (RSO2H) and sulfonic 
(RSO3H) acids (123).   
Published data (154-155), reveal that the rate of self oxidation of CPT is linearly dependent 
on the concentration of oxygen. However, the reaction can follow the zero- or first-order 
kinetics with respect to the concentration of thiol compounds and their source (156). Despite 
the prevalence of substantial information, the data on oxidation of thiol compounds are 
contradictory and it is difficult to estimate the reliability of many proposed reactions (156). 
This study aims to show that 2D NMR can be used to perform precise and accurate 
qualitative analysis of bulk material since the conditions of storage of raw material are 
critically important for CPT powder, in particular when oxidative degradation may prevail.  
2.1.5.  NMR  
Total assignments of 1H NMR, 13C NMR spectrum for the structures are made with the help 
of distorsionless enhancement by polarization transfer (DEPT), 1H-1H correlation 
spectroscopy (1H-1H COSY), as well as heteronuclear multiple quantum coherence (HMQC) 
and heteronuclear multiple-bond correlation (HMBC) techniques. 13C NMR data are well 
known for better dispersion and significantly less sensitivity to environmental effects, such as 
that due to pH, solvent used, temperature, etc., than those of protons. Yet 1H has remained a 
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favourable tool for identification and/or high-throughput analysis of small and medium sized 
molecules and for the characterization of complex mixtures, such as those of metabolites due 
in part to sensitivity concerns. 
 
2.1.5.1. 1H and 13C-NMR 
Both 1H and 13C-NMR give information about the number of non-chemically equivalent 
nuclei or non-equivalent hydrogen and carbon atoms as well as information about the 
environment of the nuclei or hybridization state and attached atoms. It is convenient to use 
FT-NMR techniques for 1H NMR and it is standard practice for 13C-NMR as the signal for a 
C atom is in the order of 10-4 weaker than the signal generated for a hydrogen atom. A signal 
for a 13C nucleus is only about 1% as intense as that for 1H because of the magnetic properties 
of the nucleus. 13C are spread over a much wider range than 1H signals making it easier to 
identify and count individual responses. Separate distinct peaks appear for each of the 
carbons in the molecule of interest. 13C shifts are most affected by the hybridization state and 
electro-negativity of the carbon and attached functional groups. 
  
CPT has three functional groups of importance viz., thiol, amide and carboxylic acid. The 
best estimate for the S-C-C- bond in CPT is 109.5˚. As can be seen from the structure of 
CPT, there are 9 lone pairs, 0 open octets, 10 sp3 hybridized atoms, 4 sp2 hybridized atoms, 0 
sp hybridized atoms and 15 atoms that are unhybridized. The hydroxyl (OH) group is the 
most polar bond in CPT. The sp3 hybridized C atom is shielded more than that of the sp2 and 
an electronegative atom deshields the carbon to which it is attached.  
 
2.1.5.2. DEPT-135 
DEPT-135 is a distorsionless enhancement of polarization transfer that uses a 135 degree de-
coupler pulse. It is a technique that is used to distinguish different types of carbons in a 
spectrum. A DEPT spectrum is made up of 3 components, viz., (i) regular spectrum (ii) 
DEPT-90 spectrum and (iii) DEPT-135 spectrum. To analyze CPT, only the DEPT-135 
spectrum that shows positive peaks for carbon atoms inCH3 and CH groups, and DEPT-135 
that shows negative peaks of carbon atoms from CH2 groups were evaluated. DEPT-135 is 
used to count the H attached to C. In DEPT-135, a second transformer irradiates H, which 
affects the appearance of C spectrum. Some C signals stay the same, some disappear and 
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some are inverted. The experiment (distortionless enhancement by polarization transfer, 
DEPT) were obtained using variable pulse q = 135°.       
 
2.1.5.3. COSY, HSQC and HMBC 
The term COSY is an acronym for correlation spectroscopy. In COSY experiments, chemical 
shifts between nuclei that are J-coupled or separated by two or three covalent bonds are 
generated, resulting in every peak having two chemical shift values (viz., an x- and y- value). 
Those that have identical x- and y- values are called diagonal peaks. Those that have different 
x- and y- values are called off-diagonal or cross peaks. Identifying COSY cross peaks and the 
two atoms that gave rise to the x-and y-shifts respectively, allows any two coupled spins to be 
identified by simple inspection. This is very useful in determining the covalent connectivity 
of all atoms within a molecule (157).  
COSY spectra are therefore useful to identify coupled protons. Cross-peaks indicate pairs of 
protons that are coupled. The 2D 1H-1H correlation spectroscopy (COSY) and heteronuclear 
simple quantum correlation (HSQC) spectra were obtained with a digital resolution of 
5.425 Hz after zero filling. Zero filling (one) were performed in the F1 dimension of a 
512´512 matrix, the data were 2D transformed and the magnitude spectra multiplied by a sine 
window in each dimension and symmetrised along the diagonal (158).  
HSQC is an acronym for heteronuclear simple quantum correlation, meaning that two 
different types of nuclei (usually 1H and 13C) are correlated in a 2D experiment by the 
evolution and transfer of single-quantum (SQ) coherence, the simple magnetization that can 
be represented by vectors in the x-y plane. HMBC is heteronuclear multiple bond correlation, 
which is identical to HMQC except that the J- value selected for the coherence transfer is 
much smaller (10 Hz for HMBC versus 100 Hz for HMQC), so that the two and three bond 
relationships are detected (2,3JCH~ 10Hz) and the one bond relationship is rejected (1JCH ~ 
100Hz) (158). 
To date, only a small number of manuscripts describing the use of NMR to study ACE 
inhibitors have been published (97, 98, 101-105), none of which have focused on the use of 
2-D NMR evaluation of the drug. The purpose of this work is to describe an NMR method for 
the determination of the purity of CPT.  
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2.2. EXPERIMENTAL 
2.2.1. Materials and methods 
NMR spectra were generated in deuterated chloroform (CDCl3) using a Brucker 400 MHz 
NMR spectrometer (Rheinstetten, Germany) in the 2H lock mode. Chemical shifts were 
reported in parts per million (ppm) relative to tetramethylsilane (TMS) which was used as 
standard in 1H and 13C measurements. Each sample was transferred to 178 mm glass ultra 
precision ASTM Type 1 Class A borosilicate thin-walled NMR tubes (Norell, Inc. Mays 
Landing, NJ).  These tubes are specifically designed to be used for high resolution NMR and 
are recommended for chemical structure determination, low and high temperature 
applications, and low temperature sample storage. The 1H (400 MHz), 13C (100 MHz), 
DEPT-135, HMQC, HMBC, COSY-90 NMR spectra were all recorded using standard pulse 
sequences. Experimental data was obtained using the following conditions: All NMR spectra 
were recorded at 298 K, at a frequency of 400.13MHz with a 5mm probe and                      
pw (90◦) = 12.6 s. All chemical shifts were recorded and analyzed using MestRe-C and 
MestRe Nova software.  
 
2.2.2. Analysis of drugs 
CPT was donated by Protea (Midrand, South Africa), and Deuterochloroform (CDCl3) and 
tetramethylsilane (TMS, Si (CH3)4) were obtained from Sigma Aldrich Chemical Co. 
(Milwaukee, WI, USA). Because all twelve hydrogen atoms in a tetramethylsilane molecule 
are equivalent, the chemical shift of this singlet is assigned as δ0.0, and all other chemical 
shifts are determined relative to it. The majority of compounds studied by 1H NMR 
spectroscopy absorb downfield of the TMS signal, and thus there is usually no interference 
between a standard and sample being tested. Samples of CPT were dissolved in CDCl3 and 
1H NMR spectra recorded on a 400 MHz instrument. Deuterated solvents are used as they 
enhance spectral resolution and solvents containing hydrogen yield signals that may swamp 
those of the sample of interest. Approximately 20 mg of CPT powder was dissolved in 1 ml 
of solvent to yield a sample depth of at least 4.5 cm in the NMR tube. Despite these 
advances, NMR measurements are usually made on single samples, and therefore throughput 
is limited by this serial approach.  
Following analysis, samples were transferred from NMR tubes into screw-cap glass vials and 
labelled appropriately. Prior to commencing analysis, cleanliness of the tubes was ensured so 
as to avoid the development of poor quality spectra. Additionally, caution was made so that 
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they had no cracks or chips. Labels were therefore put on the tube caps. It is better to have a 
slightly lower concentration and a sample of reasonable height than a shorter sample with a 
higher concentration. The natural ‘magnets’ in the atoms of the sample align with the NMR 
magnet just as iron filings would on a toy magnet. The sample was then exposed to a series of 
split-second radio-wave pulses that disrupt the magnetic equilibrium in the nuclei of selected 
atoms.  
Prior to dissolving CPT, the deuterated chloroform was spiked with 1% TMS, as an internal 
standard.  
 
2.3. RESULTS AND DISCUSSION 
To prove the purity of CPT, NMR studies were conducted. Proton NMR spectroscopy has 
been used to study flurazepam dihydrochloride (159). Kuwayama et al (160) examined the 
solvated species of flurazepam dihydrochloride using 1H- NMR but found the spectra to be so 
complex that assignment of signal was not possible and therefore 13C-NMR spectroscopy was 
selected as the method of choice. It is for this reason that both 1H- and 13C-NMR studies were 
conducted in this work and results of these studies are shown in Figures 2.1 and 2.2.  
 
Kuwayama and Yashiro (161) studied the 13C-NMR spectra of diazepam and fludiazepam. 
The use of NMR for the detection and quantitation of various benzodiazepines was 
summarized by Dawson (162) as one of several categories of abused drugs easily assessed 
using this technique.  
 
The usefulness of 1H and 13C Fourier transform (FT) NMR spectroscopy (1H- and 13C-NMR) 
as quantitative methods, stems from the potential direct relationship between the area under 
an NMR peak and the number of a particular type of nucleus that give rise to that signal. 
Experimental limitations that have to be overcome in order to obtain quantitative 13C-NMR 
spectra are associated with the relaxation time, the nuclear Overhauser effect (NOE), and the 
NMR instrument itself (filter characteristics, power level of the exciting pulse, dynamic range 
and digital resolution). Practical problems aside, 13C-NMR has a greater potential than 1H-
NMR for the study of organic systems. The sensitivity of 13C chemical shifts to small 
differences in the molecular environment, and coupled with a large chemical shift range, 
gives a “chromatographic” separation of resonances of interest and has made 13C-NMR 
attractive as a potentially useful technique for quality assurance of pharmaceuticals (163).  
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Figure 2.1. 400 MHz 1H NMR spectrum of CPT in CDCl3 
 
The structure of CPT is shown in § 1.2.1 and in Figure 2.1 together with the tentative peak 
assignments. The 1H NMR spectrum (Figure 2.1) of CPT reveals: a doublet at 1.21 ppm 
corresponding to 2’-methyl protons; a triplet at 1.55 ppm corresponding to the thiol proton; a 
multiplet at 2.05 ppm corresponding to the diastereotopic 4-methylene protons; two 
multiplets at 2.10 and 2.38 ppm corresponding to the diastereotopic 3’-methylene protons; a 
multiplet at 2.81 ppm corresponding to the 2’-methine protons; two multiplets at 2.49 and 
2.89 ppm corresponding to the diastereotopic 3-methylene protons; a multiplet at 3.63 ppm 
corresponding to the 5-methylene protons; a multiplet at 4.63 ppm corresponding to the 2-
methine proton; and a broad peak at ca. 5.85 ppm corresponding to the carboxylic OH.  
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Solid-state 13C NMR spectroscopy has also been successfully applied in the determination of 
polymorphism in certain groups of molecules and both solid-state 13C NMR spectroscopy and 
powder X-ray diffraction have been used to analyze mixtures of solid forms of neotame 
(164).   
One- and two-dimensional (1H, APT, gCOSY, gHSQC and gHMBC) NMR spectra have 
been used in combination with LC-MS for structure elucidation of unknown impurities in 
compounds (165).  
Three impurities in the API anastrozole were detected by simple isocratic reversed-phase 
high performance liquid chromatography (HPLC). The impurities were isolated and 
characterized by LC-MS/MS, GCMS and 1H, 13 C and DEPT NMR experiments (166).  A 
rapid, selective and accurate quantitative 2D NMR (HMBC) method was developed for the 
simultaneous analysis of obidoxime chloride and atropine sulphate (167). The conformational 
properties of the AT1 antagonist, valsartan, have been analyzed in solution and at receptor 
binding sites. Low energy conformations of valsartan in solution were explored and 
elucidated using a combination of NMR spectroscopy (1H, 13C, HSQC, HMBC, ROESY and 
NOESY) and molecular modeling techniques. The NMR results revealed the existence of two 
distinct and almost isoenergetic conformations for valsartan (with a cis:trans ratio around the 
amide bond of 40:60) (168).  
It is abundantly clear that the physical characterization of API is crucial to the successful 
development of a successful product (169-171). It has long been known that pharmaceutical 
solids can exist in more than one solid form (crystal, amorphous) (169, 172-174) and that 
different solid forms of a drug may display significantly different physical and chemical 
properties, including colouration, morphology, stability, dissolution and bioavailability (169, 
172). Typically, the most thermodynamic and stable form of a compound is chosen for 
development into a product, however metastable forms have been used due to enhanced 
dissolution or bioavailability profiles. In either case, a full characterization of the API is 
necessary in order to understand the chemical and physical properties of the material. 
Extending this concept, qualitative analysis must encompass the API at two levels: the bulk 
drug substance as well as the final drug product (169, 171), and quantitative analysis at both 
levels may also be necessary. 
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The 13C NMR spectrum (Figure 2.2) reveals 9 carbon signals. The C-2’ methyl nucleus 
resonates at 17.2 ppm; the C-4, C-3 and C-3’ methylene nucleus at 24.8, 27.5 and 27.6 ppm; 
the C-2’ methine nucleus at 42.6 ppm; the C-5 methylene nucleus at 47.8 ppm; the C-2 
methine nucleus at 65.9 ppm; and the two carbonyl carbons at 172.8 and 176.5 ppm. The 
molecular formula of CPT is C9H15NO3S. 13C NMR spectrum (Figure 2.2) shows 9 peaks of 
different C atoms, which is consistent with the basis of molecular symmetry. 
 
 
 
 
Figure 2.2. 400 MHz 13C NMR spectrum of CPT in CDCl3 
 
The DEPT 135 spectrum (Figure 2.3) confirms the presence of four methylene carbons, C-4, 
C-3, C-3’ and C-5, which resonate at 24.8, 27.5, 27.6 and 47.8 ppm respectively; and two 
methane carbons, C-2’ and C-2, which resonate 42.6 and 59.7 ppm respectively. The DEPT 
spectrum gives the CH, CH2 and CH3 signals in which CH and CH3 carbons appear as 
positive peaks and CH2 appear as negative peaks in DEPT 135 spectrum. The C recorded in 
13C NMR are not shown in DEPT are C without any attached H.   
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Figure 2.3. DEPT 135 NMR spectrum of CPT in CDCl3. 
 
The COSY spectrum (Figure 2.4) reveals a vicinal coupling (at cross peak A) between the 2’-
methine proton and 2’-methyl protons; a long range coupling (at cross peak B) between 2-
methine proton and 4-methylene protons; vicinal coupling (at cross peak C) between 4-
methylene protons and 3-methylene protons; and a geminal coupling (at cross peak D) 
between 3-methylene protons.   
 
The HSQC (Figure 2.5) reveals that in cross peak A the 2’-methyl protons are bonded to the 
carbon that resonates at 17.2 ppm; cross peak B reveals that 4-methylene protons are bonded 
to the carbon that resonates at 24.8 ppm; cross peak C reveals that diastereotopic 3’-
methylene protons are bonded to the carbon that resonates at 27.5 ppm; cross peak D reveals 
that diastereotopic 3-methylene protons are bonded to the carbon that resonates at 27.6 ppm; 
cross peak E reveals that 2’-methine proton is bonded to the carbon that resonates at 42.6 
ppm; cross peak F reveals that 5-methylene protons are bonded to the carbon that resonates at 
47.8 ppm; and cross peak G reveals that 2-methine proton is bonded to the carbon that 
resonates at 59.7 ppm. 
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Figure 2.4. 400 MHz COSY NMR spectrum of CPT in CDCl3. 
 
The HMBC spectrum (Figure 2.6) was used to support the structural assignment which 
reveals that 2’-methyl protons connects to C-3’ (3JC,H), C-2’ (2JC,H) and 1’- C=O (3JC,H); 5-
methylene protons connects to C-4 (2JC,H); and 2-methine proton connect to C-4 (3JC,H) and 
1’-C=O (3JC,H). 
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Figure 2.5. 400 MHz HSQC NMR spectrum of CPT in CDCl3. 
 
 
 
Figure 2.6. 400 MHz HMBC NMR spectrum of CPT in CDCl3. 
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The structural elucidation of CPT was accomplished by use of a combination of 2D COSY 
techniques, 1H-1H and HSQC with 1H and 13C NMR spectra. In this study, all functional 
groups were well characterized. The elucidation of the structure was very important in the 
analysis of the bulk material. The 1H chemical shift values were reported on the δ scale in 
ppm, relative to TMS (δ = 0.00 ppm)  
2.4. CONCLUSION 
The characterization of CPT using 2D heteronuclear correlated spectra is arguably the first of 
its kind using these techniques. By use of 1H NMR, 13C NMR, DEPT 135, COSY, HMBC 
and HSQC, complete information of the structure of CPT was obtained. Confirming the 
structure of a bulk material using NMR is the first in a process that can ultimately help 
confirm whether there have been changes in a drug in a bulk material during shipment, 
storage and exposure to humidity and air. NMR is a powerful and useful tool in 
pharmaceutical analysis and identification of small molecules. This study has demonstrated 
the usefulness of NMR, and it is quite clear that NMR will play a leading role in drug 
discovery, development and analysis. The technique can be used with other analytical tests 
for the elucidation of chemical and structural information pertaining to molecules under 
investigation. The spectra obtained in deuterated chloroform showed well-separated signals 
which did not suffer interference for the residual proton of chloroform, which sometimes may 
pose a problem in 1H during analysis. Aside from the costs involved and expertise needed, it 
is proposed that this method can be an effective tool to monitor degradants and to facilitate 
chiral discrimination and may result in the development of products in which chiral 
compounds are delivered as single enantiomers, thereby addressing the requirements being 
imposed by many regulatory authorities. In particular, this can also help and generate a fresh 
enthusiasm in the interest of improving enantioselective synthesis and increase demand for 
accurate, reliable and convenient methods of measuring enantiomeric compositions.    
  
Additionally, NMR technology has been proposed in other studies (175) as a valuable tool for 
fast identification of illegally produced sildenafil citrate tablets. It can be used in 
stereochemical differentiation or conformational polymorphism. This tool can also help equip 
researchers with advanced understanding in accelerated pace within pharmaceutical research 
and development. While these advances create high optimism for the analysis of 
pharmaceuticals, they also challenge the analytical methods that are integral components in 
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the drug development and formulation. Thus far, it seems that this technique is underutilized 
in modern pharmaceutical research as a consequence of resource barrier.  
A detailed NMR spectroscopic study of CPT was carried out and can be applied for the 
analysis / and or certification of CPT bulk material.  
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CHAPTER 3 
THE USE OF EXPERIMENTAL DESIGN IN THE DEVELOPMENT OF AN 
HPLC METHOD WITH ELECTROCHEMICAL DETECTION FOR THE 
ANALYSIS OF CAPTOPRIL  
 
 3.1. INTRODUCTION 
Over the past few decades there have been extensive developments in the automation of 
chemical and pharmaceutical methods of analysis. The use of automation has been stimulated 
by the need for rapid analyses of increased numbers of samples in the clinical, 
pharmaceutical and environmental chemistry disciplines in addition to the demand for 
continuous monitoring of different analytes during industrial processes (176). A significant 
part of these modern approaches of automated analysis has been based on liquid flow 
analytical techniques operated under hydro-dynamically controlled conditions (177).  
Several methods of detection have been used in flow analytical techniques (177). 
Electrochemical detection is the one most commonly used in the chemical industry (178-
183).   
Electrochemical detectors (ECD) are highly selective detectors that have a limited range of 
application, as compared with the commonly used spectrophotometric detectors.  However, 
the appropriate application of ECD allows for analytical methods that can be superior to those 
using other detection systems. ECD are simple in design and relatively easy to use. However, 
their use requires knowledge and experience in the use of electrochemistry, in contrast to the 
use of UV-Vis spectrophotometric detectors (183).  
A response using ECD depends on the transport of an analyte towards an electrode. The 
selectivity of electrochemical detectors is their prominent advantage and their selectivity can 
be modified or controlled through physical and chemical modification of the electrode 
surface in use (184-187).   
ECD are of two types: Bulk and Solute property detectors. Bulk property detectors measure 
changes in an electrochemical property of bulk fluid flowing through the detector cell. The 
most popular detectors of this class are conductivity detectors in which a potential is applied 
across a cell, thereby allowing ions in solution an opportunity to move towards an electrode 
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(depending on the charge) with a consequent change in the conductivity of the           
electrode (188).  
Two major disadvantages of conductivity detectors are that the use of buffer salts in the 
mobile phase should generally be avoided, and the system is temperature sensitive (189).  
Nevertheless, these detectors have found some application in the quantitation of both organic 
and inorganic ions in a variety of matrices (190-192).  
 
In contrast, solute property detectors monitor the change in potential or current at the 
electrode as a solute passes through the detector cell. The more popular of these detectors are 
coulometric and amperometric detectors, of which the latter are more widely used. If a solute 
passes over an electrode which is held at a constant potential sufficiently high to allow 
electron transfer and oxidation or reduction to occur, a current will be produced which is 
proportional to the solute concentration (189). The difference between amperometric and 
coulometric detectors is that for the former, the concentration of solute entering and leaving 
the detector is nominally the same (in practice up to 5% may be converted to product) 
whereas in coulometric detectors about 95% of the solute is almost completely          
converted (193).  
 
A limitation of electrochemical detection in general is that the mobile phase composition 
cannot use high concentrations of non-polar organic solvents since these do not support 
conductivity. To ensure conductivity of the mobile phase, buffers in the 0.01-0.1 M 
concentration range are used to provide conductivity whilst maintaining a low background 
current. It must be emphasized that the constituents of a mobile phase must be of the highest 
purity to minimize excessive background current (189). The most popular detector cells for 
electrochemical detection are thin layer in nature, and may be used with either amperometric 
or coulometric detectors (188).  
 
The classes of compounds that have been analyzed using electrochemical detection include 
aromatic amines (194, 195), thiols (196), phenothiazines (197) and tricyclic antidepressant 
drugs (198). A number of hints / guidelines (188) specific to the successful use of 
electrochemical detection include:  
 
Page | 41 
 
i) Ensuring that the electrode materials are  compatible with the components  of the 
mobile phase and that the electrode surfaces are in good condition, 
ii) Operation of the detector at the minimum potentials required to oxidize or reduce 
the solute of interest, 
iii) Minimization of temperature fluctuations around the detector cell, 
iv) Ensuring that no air bubbles are present in the flow cell, 
v) Ensuring that all constituents of the mobile phase are of the highest quality and are 
pure. 
 
3.1.1. Electrochemical cell design 
At present the ESA Coulochem® coulometric detector is the only commercially available 
detector of its type. Several types of cell are now available, most of which contain two 
analytical electrodes in series and the standard cell (Model 5010, Figure 3.1) contains porous 
graphite electrodes (PGE) of equal size.   
 
 
 
 
 
 
 
 
Figure 3.1. Schematic diagram of a Coulochem® Model 5010 detector cell, showing the relative positions of the 
working electrode and the counter and reference electrodes.  
Coulochem® cells are unique in their design and use a patented Environmental Sciences 
Associates (ESA) flow-through porous graphite electrode. The low-volume analytical cells 
contain two working electrodes with a large surface area resulting in a complete reaction of 
the electroactive compound. The first or screening electrode can be used to eliminate 
compounds that have the potential to interfere with the analysis of the compound(s) of 
interest at the second or analytical electrode. The cell contains two thin, porous graphite 
electrodes with solid state hydrogen reference electrodes (199-200). The detector cells with 
Test electrode Test electrode 
Counter and reference 
electrode 
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dual PGE can be operated in one of three modes that are often referred to as ‘screen’, 
‘difference’ and ‘redox’ modes. In the screen mode the potential of the first electrode (E1) in 
the analytical cell is typically set at a potential of 0.2-0.3 V below that of the second electrode 
(E2). The aim of this strategy is to reduce the concentration of any unwanted readily 
oxidizable components that may interfere with the analyte reaching the second electrode 
(201). 
Electrochemical selectivity is achieved by oxidizing or reducing many undesirable 
electroactive compounds that may interfere with the analysis at the first electrode. Any 
compound with a reaction potential less than that of the compound of interest reacts at the 
first electrode and is therefore excluded from reacting at the analytical electrode. In addition, 
many compounds can be readily oxidized and reduced in sequence which may ensure greater 
selectivity of this technique than with other detection systems (202).  
The Model 5010A Standard Analytical Cell provides excellent long-term stability and day-to-
day reproducibility for analysis and the large surface area of the coulometric electrodes 
permits long periods of operation without reduction in sensitivity and signal response. 
The Model 5020 Guard Cell (Figure 3.2) is designed to withstand high pressure and has a 
single large porous graphite electrode that removes electroactive impurities from the mobile 
phase prior to the mobile phase passing through the injection port, column and analytical cell. 
This approach results in a decrease in background current and therefore a reduction in 
baseline noise (202-203).   
 
 
 
 
 
 
Figure 3.2. Schematic diagram of a Coulochem® Model 5020 Cell showing the relative position of the 
electrode, counter and reference electrode. 
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ECD has been used for immunoassay of heterogeneous enzymes 
The analysis of serotonin (204
has also used ECD. Furthermore non
electrophoresis (206) and environmental pollutants 
ECD. Trace carbofuran (208),
petroleum (210) have also been monitored using ECD. 
electrochemical detection to analyze benzodiazepines in forensic samples. The number of 
publications and disciplines that have used ECD in analysis are summarized in 
Figure 3.3. 
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Figure 3.3. Disciplines that have use
(203) in clinical chemistry
) and DNA entrapped in polypyrrole-polyvinyl sulfonate 
-electroactive and electroactive analytes in
(207) have also been monitored using 
 low level of antioxidants in food (209) and trace metals in 
Wilhelm et al (211
etection for the period   1980-2008 
Number of Publications 
 3222 
 1890 
1478 
1405 
2881 
1136 
829 
201 
 
d ECD for the period 1980-2008  
Pharmaceuticals
Clinical chemistry
Neuroscience
Biochemistry
Chemical 
Environmental
Industrial 
Forensic 
 
. 
(30) 
 microchip 
) used reductive 
Table 3.1 and 
Page | 44 
 
When using ECD, the eluant flows over the surface of an ‘inert’ electrode maintained at an 
appropriate positive or negative potential relative to a reference electrode. At the electrode 
surface analytes possessing functional groups that are electroactive undergo oxidation or 
reduction depending on their characteristics (212).  
ECD is at least 100 times more sensitive towards responsive compounds than standard UV 
detectors, with the added benefit that they are more selective. Unfortunately over time 
reaction products of oxidation tend to accumulate at the electrode surface leading to a loss of 
activity and hence loss of detector response, which is a major reason for the use of EC 
detection remaining specialized field (201). 
ECD requires more care and thought in routine analysis than does the use of 
spectrophotometric detectors, principally because of the problems of electrode deactivation 
when operating at higher potentials (213).    
3.1.2. Electrochemistry 
In the solid state atoms in a metal are closely packed and the well-defined electron energy 
levels that are found in single atoms are not present. There is a continuum of levels and the 
available electrons fill the states from the lowest energy state upwards towards the highest 
level known as the Fermi level. Hence electrons in metals are relatively mobile and metals 
are generally good conductors of electricity. When a metal electrode is dipped into a solution 
of corresponding ions it will equilibrate according to Equation 3.1: 
                        Mn+ + ne- ↔ M                                                      Equation 3.1 
and the potential at the electrode will be a function of the equilibrium position for a reaction 
(201). The potential of an electrode is therefore the difference in the potential established 
between an electrode and a solution when the electrode is immersed in that solution.  
The empirical laws of electrolysis developed by Faraday relate the current of an 
electrochemical reaction and state that ‘the amount of substance deposited at each electrode 
of an electrolytic cell is directly proportional to the quantity of electricity that passes through 
the cell (214). When all the analyte in a solution is electrolysed at an electrode, the 
measurable response is directly related to the molar amount of analyte as shown by     
Equation 3.2: 
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                                                    Q = nFN                                                             Equation 3.2 
where Q = the total amount of charge transferred, 
 n = the number of electrons transferred or equivalents per mole, 
 F = Faraday’s constant, 
 N = the number of chemical equivalents of analyte present. 
Thus, Faraday’s constant is the product of the charge on an electron multiplied by 
Avogadro’s number. By definition, an electrical current (i), measured in amperes (A), is 
determined as coulombs per second as shown in Equation 3.3: 
                                                           i = 
dt
dN
nF
dt
dQ
−                                           Equation 3.3 
The equation shows that the rate at which electrons are moved across an electrode-solution 
interface, or the current, is directly related to the rate of the reaction occuring at the surface of 
the interface (201).  
There are some other sources of current in addition to Faradic current. This current is due to 
the reaction of the analyte. Such currents are collectively referred to as background current. 
This current is due to the electrolysis of impurities, the electrolyte, the electrode material and 
capacitive or charging current. The first three contributions are Faradic currents of the 
system, whereas the last is a property of the interface between the electrode and the solution. 
This interface behaves in a similar fashion to an electrical capacitor in that it can store charge 
and at a first approximation it obeys Equation 3.4: 
                                                                  Q = CV                                                 Equation 3.4 
  where Q = the charge stored 
  C = the capacitance in Farads 
  V = the potential difference across the interface 
An equation for the capacitance current (ic), can be obtained by differentiating Equation 3.4 
to generate Equation 3.5: 
                                                     ic = 
dt
dQ
= C (
dt
dV )                                    Equation 3.5 
The total current (ic) is the summation of all currents, including the Faradic currents for the 
analyte, the electrolyte and the electrode material in addition to the capacitive current. 
Currents other than those derived from the analyte are generally undesirable and their 
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magnitude should be minimized. The capacitive current can be eliminated by operating the 
electrode at a fixed potential and that is indicated by Equation 3.6: 
                                                                  (
dt
dV
= 0)                                              Equation 3.6 
An electrochemical reaction at a solid surface electrode over which a liquid stream is flowing 
as shown in Figure 3.4 is characterized by the following three separate and distinct stages; 
i) Diffusion of the electroactive analyte to the electrode surface, 
ii) Electron transfer as dictated by the electrochemical reaction, and 
iii) Diffusion of the reaction product(s) away from the electrode surface. 
 
 
 
 
 
        
 
 
 
 
 
Figure 3.4. Schematic diagram of processes occurring at an electrode when an analyte flows over a static 
electrode held at an appropriate voltage. 
The rate-limiting component in this reaction scheme is the slowest of the necessary steps and 
in ECD it is usually a mass transfer step (i.e. i or iii). Due to flow induced mixing, the analyte 
is always present at a constant concentration throughout the eluant flow except for a narrow 
layer of thickness δ that is located immediately above the electrode surface. Consumption of 
the analyte, either by oxidation or reduction, creates a concentration gradient as shown in 
Figure 3.5. The thickness of the diffusion layer above the electrode surface is therefore 
critical to the electrochemistry that occurs in the system (201). 
The diffusion equation or Fick’s second law describes the rate of change of the analyte 
concentration above any planar surface. This analyte flux is proportional to the diffusion 
coefficient of the analyte (D) and the flux therefore governs the limiting current (ilim) and is 
Liquid flow 
Oxidized analytes Reduced analytes 
Electrode surface 
Electron flow 
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directly proportional to the surface area of the electrode and concentration of the analyte, (C) 
and is inversely proportional to the thickness (δ) of the diffusion layer (Equation 3.7): 
                                                    ilim = δ
nFADC
                                                    Equation 3.7 
 
 
            Analyte Concentration 
 
 
 
 
 
Figure 3.5. Concentration profile for an analyte near an electrode surface with laminar dynamic flow 
Under hydrodynamic conditions the solution beyond the electrode surface consists of the 
Nernst diffusion layer (δ) just adjacent to the electrode surface, the laminar flow region and 
the turbulent flow region. Hydrodynamic voltammetry is the application of voltammetry 
under forced convection. The concentration gradient remains constant and current does not 
decay over time. The Nernst diffusion layer remains stagnant owing to the friction between 
the solution and the surface of the electrode. Immediately beyond the Nernst diffusion layer 
is a laminar flow region where the flow of a solution is parallel to the surface of the electrode. 
Any solution beyond the laminar flow region in a turbulent flow region as there is no specific 
direction to the flow at this point. The diffusion layer remains narrow and fixed under 
hydrodynamic conditions (215).   
 
3.1.3. Electrode material 
In order for an electrode to function in an HPLC application the working electrode material 
must: 
i) Be able to conduct electrical currents,  
ii) Operate at a low potential for the required EC measurement, 
E
l
e
c
t
r
o
d
e 
δ 
Distance from electrode surface 
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iii) Be mechanically robust and malleable to form suitable shapes, 
iv) Be able to be polished to a very smooth surface, 
v) Withstand a constant flow or jet of eluant (201). 
In addition the material must be inert with respect to the mobile phase composition, 
impurities in the eluant, other sample components and any reactive species that might be 
formed by electrolysis of the analyte. The most popular material used for solid electrodes is 
carbon, since it is a robust and not readily deactivated during routine use. Carbon is therefore 
particularly useful for oxidative electrochemistry applications (196-198).     
Carbon paste electrodes exhibit low background current at positive potentials and have 
excellent mechanical stability. However, carbon paste electrodes are incompatible with 
mobile phases containing more than 20 % v/v organic solvent and therefore glassy carbon 
electrodes have become more common than carbon paste electrodes in HPLC applications.  
Glassy carbon electrodes are compatible with organic solvents and are easier to use. In 
addition, glassy carbon typically exhibits lower background current than do carbon paste 
electrodes at negative potentials (189).  
More recently, diamond electrodes have been investigated due to their chemical stability, 
high electrical conductivity and to the large amplitude of their electroactive window in 
aqueous media (216). Mercury electrodes have also been used with ECD (217). However, 
due to poor mechanical stability of mercury alone it is often amalgamated with gold to form 
the electrode (218-221).  
Progressive loss of sensitivity due to contamination of the electrode surface with the products 
of an electrochemical reaction of both a solute and components of the mobile phase is 
unavoidable since ECD are based on an electrochemical reaction at the operating electrode(s) 
(222-223). 
 
 
3.2. METHOD DEVELOPMENT  
3.2.1. Experimental design and statistical analysis 
Successful HPLC method development depends on the selection of suitable operating 
variables in order to optimize a separation. Therefore, it is important to determine the 
operating variables or parameters at which the required response reaches an optimum level. 
The optimum level may be either a maximum or a minimum of a function of the design 
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parameters. One of the methods for determining optimum results for a specific set of 
experiments is response surface methodology (RSM). 
 
RSM is a collection of statistical and mathematical methods that have been used in modeling 
and analyzing engineering problems. The main objective is to optimize the response surface 
that is influenced by different process parameters. RSM also quantifies the relationships 
between controllable input parameters and the resultant response surfaces that have been 
generated (224).  It has been reported that RSM helps provide information about surface 
contours, and this can help visualize potential interactions between the parameters under 
investigation. In engineering applications RSM has been used to identify critical steps or 
parameters that optimize method development responses (225).  RSM approach was used to 
study factors that are important in HPLC method development in these studies. 
Therefore a RSM study begins with the definition of a problem concerning which response is 
to be measured and how it is to be measured. The experiment plan is then designed. The 
initial step was to construct a model using experimental data relating design parameters to 
measured responses. The next step involved identifying the most appropriate design 
parameters based on this model. The model itself provides only an approximation of the true 
relationship between the design parameters and resultant responses.  
If the model developed is appropriate, three-dimensional and contour graphs are plotted and 
interpreted. In brief, in an appropriate model the goodness of fit must be significant and the 
lack-of-fit insignificant. The coefficient of determination or R2 values should be as close to 1 
as possible and diagnostic plots should exhibit trends that are associated with an appropriate 
model with an excellent fit (226). The literature is replete with reports advocating the use of 
optimization techniques to improve analytical method development in the pharmaceutical 
sciences (227-229).   
In the context of this study a RSM approach was used sequentially to identify the optimal 
solution to an HPLC method development problem for CPT using ECD. The iterative 
procedure used in these studies included performing experiments in the region of the best 
known solution, fitting a response model to the experimental data and then optimizing the 
estimated response model.   
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The use of central composite design (CCD) methodologies has been successful in designing 
an experimental program to model the effects of different variables (230). Box-Behnken 
designs have been used for the optimization and modeling of many methods (231). Screening 
experiments such as fractional and Plackett-Burman designs have also been used to identify 
important factors that affect analytical method performance (232).    
CCD is an effective alternative to a factorial design approach. It was originally developed by 
Box and Wilson (233) and improved upon the method reported by Box and Hunter (234). 
CCD gives almost as much information as a three-level factorial design approach but requires 
fewer tests to be conducted than a full factorial design technique and has been shown to be 
sufficient to describe the majority of steady-state process responses (235 - 237).  
The number of tests required for a CCD approach includes the standard 2k factorial with its 
origin at the centre, 2k points fixed axially at a distance, say β, from the centre to generate 
quadratic terms in addition to replicate tests at the centre, where k is the number of variables. 
The axial points are chosen such that they allow rotatability (234), which ensures that the 
variance of model prediction is constant at all points equidistant from the centre of the 
experimental design. Replicate conduction of experiments at the centre of the design is most 
important, as they provide an independent estimate of the experimental error. For three 
variables, the recommended number of tests to be conducted at the centre is six (234). Hence 
the total number of tests required for three independently chosen variables (buffer pH, buffer 
molarity and organic solvent concentration) is 23 + (2 × 3) + 6 = 20 (234, 238). 
Once the desired range of values of the variables was defined, they were coded to lie at ± 1 
for the factorial points (Fact), 0 for the centre points (Centre) and ± β for the axial points 
(Axial) (239). The codes are calculated as functions of the range of interest of each factor as 
shown in Table 3.2. When the response data are generated, regression analysis is performed 
to determine the coefficients of the response model (β1, β2, …, βn),  standard errors of the 
estimation of the coefficients and the significance of the coefficient. In addition to the 
constant (β0) and error (ε) terms, the response model incorporates the linear, interaction and 
quadratic terms (238, 240). 
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Table 3.2. Presentation of 20 experiments (Exp 1 – 20) with coded values for factor levels for the CCD 
Experiment (run) Standard  Type Mobile phase 
pH 
Mobile phase 
molarity 
Organic solvent 
concentration 
 Run number  X1 X2 X3 
1 8 Fact -1 -1 -1 
2 9 Fact +1 -1 -1 
3 10 Fact -1 +1 -1 
4 4 Fact +1 +1 -1 
5 6 Fact -1 -1 +1 
6 1 Fact +1 -1 +1 
7 3 Fact -1 +1 +1 
8 11 Fact +1 +1 +1 
9 12 Centre 0 0 0 
10 5 Centre 0 0 0 
11 2 Centre 0 0 0 
12 7 Centre 0 0 0 
13 16 Axial -1.682 0 0 
14 15 Axial 1.682 0 0 
15 13 Axial 0 -1.682 0 
16 19 Axial 0 1.682 0 
17 14 Axial 0 0 -1.682 
18 20 Axial 0 0 1.682 
19 17 Centre 0 0 0 
20 18 Centre 0 0 0 
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The 20 experiments can be divided into three groups as follows; 
i. NF = 20 factorial experiments carried out at the corners of the cube, 
ii. Na = 2 x 3 axial experiments carried out on the axes at a distance of ± α from 
the centre of the design, 
iii. The distance a is calculated so as to obtain the rotatability and a three variable 
CCD is rotatable if  
α = ± (NF)1/ 4 = ± 1.6818 
iv. N0 experiments are performed at the centre of the experimental domain.  
In this case, the N0 value is fixed at 6 so as to obtain rotatability. The coefficients, i.e. the 
main effect (bi) and two-factor interactions (bij) can be estimated from the experimental 
results using Design Expert (Version 7.0.1, Stat-Ease Inc., Minneapolis, USA). 
The response model for the three variables under consideration is shown in Equation 3.8: 
                           Y = ( )εβ +o  + ∑
=
+
3
1i
iixβ ∑ ∑∑
= = +=
+
3
1
3
1
3
1
2
i i ij
jiijiii xxx ββ
          Equation 3.8
 
Y is the experimental response to be optimized, βo is a constant term, β1, β2 and β3 are co-
efficients of the linear terms, β11, β22 and β33 are co-efficients of the quadratic terms and β12, 
β13 and β23 are co-efficients of the interaction between the factors under investigation . 
3.2.2. Inspection of response surface plots 
In an analytical process where several independent variables (X1, X2 and X3) influence an 
experimental response, the observed response (Y) is a  function of the levels of the variables, 
Y = f (X1, X2, ….. Xn). The surface that is represented by this function is called the response 
surface, which is an n-dimensional surface in the (n +1) dimensionl space. In order to plot a 
useful graph, a 2D representation of a 3D or a contour graph can be drawn. When a response 
surface can be generated, inspection of the 2D surface or corresponding contour diagram 
allows for the assessment of the geometrical nature of the surface, eg. a stationary ridge, a 
rising ridge, a simple maximum, a simple minimum or a saddle point (minimax) (241, 242). 
A saddle point is defined as the stationary point of a surface response which presents the 
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maximum response for the levels of some variables and simultaneously the minimum 
response for the levels of other variables of the analytical system under investigation (243).  
The response surface can be inspected using Canonical analysis and / or Lagrange’s criteria 
(241). In this study Lagrange’s criterion was used to determine the nature of the response 
surfaces generated. Lagrange’s criterion is based on the calculation of the Hessian 
determinant of Y (241).   
If the quadratic function shows only one stationary point (X1, X2, X3), four situations are 
possible: 
i). There is no information: ∆2=0, 
ii). A relative maximum exists: ∆1<0; ∆2>0; ∆3<0,  
iii). A relative minimum exists: ∆1>0; ∆2>0; ∆3>0,  
iv). The presence of a saddle point exists: none of the above situations applies. 
where,  ∆3 is the Hessian determinant of the function H (X10, X20, X30), ∆2 and ∆1 are 
calculated using Equation 3.9: 
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Det (A) = 
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3.9 
A critical point of the function of several variables is a point at which the gradient of the 
function is either the zero vector 0 or is undefined. A first partial derivative will always 
vanish at the critical point if a function is made equal to 0. 
The traditional approach of changing one factor at a time in method development is not an 
efficient or economic strategy since it does not provide any information about the position of 
the optimum and can, at best, lead only to a local optimum of the system. The one-at-a-time 
optimization approach also ignores interactions between factors and results in the need to 
conduct numerous analytical experiments. With the rapid increase in costs of experiments, it 
is vitally important that the development and optimization of any analytical method is 
achieved with as few experiments and as low a cost as possible (244-245).    
In HPLC with ECD the composition, molarity and pH of the mobile phase are three critical 
factors that must be carefully selected in the early stages of method development.  
Bearing these considerations in mind, an experimental design was performed to establish the 
characteristics of the mobile phase that produced the best analytical signal, since these 
parameters are known to influence the shape and retention of the analytical response of both 
the experimental blank and samples of CPT. The factors studied were the percent 
composition of acetonitrile, the pH and the molarity of the buffer used in the mobile phase. 
When applying experimental design methodologies, it is advisable to keep the number of 
variables to a minimum in order to avoid the development of highly complex response 
models and large degrees of variability (246).  
A CCD approach was used to locate the optimum pH and molarity of buffer and organic 
solvent concentration conditions for the HPLC analysis of CPT by mapping the 
chromatographic response surface. This design is considered an efficient option in response 
surface methodology and an ideal alternative to the use of Box–Behnken designs (247-249). 
Furthermore CCD is a rotatable design and therefore, the factor levels are evenly spaced and 
readily coded for low, medium and high settings, as −1, 0 and +1.  
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The CCD approach combines a fractional factorial with incomplete block designs to avoid 
extreme vertices and to present an approximately rotatable design with three levels per factor. 
The three chromatographic factors and levels selected for evaluation and in which 
experimental optimization, in terms of overall response (Y), could be performed are shown in 
Table 3.3.  
Table 3.3 Experimental factors and levels used in the CDC 
Factor Level (-) Level (0) Level (+1) 
Buffer pH 2.7 3.0 3.3 
Buffer molarity (mM) 25 50 75 
Organic solvent concentration (v/v) 25 30 35 
The factors and ranges selected for consideration were based on previous univariate studies 
and chromatographic intuition. The composition of the mobile phase was defined as the 
volume of ACN with respect to total volume of solution. 
The data generated were analyzed using Design Expert (Version 7.0.1, Stat-Ease Inc., 
Minneapolis, USA) statistical software. The significance of the Factors was calculated by 
Fisher’s statistical test for Analysis of Variance (ANOVA) models that were estimated and 
run to their first order interaction terms. ANOVA for linear regression partitions the total 
variation of a sample into components. These components were then used to compute an F-
ratio that evaluates the effectiveness of the model. If the probability associated with the F-
ratio is low, the model is considered a better statistical fit for the data.  In these calculations 
the higher-order interaction terms were assumed not to contribute to the behaviour of the 
statistical model to any great extent.  
3.2.3. Voltammetry 
The technique for studying the relationship between applied potential and current generated is 
known as voltammetry. Voltammetry can be performed in a number of ways including Cyclic 
(250), Square-wave (251), Staircase (252), Linear-sweep (253), Fast cyclic (254), Stripping 
(255) and Hydrodynamic voltammetry (256).  
Most of the voltammetric procedures have been applied to research applications for HPLC 
with ECD, however they have rarely been used for the routine analysis of pharmaceuticals. 
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Therefore only the hydrodynamic voltammetric approach relevant to the current study is 
discussed. 
3.2.3.1. Hydrodynamic voltammetry 
Hydrodynamic voltammetry (HDV) is a steady state technique in which the electrode 
potential is altered prior to the injection of an analyte and the resultant current is plotted as a 
function of potential. An ideal HDV for a mobile phase and an oxidazable species are shown 
in Figure 3.6. The HDV of a compound commences at a potential where the compound is not 
electroactive and therefore no Faradic current is evident and proceeds through a region in 
which the current increases to a plateau, where the compound reaching the electrode surface 
is completely oxidized. The HDV is characterized by the half-wave potential, E1/2 , which is 
defined as the potential at which the current is one-half its limiting value. The HDV is used to 
select the operating potential for liquid chromatography-electrochemical detection (LCEC) 
experiments. Two considerations are of major importance. Firstly quantitative determinations 
are based on the extent to which the redox current from the analyte can be distinguished from 
the background current, therefore, operating at the lowest applied potential means that the 
background current will increase with an increase in the applied potential. Secondly, 
operating on the limiting current plateau means that the redox current from the analyte is 
independent of an applied potential.  
 
Figure 3.6. Typical hydrodynamic voltammograms used to study electrode kinetics 
Page | 57 
 
As can be seen in Figure 3.6 a voltammogram is a plot of current/ height or area response vs 
applied voltage (Eappl). From this arrangement the current / response generated will measure 
the rate at which a species can be brought to the surface of an electrode. 
Most analysts rely on HDV to determine operating potentials as cyclic voltammetry is not 
available to everyone. It is possible to construct a peak height –voltage curve through repeat 
injections of solutions of the analyte at different detector voltages.  
CPT has a thiol functional group that may act as a scavenger of free radicals in living systems 
(257, 258). Several methods have been reported for the determination of CPT, including 
HPLC (259-263), Capillary Zone Electrophoresis (CZE) (264), GC (265-266) and GC-MS 
(267). The thiol functional group of CPT can undergo electrochemical oxidation at the 
surface of various electrodes (268-270) and therefore coulometric detection was selected for 
use in these studies to develop a method for the determination of CPT in pharmaceutical 
dosage forms.  
CPT is a relatively unstable compound lacking appreciable UV absorbance. This makes assay 
of dosage forms very difficult (271), and the development of a simple ECD method may 
therefore play a major role in the analysis of CPT in dosage forms.    
None of the analytical methods makes use of coulometric detection. Electrochemical 
detectors are able to detect weak currents of <1 nA generated in oxidative or reductive 
reactions of interest (272).     
 
3.3. LITERATURE REVIEW 
 Several methods for the analysis of CPT have been published using a variety of analytical 
techniques (259-267) and include the assay of CPT in dosage forms (268-275). 
A summary of the information pertaining to the analysis of CPT is listed in Table 3.4. It is 
clear that derivatization is commonly used to facilitate the detection of CPT (259, 260, 262, 
265) and that the most commonly used organic modifiers include ACN and MEOH (259, 
263). ACN is preferred due to its low viscosity and polarity (273). Therefore, prior to 
commencing method development for the analysis of CPT it was decided that none of the 
conditions of published methods was suitable as derivatization formed part of most of the 
methods. Consequently it was decided to develop a HPLC-ECD method for the determination 
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of CPT. The parameters considered important were choice of column, internal standard, 
mobile phase composition and buffer due to the fact that CPT is a highly unstable drug in 
solution. 
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Table 3.4. Summary of the published analytical methods for the determination of CPT. 
Compound Sample Technique Mobile Phase /column conditions Internal Standard λ (nm) Reference 
CPT Plasma 
Tablets 
HPLC 0.2% trifluoroacetic acid (pH 1.8)] and (acetonitrile): 87:13 (A:B)- pBPB as the 
derivatization reagent 
sulphadimidine 263         259 
CPT Plasma HPLC n-hexane-2-propanol-methanol-acetic acid (68:15:15:2)- 2-bromo-2'-
acetonaphthone  
3,5 dinitro benzoic acid 246 260 
CPT Plasma HPLC acetonitrile-acetic acid 100%, pH 2.30 (42:58, v/v), N-(1-Pyrenyl)maleimide 
(NPM), 
N-Acetyl-L-cysteine 340 (ex) 389(em) 261 
CPT Plasma HPLC acetonitrile-water acetic acid, (225:270:5, v/v/v)- pBPB as the derivatization 
reagent 
Thiosalicylic acid  263 262 
CPT Plasma HPLC 72.5:27.5 mixture of 0.1% phosphoric acid and methanol  Ascorbic acid 220 263 
CPT Tablets 
Plasma 
CZE 100 Mm Borate at pH 9.0    264 
CPT Plasma GC n-hexane–2-propanol–methanol–acetic acid (68:15:15:2)- 2-bromo-2′-
acetonaphthone as a derivatization reagent 
3,5 dinitro benzoic acid 246 265 
CPT Plasma 
Urine 
GC The flow-rate of carrier gas (helium) was 30 ml/min. 
The temperature of the column was 195” and those of the injection port and ion 
source were 27W. The acceleratig voltage, ionization voltage and trap current 
were 3.5 kV, 70 eV and 60 PA, respectively-Flame ionization detector 
captopril-N-
hexylmaleimide adduct 
 266 
CPT PlasmaUrine GC-MS The flow-rate of carrier gas (helium) was 30 ml/min. 
The temperature of the column was 230 o C, and the injection port and ion source 
were kept at 270°C. The accelerating voltage, ionization voltage and trap current 
were 3.5 kV, 70 eV and 60 P-IA, respectively-derivatized with N-ethylmaleimide 
(NEM) 
S-benzylcaptopril  267 
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3.3.1. Column choice 
In all cases columns were allowed equilibrate for 30 minutes with the mobile phase delivered 
at a flow rate of 1.0ml/min prior to sample injection. Chromatographic system efficiency was 
established quantitatively by calculating the number of theoretical plates of the column using 
either Equation 3.12 or Equation 3.13:  
                                                 
2/1
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tN R=                      Equation 3.12  
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tN R           Equation 3.13  
where 
N     = the number of theoretical plates,  
 t R      = the retention time of a test peak, 
 W ½  = the peak width at half peak height, and 
 W     = the peak width at the baseline. 
Band shape (101) was characterized by determining the asymmetric factor or tailing factor 
and the peak asymmetry factor, As, was calculated using Equation 3.14: 
                                               As = 
A
B
                                                      Equation 3.14 
where 
     As     = the peak asymmetry factor, 
       A      = the width of the peak to the leading edge of the peak at 10% of the peak      
height  height, and                      
  B     = the width of the peak to the tailing edge of the peak at 10% of the peak   
height     height. 
Symmetrical peaks will have a value of As = 1.0 and usable columns produce peaks with As 
values of 0.90 to 1.3. Peak asymmetry was measured at 10% of the full peak height (276) and 
the calculation of column efficiency or number of theoretical plates, N, for these columns 
using equations 2.1 or 2.3 was based on the assumption that the peaks were Gaussian in 
nature (276, 277).  
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During the development of the analytical method an Inertsil® ODS 5 µm, 15 cm x 4.6 mm 
column (Metachem Technologies Inc. Torrance, CA, USA), Supelcosil® ODS 5 µm, 15 cm x 
4.6 mm column(Alltech, Deerfield, IL, USA) and Phenomenex® C18 Luna column,  150 mm 
x 2 mm, i.d. 5 µm (Phenomenex®, Torrace, CA, USA) were tested. The Phenomenex® 
column was determined to have a plate count number of approximately 6000 and both the 
Inertsil® and Supelcosil® columns had N values of < 4500. Peak resolution and retention 
times were different for all columns.   The peak tailing factor (PTF) calculated at 5% of full 
peak height for CPT (n = 3) was 1.17 and the % RSD was 1.91. The asymmetric factor 
measured at 10% of full peak height was 1.33 with a % RSD of 1.73. Therefore the peaks 
generated when using the Phenomenex® column were better in terms of peak shape than 
those obtained using the other two columns. The Phenomenex® column was selected as a 
column of choice for use in the analysis of CPT 
The effects of organic modifier, buffer molarity and mobile phase pH on the retention 
characteristics of CPT were also investigated.  
 
3.3.2. Internal standard 
Many analysts prefer the use of an internal standard for quantitative analyses (278-280). The 
purpose of including an internal standard is to minimise system and procedure variability 
thereby eliminating variations in precision as a function of sample volume (281). The use of 
an IS minimises error that may be introduced as a result of sample preparation, apparatus and 
analytical technique (282, 283). Lindholm et al (283) and Hammerstrand (284) reported that 
the use of an internal standard is one method used to improve the accuracy of an analytical 
method and it compensates for varying injection volumes and day to day instrumental 
changes, thereby promoting method accuracy.  
A known compound of fixed concentration is added to a sample of unknown concentration to 
produce a separate peak on the chromatogram. A plot of ratio of peak area/height to internal 
standard peak area/height versus concentration may be used to generate a calibration curve 
from which data from analysis of samples of unknown concentration can be determined by 
interpolation. The choice of an internal standard is most important and the peak must be 
completely resolved from all other peaks that may be present and the IS should elute near the 
peaks of interest. Other important considerations are that it must not react with other 
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components in the sample matrix and it must not be present in the original sample matrix 
(282).  
Enalapril maleate, flouxetine, diazepam, acyclovir, fluconazole, imipramine and CYC were 
considered possible choices for use as internal standards due to their structural similarity to 
CPT.  
CYC was selected as the internal standard of choice for this assay, based on chromatographic 
resolution, peak shape, run time and a hydrodynamic voltammogram or current-voltage (CV) 
curve at the working electrode similar to that generated for CPT.  
 
3.4. METHOD 
3.4.1. HPLC apparatus 
A modular HPLC system consisted of Waters Model M 6000A dual piston constant flow 
pump (Waters Associates, Milford, MA, USA), an automated Waters Intelligent Sample 
Processor Model 710B (Waters Associates, Milford, MA, USA.), a Model 5100A Coulochem 
dual electrode electrochemical detector with a Model 5010 analytical cell (Environmental 
Sciences Associates, Bedford, MA, USA) preceded by a carbon filter and a Spectra-Physics 
Integrator Model SP4290 (San Jose, California, USA) with attenuation set at 128. The mobile 
phase was constantly degassed using an in-line degasser Model ERC- 3000 (Erma Optical 
Works, Tokyo, Japan). The system included a Model 5020 guard cell (Environmental 
Sciences Associates) preceded by a carbon filter. The analytical column was 15 cm × 4.1 mm 
i.d. stainless-steel, packed with Phenomenex® Luna 5µm (C18) material (Phenomenex®, 
Torrance, CA, USA). This column was preceded by an Uptight Precolumn Kit (Upchurch 
Scientific, Oak Harbor, WA, USA) packed with glass beads. Both the guard and analytical 
columns were maintained at 22° C with a Model LC-22 temperature controller (Bioanalytical 
Systems, West Lafayette, IN, USA). 
 
3.4.2. Chemicals and Reagents 
All reagents were HPLC grade. CPT was akind donation from Protea Chemicals (Midrand, 
South Africa) and the internal standard (IS), cyclizine (CYC) were donated by Aspen 
Pharmacare (Port Elizabeth, South Africa). As there are no solvents designed specifically for 
ECD, HPLC far UV grade acetonitrile (ACN) was purchased from Microsep (Port Elizabeth, 
South Africa).  A Milli-Q Academic A10 water purification system (Millipore, Bedford, MA, 
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USA) that consisted of an Ion-ion®-exchange cartridge and a Quantum EX-ultrapore organex 
cartridge, which was fitted with a 0.22 µm Millipak® 40 sterile filters (Millipore®) prior to 
use was used in-house to further purify water that was used for the preparation of buffers. 
Potassium hydrogen phosphate, o-phosphoric acid (85%) and Sodium hydroxide pellets 
(analytical grade) were purchased from Merck Laboratories (Merck, Wadeville, South 
Africa).  
 
3.4.3. Preparation of stock solutions 
Standard stock solutions of CPT (100 µg/ml) and 500 µg/ml IS were prepared by accurately 
weighing approximately 10 mg and 50 mg of CPT and CYC, respectively on a top-loading 
analytical balance (Mettler Model AE163, Zurich, Switzerland) and then dissolving in 100 ml 
mobile phase. The stock solutions were sonicated for 5 minutes using a Branson B12 
sonicator (Shelton, CN, USA). The stock was diluted serially with mobile phase to produce 
solutions of CPT of 2, 3, 5, 10, 20, 30, 50 and 70 µg/ml concentrations. All working 
standards were prepared with the internal standard, CYC at a concentration of 20 µg/ml. The 
solutions were stable for one day when stored at room temperature. Stock and standard 
solutions were protected from light using aluminium foil and placed at a cool temperature. 
Samples were not refrigerated as ECD is sensitive to dissolved gases and cold solutions 
contain more gas. The solutions were prepared on a daily basis, stored in the dark at about   
10 ºC, and used on the day they were prepared. 
 
3.4.4. Preparation of buffers 
Phosphate buffer (50mM) was prepared by accurately pipetting 3.4 ml of o-phosphoric acid 
(85%) into a 1L volumetric flask and making up to volume with HPLC grade water. The pH 
of the buffer was adjusted with 0.1M NaOH to a pH of 3. 0.1M NaOH was prepared by 
dissolving exactly 4.0 g of sodium hydroxide pellets in a 1L volumetric flask containing 
HPLC grade water. The pH was measured with a Crison GLP 21 pH-meter (Crison 
Instruments, Johannesburg, South Africa) at ambient temperature prior to the addition of 
acetonitrile. This approach leads to some uncertainty as to the actual pH of the final mobile 
phase, as the addition of organic solvents may change the pH of the mobile phase. However, 
this is much less important than poor reproducibility of the mobile-phase pH (ie. when the pH 
is measured after addition of the organic solvent) (273).  
 
Page | 64 
 
3.4.5. Preparation of mobile phase 
The initial mobile phase was comprised of 50mM phosphate buffer: acetonitrile (70:30, v/v) 
adjusted to pH 3.0. The mobile phase was prepared daily, degassed by sonication and filtered 
using 0.45 µm Durapore® membrane HVLP filters (Millipore Corporation, Ireland) before 
use. The mobile phase was recycled during long term analysis.  
 
3.5. CHROMATOGRAPHIC CONDITIONS  
The mobile phase was 50 Mm phosphate buffer (pH 3)-acetonitrile (70:30, v/v) which had 
been degassed and filtered through a 0.22µm Millipore membrane filter (Durapore type 
HVLP, Millipore). The flow rate was 1.0 ml min -1 with a column back pressure of 120 atm. 
A full scan multi channel ESA Coulometric 5100A model detector was operated in the 
“oxidative-screen” mode with the upstream electrode (E1) set at +600 mV and the 
downstream or analytical electrode (E2) set at +950 mV, while the potential of the guard cell 
was set at +1050 mV. The detector gain was set at 300. E1 was set at a lower voltage than E2 
and was used as an oxidative screen to eliminate compounds that oxidize at lower potentials 
than the compounds of interest, thereby minimizing the potential for interference. In order to 
ensure selectivity the potential for E2 was set at or above the oxidation potential that had been 
established for the compounds of interest. The potential applied to the electrodes of the 
analytical and guard cells were optimized to ensure oxidative efficiency and to reduce 
background noise. The voltage applied to the guard cell allowed mobile phase oxidation 
without modification of the response generated by the electrodes of the analytical cell. The 
potentials used generated a peak area response with minimum background noise and were 
therefore used as the basis for quantitation. Under these conditions CPT and CYC eluted at 
approximately 3.5 min and 7.5 min, respectively.  
 
3.6. RESULTS AND DISCUSSION 
CPT undergoes oxidation to form a dimer, captopril disulfide (285, 286). Amide hydrolysis 
has also been reported in aqueous solution (286). Timmins (286) showed that oxidation of 
CPT predominates in the pH range 2 to 5.6 and becomes an increasingly important 
consideration as the pH increases. A buffer pH of 3.0 was selected as the starting pH for these 
studies. 
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In addition, the wavelength of maximum absorption for CPT is situated in the far ultraviolet 
range (200 nm) (287-288), in which a lot of interferences may occur, therefore ECD was 
selected as a potential method for detection of CPT. 
 
The HDV for the oxidation of CPT and CYC is shown in Figure 3.7. The limiting current 
plateau is reached at potentials > +1.1 V for CPT and at potentials > +1.0 V for CYC. 
Therefore a potential of + 0.9 V was selected for the detection of CPT. As can be seen, the 
response for CPT was sigmoid, and can be mathematically explained as a logistic function 
voltammogram. The porous graphite electrodes exhibited low residual current and noise. The 
background current was found to be < 14 nA for the electrode settings selected for use.  
 
 
 
 
 
 
 
Figure 3.7. HDV for the oxidation of CPT and CYC recorded in the potential range 0.0–1.2 V. 
The chosen chromatographic conditions revealed a good separation for CPT (50 µg/ml) and 
the internal standard, CYC (20 µg/ml) and no decomposition of CPT was observed during 
analysis. A typical chromatogram of the separation is shown in Figure 3.8. 
The capacity factor calculated for this separation was within accepted values of > 2 for the 
first peak and < 1 for the second peak. The tailing factor was within the limits established by 
the FDA (289) guidelines. Lastly the resolution between the two peaks of interest was more 
than adequate for the method. Therefore, this method can be applied to its intended purpose. 
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Figure 3.8. Typical HPLC chromatogram of CPT (50 µg/ml) in the presence of the I.S. CYC (20 
µg/ml)  
 
 
Two-dimensional contour plots and three-dimensional response plots are presented in   
Figures 3.9-3.14, which are very useful for studying the interaction effects of the factors on 
the responses. The retention time for CPT decreases as the ACN v/v % increases (Figure 3.9), 
when the molarity and pH of the buffer are constant. An increase in buffer molarity at 
constant pH and constant ACN v/v % results in decrease in the retention time of CPT (Figure 
3.10), most likely due to the increasing competition of buffer cations for silanol sites which 
are preferentially attached to the column. This effect is prominent when the buffer molarity is 
greater than 50 mM. 
 
Silica-based analytical columns show optimum stability and performance at pH values above 
2.0. The effect of mobile phase pH on the retention time of CPT was therefore investigated in 
a pH range of 2.8-3.2. As can be seen from the contour plots, an increase in buffer pH (Figure 
3.9, constant % v/v ACN) did not produce any change in retention time of CPT. However, the 
effect of buffer molarity and buffer pH on retention time showed a non-linear relationship 
(Figure 3.10). Figure 3.11 exhibits a nearly-linear relationship of buffer molarity and ACN 
concentration. Once more, the effect of % ACN is significant. An increase in buffer molarity 
slightly decreased the retention time of CPT as a consequence of increasing competition of 
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buffer cations for active silanol sites on the stationary phase. Since an increase of buffer 
molarity resulted in shorter retention times, a buffer of 50mM was chosen. The contour and 
response surface plots for the peak height ratios were not shown. Retention time was 
considered more critical in terms of sampling times during analysis.  Buffer molarity and 
ACN concentration were significant for the regression model assumed.  
 
 
 
Figure 3.9. Contour plots for the retention time as a function of   buffer pH (X-axis) and ACN concentration   
(Y-axis) of the mobile phase  
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Figure 3.10. Contour plots for the retention time as a function of   molarity (X-axis) and buffer pH (Y-axis) of 
the mobile phase  
 
 
 
Figure 3. 11. Contour plots for the retention time as a function of   molarity (X-axis) and ACN concentration 
(Y-axis) of the mobile phase. 
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Response surface plots (Figure 3.12-3.14) show the relationship between these factors even 
clearer.  
 
Figure 3.12. Response surface plots for the retention time as a function of   buffer pH (X-axis) and ACN 
concentration (Y-axis) of the mobile phase  
 
 
Figure 3.13. Response surface plots for the retention time as a function of   buffer molarity (X-axis) buffer pH  
(Y-axis) of the mobile phase  
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Figure 3.14. Response surface plots for the retention time as a function of   buffer molarity (X-axis) and ACN 
concentration (Y-axis) of the mobile phase  
 
The chosen model had seven main effects and nine first-order interactions. All experiments 
were performed in a randomized fashion in order to minimize the effects of uncontrolled 
factors that may introduce bias on the response. A classical second-degree model with a cubic 
experimental domain was postulated. The coefficients for the second-order polynomial model 
were estimated by least squares regression. The equation for the Y1 (retention time) factor is 
shown in Equation 3.15:  
 
Y1 = 3.54 – 0.077X1 + 0.011X2 – 0.26X3 – 0.061X1X2 – 0.061X1X3  
+0.054X2X3 –0.019X21+ 0.00704X22 + 0.076X23  
      Equation 3.15 
 
Retention time = 3.54 – 0.077Molarity + 0.011Buffer pH – 0.26ACN concentration
 
– 0.061 Molarity Buffer pH 
– 0.061Molarity: ACN concentration +0.054 Buffer pH: CAN concentration –0.019 Molarity2+ 0.00704 Buffer 
pH2 + 0.076 ACN Concentration2
 
 
The equation for Y2 (peak height ratio) is shown in Equation 3.16: 
Y2 = 0.53 + 0.11X1 - 0.10X2 + 0.52X3 + 0.67X1X2 – 0.35X1X3  
-0.49X2X3 +0.20X21+ 0.24X22 + 0.62X23  
      Equation 3.16 
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The solution of the quadratic models was obtained by matrix calculation with Cramer’s rule 
and Eigenvalue method (290) using determinants and Eigenfunctions, respectively to 
determine the optimized conditions of chromatography. The solutions that were obtained for 
Y1 (retention time) were:  
1. X1 (buffer molarity) = 51 mM,  
2. X2 (buffer pH) = 2.97  
3. X3 (% ACN) = 31.01 % v/v    
The optimized chromatographic conditions were then used for all future analytical studies. 
The typical chromatogram shown (Figure 3.8) in § 3.6 was obtained by using the set 
conditions.  
The model was validated by analysis of variance (ANOVA) using Design Expert software 
that had been used to develop the experimental plan for RSM. The test was performed and 
the Fisher F-ratio was calculated. This ratio was used to measure the significance of the 
model under investigation with respect to the variance of all the terms included in the error 
term at p = 0.05. In ANOVA analysis, a model that is significant is desired. The p-values 
listed in Table 3.5 reveal that for all responses, the cross product contribution of the model 
was not significant.  
The Model F-value of 2.81 (Table 3.5) implies there is a 7.00% chance that a "Model F-
Value" this large may  occur due to noise. The values of "Prob > F" less than 0.0500 indicate 
that the terms in a model are significant, however in this case Prob > F is greater than 0.05 
which indicates that the model is not significant. This means that the terms in the model do 
not have a significant effect on the response. Conversely, the effect of ACN concentration is 
significant. The lack of fit is said to be not significant and this is desirable as a model that fits 
the data is essential  in optimisation studies.  Since there are  a number of model terms that 
were not significant it was necessary to perform a model reduction step in order to improve 
the model.    
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Table 3.5. ANOVA Table for Response Surface Quadratic Model for retention time 
Source Sum of Squares df Mean 
Square 
F-value p-value 
Prob > F 
 
Block 0.035 1 0.035    
Model 1.20 9 0.13 2.81 0.0700 not significant 
 A-Buffer Molarity 0.080 1 0.080 1.69 0.2257  
     B-Buffer pH 1.618E-003 1 1.618E-003 0.034 0.8576  
      C-ACN Conc 0.94 1 0.94 19.82 0.0016 significant 
AB 0.030 1 0.030 0.63 0.4470  
AC 0.030 1 0.030 0.63 0.4470  
BC 0.023 1 0.023 0.49 0.5029  
A2 5.459E-003 1 5.459E-003 0.12 0.7423  
B2 7.148E-004 1 7.148E-004 0.015 0.9050  
C2 0.083 1 0.083 1.75 0.2183  
Residual 0.43 9 0.047    
Lack of Fit 0.43 5 0.085    
Pure Error 0.000 4 0.000    
Cor Total 1.66 19     
  
Std. Dev. 0.22 R2 0.7374 
Mean 3.58 Adj R2 0.4748 
C.V. % 6.09 Pred R2 -1.7108 
PRESS 4.41 Adeq Precision 6.680 
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A background elimination procedure was selected as the method of choice to reduce the 
number of insignificant terms and the resulting ANOVA table for the reduced quadratic 
model is shown in Table 3.6. The  results clearly indicate that the model is significant. To 
reduce a model in the presence of collinearity, backward selection is considered more robust 
than forward or stepwise selection. The significant model term is the concentation of  ACN 
and this is the only variable that significantly influences the retention time of CPT                
(p = 0.0016). The lack of fit is also not significant. The R2 value obtained is 0.5783. The 
predicted R2 value is in agreement with the adjusted R2 value. The adjusted R2 value is 
particularly useful when comparing models with different numbers of terms. This comparison 
is however performed in the background when model reduction is undertaken. Precision was 
used to compare the ranges of predicted values generated at the points of the experimental 
design to the average prediction error. Values for the ratio > 4 indicate adequate model 
discrimination. In this particular case the value was well above 4. 
A negative "Pred R-Squared" implies that the overall mean is a better predictor of  
response than the current model. The term “Adeq Precision" was used to measure the signal 
to noise ratio.  The ratio of 6.680 indicates an adequate signal and hence this model can be 
used to navigate the resultant design space. 
The "Model F-value" of 2.00 (Table 3.7) for peak area ratio implies that the model is not 
significant relative to the noise.  There is a 15.79 % chance that a "Model F-value" this large 
would  occur due to noise. Values of "Prob > F" less than 0.0500 indicate that the model 
terms are significant.  
In this case B2 and C2, the square of the buffer pH and ACN concentration, respectively, are 
significant model terms.Values greater than 0.1000 indicate that the model terms are not 
significant. If there were many insignificant model terms excluding  those required to support 
hierarchy, model reduction was to be performed  to improve the model.  
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Table 3.6. ANOVA Table for Response Surface Model for retention time (model reduction)  
Source Sum of Squares df Mean 
Square 
F-value p-value 
Prob> F 
 
Block 0.035 1 0.035 23.31 0.0002  
Model 0.94 1 0.94 23.31 0.0002 significant 
C-ACN Conc 0.94 1 0.94    
Residual 0.69 17 0.040    
Lack of Fit 0.69 13 0.053    
Pure Error 0.000 4 0.000    
Cor Total 1.66 19     
 
          
   
Std. Dev. 0.20 R2 0.5783 
Mean 3.58 Adj R2 0.5535 
C.V. % 5.61 Pred R2 0.3195 
PRESS 1.11 Adeq Precision 11.346 
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Table 3.7. ANOVA Table for Response Surface Quadratic Model for peak area/height ratio  
Source Sum of Squares df Mean 
Square 
F-value p-value 
Prob > F 
 
Block 424.64 1 424.64    
Model 4496.35 9 499.59 2.00 0.1579 not significant 
        A-Buffer Molarity 17.48 1 17.48 0.070 0.7972  
B-Buffer pH 840.02 1 840.02 3.37 0.0997  
C-ACN Conc 4.14 1 4.14 0.017 0.9004  
AB 361.75 1 361.75 1.45 0.2593  
AC 98.50 1 98.50 0.39 0.5454  
BC 192.55 1 192.55 0.77 0.4026  
A2 100.88 1 100.88 0.40 0.5407  
B2 1578.55 1 1578.55 6.33 0.0330 significant 
C2 1375.91 1 1375.91 5.51 0.0434 significant 
Residual 2245.89 9 249.54    
Lack of Fit 2242.63 5 448.53 551.47 < 0.0001  
Pure Error 3.25 4 0.81    
Cor Total 7166.87 19     
  
 
Std. Dev. 15.80 R2 0.6669 
Mean 19.08 Adj R2 0.3338 
C.V. % 82.79 Pred R2 -2.3726 
PRESS 22738.61 Adeq Precision 4.455 
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As noted earlier, the negative "Pred R-Squared"  implies that the overall mean is a better 
predictor of response than the current model.  A ratio of 4.455 indicates an adequate signal 
and that this model can be used to navigate the design space.  
The model that has been developed can be used to predict the retention time of CPT and peak 
ratio within the limits of the experiments. The normal probability plot of the residuals and the 
plot of the residuals versus the predicted response for both the retention time and peak areas 
are shown in Figures 3.15-3.18. 
Close inspection of Figures 3.15 and 3.17 reveals that the residuals generally fall on a straight 
line which indicates that the errors are normally distributed, thus supporting the fact that the 
model fits the data adequately. These plots are very important and are required to check the 
normality assumption in a fitted model. This will ensure that the model provides an adequate 
approximation to the optimization process. It is clear that there is no obvious pattern followed 
in the residual versus predicted response as shown in Figures 3.16 and 3.18. The plots reveal 
an almost equal scatter above and below the x-axis, implying that the proposed models are 
adequate and there is no reason to suspect any violation of the independence or constant 
variance assumption. 
 
Page | 77 
 
 
Figure 3.15. Normal probability plot of residual for retention time. 
 
Figure 3.16. Plot of residual vs. predicted response for retention time. 
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Figure 3.17. Normal probability plot of residual for ratio of peak areas. 
 
Figure 3.18. Plot of residual vs. predicted response for peak area ratios. 
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3.7. CONCLUSIONS 
Although there are HPLC methods available for measuring CPT in dosage forms (99, 100) 
there is no reported method in which coulometric ECD has been used. In particular the major 
advantage of this HPLC-ECD method over UV detection is that time-consuming pre-column 
derivatization procedures are eliminated. The advantages of this method over the use of 
derivatisation used for detection with UV lies in the improvement of the detectability, that is 
to say lower detection limits and or more sensitive response. Furthermore, the derivatives can 
be difficult to prepare and reaction products often need to be removed before analysis. Most 
of the derivatising agents are odorous and hazardous and the reaction conditions are 
frequently severe which could result in short life time of the guard and analytical columns 
used.  On the other hand, the disadvantages of derivatisation include possible interference by 
excess reagent and the formation of artifacts.  
 
HPLC-ECD is highly selective, sensitive and is simpler than the derivatization procedure 
which has the potential of some steps in the reaction not going to completion. Furthermore, 
sample components may be absorbed by the column resulting in low retector response.  
The ESA coulometric ECD offers several advantages in that close to 100 % of the analyte is 
oxidized in the flow-through porous graphite electrodes. In the coulometric mode, 
measurement is based on oxidation of the sulfhydryl functional group of CPT and there is 
minimal electrode oxidation, a longer electrode half-life and excellent baseline stability.   
The application of RSM in conjunction with CCD to modelling and optimizing the 
performance of an HPLC method has been discussed. CCD was used to design an 
experimental program for modeling the effects of mobile phase pH and molarity and 
concentration of ACN on the peak area ratio and retention time of CPT. Twenty experiments 
including centre points were conducted. Equations for the mathematical model were derived 
for both peak height ratio and retention time for CPT by using the experimental data and the 
statistical software package Design Expert 7.1.  
 
The predicted values from the model equations were found to be in good agreement with 
observed values, and to gain a better understanding of the three variables evaluated to achieve 
an optimal retention time, the models were presented as 3D response surface plots. The 
models allow for the confident prediction of performance by interpolation of data over the 
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range of information used to construct the response surface plots. The results reveal that the 
concentration of ACN has a significant effect on retention, whereas buffer molarity has a 
smaller effect. This study demonstrates that RSM and CCD can be applied to modeling and 
optimizing retention time and that it is an economical method that can be used to generate a 
maximum amount of information in a short period of time with a small number of 
experiments. 
The observed responses were close to the predicted values for the optimized method. It can 
be concluded that the characterization and optimization of the analysis was performed in a 
very short time and with a small number of experimental runs. It is clear that experimental 
design methodology is an economic approach for extracting the maximum amount of 
information and saves significant amounts of time in addition to the minimization of use of 
materials and personnel costs. 
The proposed method will be validated to determine whether it is suitable for routine analysis 
and content uniformity testing of CPT in tablets. This study has also presented significant 
progress in the identification of optimal HPLC operating conditions for the analysis of CPT. 
The experimental design was deemed suitable for the exploration of quadratic response 
surfaces and for the construction of second-order polynomial models, thus facilitating the 
optimization process with a limited number of experiments. For the three-level three-factorial 
CCD, 20 experiments were required. The resultant model contained quadratic terms 
explaining the non-linear nature of the responses observed, and which were adequately 
predicted. The experimental design approach resolved a two-factor interaction effect for the 
individual terms and allows a mid-level setting (0) for the combination of factors.  
The mobile phase and chromatographic conditions selected for the validation process from 
the model are ACN (30 %), pH = 3 and Buffer molarity (50 mM) and the analytical method 
validation process can now be conducted.  
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CHAPTER 4 
THE VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD WITH ELECTROCHEMICAL DETECTION FOR THE QUANTITATION 
OF CAPTOPRIL   
 
 
4.1. INTRODUCTION 
The validation of bioanalytical methods has been frequently discussed over the last decade at 
meetings in London and Arlington (291-292). The main issues discussed at these meetings 
related to the type and nature of certain aspects of analytical methods that must be 
investigated and reported in a validation protocol for bioanalytical methods in order to 
support an application for market authorisation with bioavailability, bioequivalence and 
pharmacokinetic studies in man and animals. As a consequence of these discussions, the US 
Food and Drug Administration (FDA) issued detailed recommendations for validation of 
bioanalytical methods (291, 293). The International Conference on Harmonisation (ICH) has 
also provided definitions relating to validation issues included in “analytical procedures” for 
the fields of bioanalytical methodology, pharmaceutical and biotechnological processes (291, 
294-296).  
Several protocols or guidelines validation of analytical methods have been produced and are 
recommended by bodies such as the ICH, the International Union of Pure and Applied 
Chemistry (IUPAC) and FDA (297-298). Prior to use in routine analysis an analytical method 
must first be validated in order to demonstrate its suitability for the intended purpose (299). 
Validation parameters such as selectivity, linearity, accuracy, precision and recovery must be 
evaluated in every analytical application. The limits of quantitation (LOQ) and detection 
(LOD), stability, and ruggedness/robustness should also be investigated, however these have 
been evaluated to a lesser extent in the past (299). The LOQ should be included in the 
construction of the calibration curve, whereas the LOD should not, as the former is a more 
stable parameter of an analytical method. Ruggedness and/or robustness tests have rarely 
been performed in many of methods reported in the literature (299, 300).  
The validation process is often viewed as a test of the acceptability of a specific method. 
However, the real goal of a validation process is to challenge the method and establish the 
limits of variability for the conditions needed to run the method, such that a desired outcome 
will be achieved (301). It is best to prioritize the components of any validation procedure and 
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typically, specificity, linearity, accuracy, and precision studies are needed initially, after 
which stability and ruggedness studies are conducted (301). 
 
The HPLC method with ECD detection for the analysis of CPT was validated in accordance 
with some validation procedures used for validation of pharmaceutical methods (302-307).  
 
4.2. VALIDATION 
4.2.1.  Calibration, linearity and range 
The linearity within a given range of an analytical procedure is an indication of the ability to 
obtain a measured response that is directly proportional to the concentration of analyte in the 
sample The linearity of the analytical method was established by fitting calibration curve data 
to a least squares linear regression model using GraphPad Prism (Version 5.01 for windows, 
GraphPad Software, San Diego, CA, USA) software.  
The linearity of an analytical method is used to show that test results are either directly, or by 
a well-defined mathematical transformation, proportional to the concentration of an analyte in 
samples within a given range (308).  
The linear correlation co-efficient is normally used as a measure of the linearity of a method 
and a value of ≥ 0.99 is usually required to consider a method to be linear in that range        
(299, 308). However a high value for the correlation co-efficient does not necessarily indicate 
a method has a linear standard curve (309).  
The range of an analytical method is the interval between upper and lower levels, inclusive of 
the limits of analyte that have been determined with a suitable level of precision, accuracy 
and linearity using the method as described (310).  
The CPT/CYC peak area of response was plotted against concentration of CPT to generate 
the calibration curve. The response of six standard solutions of 2.0, 5.0, 10.0, 30.0, 50.0 and 
70.0 µg/ml concentration were subject to regression analysis to establish the calibration 
equation and a correlation coefficient. The detector responses were found to be linear over 
the concentration range studied and the results are summarised in Table 4.1. 
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Table 4.1. Linearity data 
Parameter  
Concentration range (µg/ml) 2- 70 
Regression equation y = 0.0131x +  0.0275 
Correlation coefficient (R2) 0.978 
Standard error on estimation (Se) 0.058 
 
Prior to analysis of samples the analytical column was equilibrated for at least 30 min with 
the mobile phase. Each sample was analysed in replicates of five to verify the reproducibility 
of detector response at each concentration level.  
The calibration curve had a slope of 0.0131 and a y-intercept of 0.0275 with a correlation co-
efficient of 0.978. 
 
4.2.2. Precision 
The precision of an analytical method is the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple aliquots of a homogeneous 
sample (311-313). Reproducibility of results using different instruments, analysts, sample 
preparations, laboratories, data obtained on a single day or over multiple days may all 
constitute an assessment of the precision of an analytical method. In addition different levels 
of precision are often assessed as part of the method development process (311-313).  
The precision of a method is usually reported as the percent relative standard deviation       
(% RSD) of a set of responses. The precision can be subdivided into three categories, viz. 
repeatability (intra-day precision), intermediate precision (inter-day precision) and 
reproducibility (between laboratories precision) (314-317). 
Precision at two levels was established for this method, viz. repeatability and intermediate 
precision and the tolerance for RSD and relative error (RE) were set at ± 5% for these studies. 
 
4.2.2.1. Repeatability or intra-day precision 
The repeatability of a method is established when analysis is performed in one laboratory by 
a single analyst using the same equipment on the same day. Repeatability can be tested by 
analysis of a minimum of five determinations at three different concentrations, viz., low, 
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medium and high within the range of concentrations expected. However the ICH guidelines 
recommend that repeatability be assessed by analysis of three different concentrations in 
triplicate or by analysing samples at 100% of the test concentration six times (317, 318). 
The intra-day precision obtained following analysis of three different standard solutions of 
CPT with the internal standard, CYC, and the resultant data are summarized in Table 4.2. 
The results reveal that all RSD and RE values were less than 5% and are within the limits set 
in our laboratory, confirming that the method is repeatable. 
 
4.2.2.2. Intermediate precision 
Intermediate precision or inter-day variability is the agreement of complete measurements 
including standards when the same method is applied to samples many times within the same 
laboratory (313). Such determinations may include complete analysis of samples on different 
days with the same or different instruments by the same or different analysts, but would 
involve the preparation of multiple samples and standards. The inter-day variability of this 
method was assessed over three days at three low, medium and high concentrations of CPT 
standard in replicates of six. Sample preparation was conducted as detailed in § 3.3.3 and the 
results are given in Tables 4.3 and 4.4.  
The inter-day precision was found to be < 5%, confirming that the method is precise.  
 
4.2.2.3. Reproducibility 
The reproducibility of a method establishes the precision between laboratories and is often 
determined in collaborative studies or method transfer experiments (301). As all analysis 
were performed by the same analyst in one laboratory using the same equipment it was not 
necessary to establish the reproducibility of this method.  
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Table 4.2. Intra-assay precision and accuracy data for CPT analysis (n = 6) 
Concentration (µg/ml) Calculated Concentration Mean ± SD;                      % RSD % RE 
5.00 4.92 ± 0.15                                                            3.05 + 1.60 
10.00  9.89 ± 0.08                                                            0.81 +1.10 
30.11 28. 97 ± 1.12                                                          3.87 +3.79 
 
Table 4.3. Inter-day precision and accuracy data for CPT analysis 
Quality Control                   CPT  
 Day 1 (n = 6) Day 2 (n = 6) Day 3 (n = 6) 
Theoretical concentration (µg/ml) 5.00                  10.14                    30.01 5.07                  10.05              30.04 5.02                10.11           30.24 
Calculated concentration (µg/ml) 5.03                  10.04                    30.34 5.10                    9.80                29.67 5.01                9.73            30.04  
% RSD % 0.91                   0.65                      1.94 0.03                  0.06                  0.02 0.02                0.06             0.59 
% RE -0.60                 0.99                      -1.10 -0.59                2.49                  1.23 0.20                3.76             0.66  
% Relative error =/[(added-/found)/added] x/100 
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Table 4.4. Inter-day precision and accuracy data for CPT analysis 
Drug Average Theoretical Value (µg/ml) % RSD % RE 
CPT 5.05               9.86              30.02 0.99          1.62         0.40   -0.40          2.38             0.27 
 
Table 4.5. Accuracy test results of blinded samples 
Theoretical   concentration (µg/ml) Mean concentration determined (µg/ml) ± SD   % RSD % Bias 
5.02 5.07     ±   0.115 2.27 + 0.99 
9.98 10.06    ±    0.042 0.42 +0.80 
30.01 30.11    ±    0.156 0.52 +0.33 
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4.2.3. Accuracy and bias 
The accuracy of an analytical method is defined as the closeness of a measured value to the 
true value of an analyte in a sample (301, 313, 315, 316). A tolerance of 2% was set for % 
RSD for this parameter as this complies with the limits set by a number of pharmaceutical 
industries (317). The bias is an indication of the influence of an analyst on the performance of 
a method. Accuracy and bias were assessed by repeat measurement of three samples of 
different concentration. The FDA recommends that accuracy studies for drug products be 
performed at 80, 100 and 120% of the target concentration (318). The results of accuracy 
studies are listed in Table 4.5, and reveal that the greatest bias was 0.99%, indicating that no 
value for bias deviated by approximately more than 2.00% of the stated value. The RSD 
values for all but the 5.0 µg/ml sample were less than 5% and the Bias values (Table 4.5) 
were all less than 1% suggesting that the method was accurate.  
 
Accuracy was evaluated by injecting samples of three different concentrations equivalent to 
80, 100 and 120% of the intended content of active ingredient, following addition of a known 
amount of CPT to the sample and calculating the % recovery and RSD for each 
concentration.  
 
The % recovery achieved ranged between 95.65 and 99.88% (Table 4.6) and the 
corresponding % RSD values were well below 5 % indicating the method is accurate. 
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4.2.3.1. Assay 
In order to establish the applicability of the method for the analysis of CPT in dosage forms, 
five commercially available pharmaceutical products were purchased and subjected to 
analysis.  The products were: 
i. CaptoHexal® 50 
ii. MERCK-CAPTOPRIL 
iii. ZAPTO-50 
iv. Sandoz Captopril 50 
v. ADCO-CAPTOMAX 50 
The average drug content was found to be 95.65 and 99.88% of the labelled claim for all 
products tested. No interfering peaks were observed in the resultant chromatograms 
indicating that there was no interference from excipients used in the manufacture of the 
tablets. The results are shown in Table 4.6.   
Accuracy of the developed HPLC analytical method was evaluated by the recoveries of 
known amounts of CPT which were added to the drug product.  
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Table 4.6. Results of analysis of commercially available CPT products (n =5) 
Analyte  
Label claim  (50mg) 
Amount Added 
(mg) 
Found (mg / tablet) ± SD  Recovery (%) % RSD 
CaptoHEXAL® 50 
 
50.0 
 
49.56    ±    0.57 
 
99.76 
 
1.15 
MERCK-CAPTOPRIL 
 
50.0 
 
49.57    ±    1.03 
 
99.78 
 
2.08 
 
ZAPTO-50 
 
50.0 
 
49.41    ±    0.47 
 
99.46 
 
0.95 
 
Sandoz Captopril 50 
 
50.0 
 
49.44   ±    1.02 
 
99.51 
 
2.06 
 
ADCO-CAPTOMAX 50 
 
50.0 
 
49.03    ±    1.62 
 
98.69 
 
3.30 
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4.2.4. Limits of quantitation and detection 
Recent articles have included much discussion regarding the determination of the limits of 
quantitation (LOQ) and detection (LOD) values for an HPLC method (311, 320-321). Paino 
and Moore (322) described four techniques to establish the LOQ and LOD of analytical 
methods systems. The determination of the parameters may be achieved by establishing  
i) The lowest concentration for which the RSD ≤ 5%,  
ii) A plot of standard deviation versus concentration,  
iii) A confidence interval for the  best-fit line,   
iv) The signal-to-noise ratio. 
 
The LOQ is the lowest concentration of analyte that can be determined with an acceptable 
level of certainty. It should be established using an appropriate measurement standard or 
sample and it is usually the lowest calibration standard used to construct a calibration curve 
(excluding the blank).  
 
The LOD for an analyte is often determined by repeated analysis of a blank test sample and is 
the analyte concentration for which the response is equivalent to the mean response of blank 
plus three standard deviations. The value of the LOD is likely to be different for samples of 
different type and matrix (323). 
 
The LOQ is also defined as the lowest amount of analyte in a sample that can be 
quantitatively determined with precision and accuracy under the stated experimental 
conditions (313, 316) and the LOD is the lowest amount of an analyte in a sample that can be 
detected but not quantitated as an exact value (313, 316). For chromatographic analysis the 
LOD may be defined as that concentration that produces a peak height response three times 
greater than that of the baseline noise. Although various methods for estimating the LOD 
have been described, an experimental assessment provides the best measure of the operating 
limits of an analytical method and the associated instrumentation.  
 
The LOQ is generally determined by the analysis of samples of known concentration and the 
establishment of the minimum level at which the analyte can be quantitated with acceptable 
accuracy and precision. 
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The LOQ and LOD of the method developed for the analysis of CPT were established using a 
precision of ≤ 5.0%. By convention, the LOD was taken as 0.3 x LOQ (322). The LOQ was 
found to be 2.0µg/ml (%RSD = 2.27), and LOD based on this approach was 0.6 µg/ml.  
 
4.2.5. Specificity  
The specificity of an analytical method is a measure of the ability of that analytical method to 
produce a definite response to only the analyte of interest and no other compounds that may 
be present in a sample such as tablet excipients and related substances or impurities (323-
324). The specificity of the method was assessed by comparing chromatograms developed 
from the analysis of a standard solution of CPT only with that from a sample produced by 
dissolving commercially available tablets of CPT in mobile phase buffer. The peaks observed 
in the chromatograms (§ 3.6) were well resolved from the solvent front and there were no 
apparent peaks that interfered with that for CPT. Therefore, the method was considered 
specific.    
 
4.2.6.  Robustness 
As defined by the ICH, the robustness of an analytical procedure is reflected by the ability of 
the procedure to remain unaffected by small but deliberate changes in the method (302-303). 
A design of experiment (DOE) approach was used to test robustness of the method, and three 
factors were considered as described in §3.2.1. The experimental domain for the variables 
selected is described in §3.3.3. The experiments were performed in a randomized fashion so 
as to minimize the effects of uncontrolled factors that may introduce bias on the ultimate 
response of the method. The interpretation of results commences with the analysis of entire 
model equation rather than analysis of individual coefficients contained in that model. An 
examination of the ANOVA data (§ 3.6) and analysis of the response surface revealed that Y4 
is not robust for factor X1. Thus, precautionary measures need to be taken into account for 
this analytical procedure as small changes in ACN volume may result in a change in retention 
time and most likely the peak shape as well may be affected.  
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4.3.   CONCLUSIONS 
A reversed phase HPLC method for the in vitro quantitation of CPT has been validated and 
subsequently applied to the assessment of commercially available dosage forms. The linearity 
of the CPT/CYC peak area ratio versus CPT concentration was demonstrated and statistical 
analysis proved that the method is repeatable for the analysis of CPT as raw material drug 
and in pharmaceutical formulations, and that it is free from interference with the excipients. 
The method was also linear and precise and the chromatographic run time of 7.5 minutes 
permits the analysis of a large number of samples in a short period of time. This method can 
be recommended for the quality control of drug content in CPT tablets. 
The chromatographic conditions yield sharp, symmetrical peaks with a high degree of 
resolution. CPT and CYC were well separated and resolved and the retention times
 
were 
approximately 3.0 and 7.5 minutes, respectively.  
The HPLC method that has been developed is an improvement on the method presented in 
the USP monograph for CPT, where the use of UV is recommended; even though CPT lacks 
a strong chromophore. The validated HPLC-ECD method is simple, selective, accurate, 
precise, rapid, sensitive and linear. It is appropriate for the analysis of in vitro release and 
analysis of CPT in pharmaceutical dosage forms. 
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CHAPTER 5 
COMPATIBILITY STUDIES WITH CAPTOPRIL USING SPECTROSCOPIC AND 
THERMOANALYTICAL TECHNIQUES 
 
5.1. INTRODUCTION 
Recently published research has highlighted the application of differential scanning 
calorimetry (DSC), differential thermal analysis (DTA), thermogravimetric analysis (TGA) 
and infrared spectroscopy (IR) for the rapid evaluation of compatibility of active 
pharmaceutical ingredients (API) with pharmaceutical adjuncts or excipients (325-333). In 
general judgments relating to incompatibilities are expressed on the basis of the modifications 
observed in DSC thermograms of an API in the absence and presence of potential 
formulation excipients. Although some authors acknowledge that the presence of a physical 
or chemical interaction does not necessarily indicate an incompatibility, there is agreement 
that a change observed in a DSC thermogram is definite proof of an interaction between an 
API and an excipient (325).  Therefore as part of this study an investigation will be taken into 
whether a change in a DSC thermogram is sufficient to prove that an interaction will occur 
between CPT and several potential excipients. 
 
The solid-state properties of APIs are critical factors that must be considered in 
pharmaceutical formulation development. The most relevant properties can, and often do, 
affect the therapeutic efficacy, toxicity, bioavailability, pharmaceutical processing and 
stability (334, 335) of an API. Most API molecules can adopt a variety of conformations and 
therefore this may give rise to solid structures differing from each other in their lattice space 
type or molecular conformation, or simultaneously in both features when associated with 
specific interactions between polar groups that are often found in those molecules (334, 336). 
The interrelationship between the presence of an amorphous form and drug degradation has 
posed continuous challenges for the development of pharmaceutical formulations (334, 337). 
Thermal analytical techniques have been used for drug quality control whenever possible 
(334). The use of a combination of DSC and thermogravimetry/derivative thermogravimetry 
(TG/ DTG), scanning electron microscopy (SEM) and X-ray powder diffraction provides 
state-of-the-art techniques for assessing incompatibilities. These techniques offer a rapid 
means of properly interpreting potential instabilities. Furthermore their use offers the 
possibility of analytical quantification of such instabilities and incompatibilities (334, 338-
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340). The use of DSC in particular permits the acquisition of quantitative information relating 
to the purity of compounds, thereby making it possible not only to establish the melting 
temperature interval for any API, but also to study the phenomenon of polymorphism and 
associated characteristics of drug compounds. Thermogravimetric analysis is an analytical, 
quantitative, and comparative method that affords a formulation scientist the opportunity of 
producing rapid reproducible results. TGA can be used in drug quality control to improve a 
product through the determination of stability by isothermal and non-isothermal kinetic 
methods (334).  
 
Drug-excipient compatibility studies are essential in the development of different 
formulations and the results facilitate the selection of appropriate excipients and increase the 
probability of producing a stable solid oral dosage form. The use of thermoanalytical methods 
in drug excipient compatibility studies offers many advantages over the classical methods of 
incompatibility detection between an API and potential formulation excipients (341).   
Conventional methods of incompatibility detection involve adding an API to excipients and 
then subjecting the mixture to elevated levels of temperature and humidity for considerable 
periods of time. Following exposure to different climatic conditions the mixtures are 
analyzed using a variety of techniques such as HPLC and thin-layer chromatography (TLC) 
amongst others. This approach often takes several weeks or months to generate sufficient data 
to support or exclude any evidence of an incompatibility. In contrast one of the major 
advantages of using  thermoanalytical techniques is that they permit rapid assessment of 
samples and include  the possibility of detecting physical interactions such as the formation 
of eutectic mixtures or the adsorption of API to excipients or vice versa (341-343). 
 
Of all the available thermoanalytical techniques, DSC is the most important one used for 
drug-excipient compatibility studies. However, data generated using DSC are more readily 
interpreted when supported by thermogravimetry (TG). Therefore the application of DSC and 
TG in early formulation studies is common (341-347). 
 
The most frequently used DSC calibration standards are metals with melting temperatures 
and enthalpies measured using adiabatic calorimetry under near-equilibrium conditions. 
Indium is most often chosen as the standard material. However there are indications that it 
may be desirable to calibrate equipment using substances that have similar thermal properties 
to the compound under investigation (348-349). 
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In DSC heat effects associated with phase transitions and chemical reactions are monitored as 
a function of temperature.  Consequently the difference in heat flow to a sample and a 
reference, exposed at the same temperature, is recorded as a function of temperature. The 
reference is usually an inert material such as aluminium, tin, zinc or indium, or as in many 
cases, an empty aluminium pan. The temperature of both the sample and reference are 
increased at a constant rate and the resultant heat flow difference can be either positive or 
negative (350).  In this instance the rate of change of heat flow, or     is measured in         
mcal sec -1. If an endothermic process prevails, as is the case for most phase transitions, heat 
is absorbed and therefore the resultant heat flow to a sample is higher than that to the 
reference. Thus   ∆    is positive.  
 
The DSC consists of a sample holder and a reference holder as shown in Figure 5.1. Both 
holders are constructed of platinum to permit high temperature operation. Located under each 
holder is a resistance heater and temperature sensor. Current is applied to both heaters to 
increase the temperature of each holder at a specific rate. The difference in current applied to 
the holders, necessary to maintain the holders at the same temperature, is used to calculate  ∆   . An inert gas is purged over the samples to ensure that a reproducible and dry 
atmosphere is maintained for the duration of analysis. Maintenance of an atmosphere of N2 
prevents oxidation of samples at high temperatures, and the oxidation tendency is further 
reduced as the sample is sealed into small aluminium pans (350). The reference pan is usually 
an empty pan and cover. The pans hold up to about 10 mg of material.  
 
Mura et al (351) and Adeyeye and Brittain (352) have reported data from a number of 
investigations in which DSC was used as the primary tool for establishing the compatibility 
of various excipients for ketoprofen (352, 353) and picotamide (352, 354). In another study 
(355), the DSC investigations were combined with scanning electron and hot stage 
microscopy to generate the necessary data to better interpret the DSC thermograms. 
Misinterpretation of DSC results may lead to incorrect conclusions regarding 
incompatibilities. Supporting microscopic methods provide a means of infering genuine 
incompatibilities (352). 
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Figure 5.1. Differential Scanning Calorimeter 
 
The danger of false positive drug-excipient interactions is always present when only DSC 
analysis is used to detect such incompatibilities. Incorrect conclusions are more likely when 
investigators use 1:1 binary mixtures to determine whether interactions do occur. DSC 
screening of mixtures and formulations remains a viable method for the detection of reactions 
between API  and excipients, but any conclusion reached upon completion of those studies  
should be tested using a reference  method such as infra-red spectroscopy (352). 
 
It has been suggested (356, 357) that the use of thermal analysis in the development of solid 
dosage forms is invaluable. To determine the potential problem of mixing excipients with 
CPT, the decomposition process of CPT alone was initially investigated.  
 
The area under a DSC peak is directly proportional to the heat absorbed or produced by a 
thermal event, and the integration of the peak area yields the heat of reaction in units of 
joules/second. gram. An exothermic reaction is plotted as a positive thermal event whereas an 
endothermic reaction is usually displayed as a negative event. The calibration of DSC 
instruments is normally accomplished through the use of compounds having accurately 
known transition temperatures and heats of fusion. An extensive list of references is available 
for this purpose. Once a DSC system is properly calibrated, it is relatively simple to 
determine the melting point and enthalpy of fusion data of any compound on integration of its 
empirically determined endotherm profile and application of calibration parameters (358).    
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Despite the importance of drug-excipient compatibility testing, there is no universally 
accepted protocol available for this purpose. The term thermal analysis refers to a group of 
analytical techniques in which the physical properties of a substance and/or reaction products 
are measured as a function of temperature whilst the substance is subjected to a controlled 
exposure to temperature program. The use of DSC  involves the application of  a heating or  
cooling signal to a sample and to a reference (359, 360). This method has been extensively 
used for compatibility testing of excipients with a number of APIs (359, 361-366). However, 
caution needs to be exercised in the interpretation of DSC results since high temperatures are 
required (359).  
Another method commonly used to evaluate drug-excipient compatibility is isothermal stress 
testing (IST). IST involves storing the drug-excipient blends with or without moisture at high 
temperatures and determining the drug content (359, 363, 367, 368). DSC can be used in 
combination with IST to evaluate the compatibility of an API with excipients (359). 
Drug development is a complex, costly and time consuming process which makes concurrent 
use of many advanced technologies to ensure success. It is not all the compounds that are 
analyzed that will ultimately end up in a commercial formulation (369).  
 
A systematic study is presented in which, CPT alone and in 20: 80 w/w mixtures with five 
common excipients was investigated and the physicochemical characterization of the 
excipients tested was primarily inferred from published information.  
 
Due to the sensitivity of molecular vibrations to changes in chemical or physical 
environments, and the ease with which such properties can be studied, techniques such as 
vibrational spectroscopy can be extremely important in the study of API-excipient 
interactions. The energies characterising the fundamental vibrational modes of drug 
substances lie within the range of 400-4000 cm-1. This spectral region corresponds to what is 
referred to as the mid-IR electromagnetic radiation spectrum (370). Transitions in vibrational 
energy levels can therefore be observed directly through their absorbance in the IR region of 
a spectrum or indirectly though an elastic scattering of incident energy via the Raman Effect. 
IR absorption spectroscopy, especially when measured by means of Fourier Transform IR 
(FT-IR), has been shown to be a powerful technique for the physical characterization of 
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pharmaceutical solids. FT-IR spectra are often used to generate information relating to the 
chemical and physical reactions associated with API-excipient interactions (370).  
As part of an ongoing project on the development of extended release formulations of CPT, 
thermal analysis techniques were used to study CPT-excipient compatibility. The possible 
interaction between CPT and Eudragit® RS, Hydroxymethyl cellulose (Methocel K4M and 
Methocel K100M), Microcrystalline cellulose and citric acid were studied. Each of the 
identified substances was subjected to spectroscopic and thermoanalytical characterization 
and mixtures, after appropriate conditioning, were analysed by DSC, TGA and IR in an 
attempt to correlate changes in DSC analyses with chemical modification of an API in a 
blend. 
 
5.2. METHOD 
Homogeneous, binary mixtures of CPT with different excipients were prepared by 
mechanical shaking and stored in 25 ml glass-stoppered erlenmeyer flasks at 25 ˚C. Physical 
mixtures of CPT-excipient were weighed in appropriate amounts and were then stored in 4 ml 
flat-bottomed amber glass vials. The physical mixtures were prepared using a CPT: excipient 
(mass ratio) of 20:80. This composition was selected to study the influence of the relative 
amount of an excipient, in a rather wide range, using reasonable quantities of the API of 
interest. The binary mixtures were stored in the dark because CPT is light sensitive. TGA and 
DSC studies were performed in a dry nitrogen atmosphere in aluminium and/ or platinum 
crucibles with an empty platinum crucible as a reference. CPT was used without any further 
treatment.  
 
5.2.1. Differential scanning calorimetry 
DSC curves were generated using a Model DSC-7 Perkin Elmer Differential Scanning 
Calorimeter (Perkin Elmer AG, USA). Pyris Software for Windows was used to analyse the 
data that were generated. The DSC was connected to a computer via a TAC 7/ DX Thermal 
Analysis Instrument Controller. Approximately 2 mg of CPT powder was hermetically sealed 
into an aluminium pan. The sample was placed directly onto a micro hot stage DSC. 
Individual samples (CPT and excipients) as well as physical mixtures of API and selected 
excipients (all passed through 60-mesh sieve) were weighed directly into aluminium DSC 
pans. The temperature of the DSC microscopy cell was monitored using a central processor. 
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The heating rate of the DSC assembly was controlled at 10 ˚C/min over a temperature range 
of 25-500 ˚C. Each spectrum generated during the heating process was performed using 10 
scans with a resolution of 4 per cm. An inert atmosphere was maintained during testing by 
passing nitrogen gas through the system at a rate of 25 ml/min.  The DSC cell was calibrated 
with Indium (mp 156.6 C; ∆Hfus = 28.54 J/g) (371) prior to commencing studies with CPT. 
Measurements were performed in replicates of three. The heating rate of 10 ˚C/min is a useful 
compromise, in DSC, between speed of analysis and detecting any heating-rate dependent 
phenomena. In our laboratory we have an interest in developing methods for estimating 
thermal properties of compounds and much of our effort is now directed towards developing 
models for estimating enthalpies of compounds. 
 
5.2.2. Thermogravimetric analysis 
TG experiments were conducted using a Model TGA 7 Perkin Elmer Thermogravimetric 
Analyzer (Norwalk, CT, USA) fitted with a platinum sample holder. Pyris Software was used 
for data analysis.  Approximately 4 mg of dry CPT and/or the binary mixtures to be tested 
were placed in platinum crucibles. Measurements were performed in N2 atmosphere at a flow 
rate of 25 ml/min, a heating rate of 10 ˚C /min, and a temperature range of 25 ˚C to 600 ˚C. 
All sample measurements were repeated on at least three separate occasions.  
 
5.2.3. Infrared spectroscopy 
Infrared spectra were recorded using a Bruker Model Verter 70 (Beaconsfield, Bucks, 
England) apparatus and the KBr disc method in a wavelength range of 4000-400 cm-1. The 
powder samples were compressed with KBR using a stainless steel die and a Karver press. 
The microscopic spectrophotometer was equipped with a TENSOR 27 RT-Dlatgs detector. 
The velocity of the scanner was set at 10 kHz. Sample combinations showing promise in 
terms of compatibility were collected successively from the actual analysis area by a mapping 
process. An automated X-Y stage for mapping was used to obtain complete IR spectra from 
all samples at 18 mm intervals. The samples for analysis were prepared by grinding 2 mg of 
dry  powder and CPT  together with 200 mg of KBr to  produce a fine powder of  particle 
size < 5 µm. The mixture was then compressed to form a clear disk. 
 
5.3. EXCIPIENTS 
All materials used in these studies are generally recognised as safe (GRAS) and appear in the 
FDA Indicative Ingredients Guide for general inclusion in oral formulations (372).  
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5.3.1. Hydroxypropyl methylcellulose (HPMC) 
Use of HPMC in sustained-release dosage forms has been widely reported (373-380). HPMC 
is a non-ionic, non-toxic polymer that has been used in the manufacture of topical 
formulations and for tablet production. It has been used as a binder and as a sustained release 
matrix-forming excipient (372). HPMC is available in a variety of different grades depending 
on the degree of substitution and average molecular weight of the polymer components (372). 
HPMC polymer controlled release dosage forms have been classified as swelling controlled 
release systems (373-380). Generally in swelling controlled matrix technologies two major 
factors control the rate of release of API from the matrix: the rate of aqueous medium 
infiltration into the matrix and the subsequent relaxation of polymer resulting in either 
hydration or gelation and swelling of the polymer, respectively. As a consequence of these 
simultaneous processes, two fronts are evident in a matrix: the swelling front (glassy 
polymer/gel interface) and an eroding front (gel/medium interface). The distance between the 
two fronts depends on the relative rates at which the swelling and eroding fronts move in 
relation to each other, and is termed the diffusion layer (376).    
5.3.2. Microcrystalline cellulose (MCC) 
MCC is purified, partially depolymerized cellulose occuring as a white, odourless, tasteless, 
crystalline powder composed of particles of different sizes and in grades that have different 
properties and applications (372). MCC is widely used as a diluent in oral tablet and capsule 
formulations prepared by either wet-granulation or direct-compression processes (372). 
Emcocel® 90M has a mean particle size of 91 µm and a moisture content of < 5%. The angle 
of repose of MCC is 34.4° and the material has bulk and tapped densities of 0.29g/cm3 and 
0.35g/cm3 respectively (372).  
 
5.3.3. Citric acid 
Citric acid occurs as colourless translucent crystals, or as a white crystalline powder powder. 
It is odourless and has a strong acidic taste. The crystal structure of citric acid is monoclinic 
holohedral. It is widely used in pharmaceutical formulations and food products to adjust the 
pH of solutions. It has also been used experimentally to adjust the pH of tablet matrices in 
enteric coated formulations for colon specific delivery (381-382). 
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5.3.4. Methacrylic acid copolymers 
Methacrylic acid copolymer is a fully polymerized copolymer of methacrylic acid and an 
acrylic or methacrylic ester. Three types of polymers, type A (Eudragit® L, Eudragit® RL), 
type B (Eudragit® S, Eudragit® RS) and type C (Eudragit® L 30 D-55) have been defined. 
They vary in methacrylic acid ester content and solution viscosity (372). Typically, the 
molecular mass of these polymers is in excess of 100 000 mass units. Solid polymers may be 
used in direct compression tableting in proportions of 10-50% (372). 
Acrylic copolymers have been used as enteric and sustained release coatings in the 
pharmaceutical field due to their biological safety (383-387). Eudragit® RS is composed of 
poly (ethylacrylate-methylmethacrylate-trimethylammonioethyl methacrylate chloride) 
copolymers with ratios of 1:2:0.1. Eudragit® RS is a water-insoluble polymer and the drug 
delivery systems prepared from this material  show pH-independent sustained-release due to 
the presence of quaternary ammonium functional groups (384, 388-389). Some studies on 
drug release from monolithic Eudragit® RS films have been performed considering the glass 
transition temperatures (Tg) of the material. 
Eudragit ®RS is comprised of approximately 5% of quartenary ammonium functional groups. 
The ammonium groups are present as salts that impart pH-independent permeability to the 
polymers (372). The acrylate-methacrylate polymers have been used in the preparation of 
matrix tablets for oral sustained release in tablet coating and in microencapsulation 
applications for API (390). 
 
5.4. RESULTS AND DISCUSSION 
Excipients have been classified according to the function they perform in a formulation, 
although many excipients fulfil multiple roles in a dosage form. The excipients selected for 
use have been described in § 5.3. The commercial names, functions and suppliers of the 
excipients are summarized in Table 5.1. The excipients were selected for their potential 
suitability to develop sustained-release microcapsules of CPT. The polymers were selected 
for use due to their matrix forming capacity, hydrophilicity and swelling characteristics.  
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Table 5.1. Excipients used in the compatibility studies 
Excipient Commercial name Function Supplier 
Captopril  Active Aspen Pharmacare 
Hydroxypropylmethylcellulose  Methocel® Binder Colorcon 
Microcrystalline cellulose 101 Avicel®  Diluent FMC 
Acrylic copolymer Eudragit® RS Binder Rohm Pharma 
Citric Acid  pH adjuster BDH Chemicals 
 
Representative DSC scans of CPT and CPT-excipient mixtures are shown in Figures 5.2-5.8. 
The figures reveal typical heat flow curves vs temperature for DSC studies. The melting point 
endotherm for CPT occurred between 104 and 106 ºC for all mixtures studied except where 
citric acid was evaluated.  
 
The DSC trace of pure CPT (Figure 5.2) showed a sharp endotherm peak, Tpeak, at 105.8 ºC 
and Tonset = 103 ºC. The characteristic peak pattern generated indicates the presence of the 
alpha form of CPT, which undergoes thermal transition at 106 ºC, this being the melting 
endotherm of alpha form. Furthermore the ∆Hfus for the alpha form (25J/g) was in agreement 
with a previously reportedly value (391). In the majority of cases, the melting endotherm of 
CPT was unaffected in all mixtures tested, with only slight changes observed in terms of peak 
broadening or shifting towards lower or higher temperatures. It has been reported that the 
quantity of material used, especially in API-excipient mixtures, can affects peak shape and 
enthalpy in such studies (392-393). The minor changes in the melting endotherm of CPT may 
be due to the mixing of CPT and the excipient which lowers the purity of each component in 
the mixture and therefore does not necessarily indicate that a potential incompatibility       
(394) exists. To determine whether an incompatibility exists, additional techniques were 
used. 
 
Interactions in a sample are observed in DSC thermograms as changes in thermal events, 
such as the appearance of new peaks or a change in melting point of a material. However, 
broadening of peaks leading to changes in area, peak onset and changes in peak temperature 
occurred with CPT and citric acid. This may indicate an incompatibility for this binary 
mixture. 
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Figure 5.2. A typical DSC plot for CPT determined at a heating rate of 10˚ C/min. 
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Figure 5.3. A typical DSC plot for CPT: HPMC K15M generated at a heating rate of 10˚ C/min. 
 
Page | 105 
 
 
Figure 5.4. A typical DSC plot for CPT: HPMC K100M generated at a heating rate of 10˚ C/min. 
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Figure 5.5. A typical DSC plot for CPT: MCC generated at a heating rate of 10˚ C/min. 
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Figure 5.6. A typical DSC plot for CPT: Eudragit RS generated at a heating rate of 10˚ C/min. 
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Figure 5.7. A typical DSC plot for CPT: citric acid generated at a heating rate of 10˚ C/min. 
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Figure 5.8. A typical DSC plot for mixture (all excipients) generated at a heating rate of 10˚ C/min. 
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TG generated (Figure 5.9) in a nitrogen atmosphere reveals that CPT is stable up to a 
temperature of approximately 175 °C and then it decomposes in three distinct steps, the first 
of which corresponds to approximately 61% loss in mass and which is indicative of the 
elimination or degradation of the cyano (C-N) bond present in CPT. The second 
decomposition process commences at about 230°C and is complete by 360 °C with a 
maximum rate of decomposition occurring at 340°C. The last residue is completely degraded 
at about 450 and 520 °C. 
 
The shapes of all TGA curves for CPT were similar or nearly identical to that observed     in 
Figure 5.9. The TG and DTG data reveal a DTG curve roughly symmetrical around the peak 
temperature of about 245 ˚C. CPT decomposes over the temperature range of 150-550 °C 
when tested alone. 
The first noticeable blip on the DTG curve occurs at the peak temperature for melting of 
CPT. The main decomposition of CPT occurs in the region of the first peak and no residue 
was observed at the end of the TG experiment.  
The shape of the other TGA curves revealed a 3-step degradation process for all samples 
examined, indicating a high degree of stability. MCC is thermally stable up to 300 °C and 
HPMC up to 200 °C (Figures 5.9-5.15)  
The compatibility of CPT and excipients was further investigated using IR spectroscopy.  
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 Figure 5.9. A typical TGA plot generated for CPT at a heating rate of 10˚ C/min. 
 
 
Figure 5.10. A typical TGA plot for CPT:  HPMC K15 M generated at a heating rate of 10˚ C/min. 
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Figure 5.11. A typical TGA plot for CPT: HPMC K100 M generated at a heating rate of 10˚ C/min. 
 
 
 
 
Figure 5.12. A typical TGA plot for CPT: MCC generated at a heating rate of 10˚ C/min. 
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Figure 5.13. A typical TGA plot for CPT: Eudragit RS generated at a heating rate of 10˚ C/min. 
 
 
 
Figure 5.14. A typical TGA plot for CPT: citric acid generated at a heating rate of 10˚ C/min. 
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Figure 5.15. A typical TGA plot for mixture (all excipients used) generated at a heating rate of 10˚ C/min. 
Infrared studies revealed that all characteristic bands for CPT were present in all spectra 
generated. These are shown in Figures 5.16-5.20 and 5.22. No new bands or shifts in the 
characteristic peaks were evident in mixtures except in the case of CPT and citric acid 
(Figure 5.21).  
 
The IR spectrum of CPT shows an OH-stretching mode of water at 3600 cm-1, together with a 
broad band assigned to the aromatic CH at 3110-3000 cm-1. The IR bands for CPT are shown 
in Table 5.2. 
 
In DSC, samples are subjected to a higher temperature range. Therefore the identification of 
potential interactions under ambient conditions may not be a simple exercise. The results of 
this study provide factual support for the suggestion that degradation reactions, 
transformations or interactions occurring at these elevated temperatures may not necessarily 
take place at room temperature.  Therefore DSC alone should not be used for studying 
CPT/excipient interactions. The data generated in DSC studies should be supported by FT-IR 
studies.   
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Table 5.2. IR assignments for CPT 
Assignment (cm-1) Functional group 
800 C-C stretching vibration 
1300 C-H/CH3  bending /symmetric vibration 
1450 C-H stretching / asymmetric vibration 
1500 Amide band 
1580 C=C stretching 
1750 -COOH (C=O stretching)  
2600 -SH stretching vibration 
2800 CH3 stretching vibration (symmetric) 
3000 CH3 and CH2 stretching (asymmetric) 
3400 -OH functional group 
 
The FT-IR spectra of pure CPT shown in Figure 5.16 depicts triple characteristic bands for 
CPT occurring at 1300 cm-1, 1450 cm-1 and 1580 cm-1, due to C-H bending/ symmetric CH3 
bending vibrations, C-H stretching and C=C stretching,  respectively. Another sharp band is 
observed at 800 cm-1, due to C-C stretching vibrations. The carbonyl vibration band –COOH 
(C=O stretching) and amide band were demonstrated in the 1750 cm-1 and 1500 cm-1 regions 
respectively. The FT-IR spectra of CPT loaded polymer combinations and diluent (Eudragit®, 
HPMC and MCC) are shown in Figure 5.22. They indicate that the characteristic bands of 
CPT, and also of the polymers, are evident in all figures except where citric acid was tested. 
It can therefore be concluded that there is a possibility of interaction between CPT and citric 
acid. A slight shift in the bands was observed in the combination formulation, which may be 
due to the reduction in purity of the substances being tested. The spectrum of CPT, and a 
physical mixture with Eudragit®, HPMC and MCC (Figure 5.22) is of lower intensity than 
that observed for pure CPT.  
 
The plots of the FT-IR spectra of CPT within the ranges 4000-400 cm-1 are shown in    Figure 
5.16. The peaks at 3000 and 2900 cm-1 were assigned to the asymmetric CH3 and CH2 
stretching vibration and the peak at 2800 cm-1 was due to the symmetric CH3 stretching 
mode. The peak at 2600 cm-1 corresponded to the -SH stretching vibration (393-394). 
The spectra shown in Figure 5.21 also confirmed the results observed in DSC studies 
undertaken with CPT and citric acid. In particular the lack of a peak in the IR spectrum is 
indicative of a potential incompatibility / interaction for this combination. The IR spectrum 
shown in Figure 5.21 reveals the presence of a small peak at 1700 cm-1, which was of 
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decreased intensity, and there were no other peaks present. Since the carboxylic acid group of 
CPT is an H-donor, and the carboxylate anion of citric acid is likely to be a stronger H-bond 
receptor, the carboxylic acid and CO- function of acid may form and might change the bond 
distance of C-O in the COO- functional group of the citric acid, resulting in a shift in the 
peaks observed.  The presence of water may also cause a shift at 3400 cm-1. Although the IR 
spectral region from 3100-3700 cm-1 corresponds to -OH functional group of many 
molecules, the –OH functional group of water molecules also makes an important 
contribution to this area and it may not be possible  to differentiate the two sources of the 
shift.  The moisture-related IR spectra were compared to TGA events. Mixing is most likely 
to cause or enhance adsorption of water from the atmosphere and the water content may  
induce an interaction of CPT with citric acid through H-bonds, leading to the formation of 
unique interactions that can be observed using IR.  
 
Similarly the endotherm peak observed in the DSC thermogram shifted to 103 ºC for the 
CPT/citric acid mixture. The enthalpy of the endothermic peak was very different from that 
observed when CPT was evaluated alone. This shift might have been caused by a change in 
the crystallinity of CPT. Citric acid is a tri-carboxylic acid and acts as an Arrhenius acid since  
it  is a source of H30+ ions when dissolved in water and can act as a Bronsted acid by 
donating a proton to H2O. Therefore the peaks for the OH- and C=O stretch vibration of CPT 
were shifted to 3430 cm-1. This suggests that there may be an H-bonding interaction between 
the OH- and COOH functional groups of CPT. 
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Figure 5.16. Infrared spectrum for CPT powder  
 
Figure 5.17. Infrared spectrum of a CPT: HPMC K 15M binary mixture  
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Figure 5.18. Infrared spectrum of a binary mixture of CPT and HPMC K 100 M (1:.4)   
 
Figure 5.19. Infrared spectrum of a binary mixture of CPT: MCC (1:4)   
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Figure 5.20. Infrared spectrum of a binary mixture of CPT: Eudragit® RS (1:4)  
 
Figure 5.21. Infrared spectrum of a binary mixture of a CPT: citric acid (1:4) 
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Figure 5.22. Infrared spectrum of physical mixture (all excipients used)  
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5.5. CONCLUSION 
To certify the quality of a pharmaceutical formulation, parameters such as the interaction 
between a selected API and excipients to be used in formulation development studies must be 
analysed. The data generated in these studies clearly indicate the excipients that are 
compatible with CPT. The presence of moisture associated with potential excipients to be 
used appears to be an important factor to consider during formulation development.  
 
Based on the results from preliminary screening, all excipients except citric acid can be 
selected for formulation development. Infrared spectroscopic studies confirmed the 
possibility of an interaction between CPT and citric acid. Consequently the model blends 
tested showed compatibility with CPT for the excipients evaluated. From the well-
constructed compatibility studies, Eudragit® RS, Methocel K4M, Methocel K100M and 
Microcrystalline cellulose were finally selected for formulation development.  
 
The DSC data generated for the different binary mixtures evaluated indicate that the 
characteristic endothermic peak of about 105.6 ºC for CPT was present in all thermograms. 
This study demonstrates that DSC and FT-IR techniques are sensitive techniques that can 
reveal potential interactions, whereas TG is not as sensitive to the presence of interactions. 
TG analysis revealed that the thermal degradation of CPT takes place in two major and one 
minor step, and that these occur in different temperature ranges. Each thermal degradation 
stage produced an endothermic peak on the DSC thermogram and where the melting 
transition was also observed immediately prior to the commencement of decomposition. It is 
clear that quality control is vital due to the potential for changes in the final product arising 
from variations in the production process.  
 
The quantitative effects on a DSC response for an API may only be revealed in excipient-rich 
mixtures. The effects appear to be related to moisture-driven mechanisms of the interaction. 
Consequently these findings may be valuable in defining the composition of the ultimate 
commercial formulation and the necessary precautions for storing the product. While DSC is 
a well known technique for the characterization of pharmaceutical and polymeric materials, it 
has certain limitations in practical use. It is unable to provide insight into the changes to 
thermal events or reactions at a molecular level. Therefore it is essential to combine DSC 
with other techniques to permit greater understanding of any changes in the materials to be 
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used. The understanding of polymorphic changes in pharmaceuticals is of great concern and 
DSC allows one to correlate structural changes with thermal events.  
 
The theoretical basis of DSC/TGA and IR experiments has been examined. The overall goal 
to provide practical guidelines for compatibility studies of CPT with several excipients has 
been achieved. Thermal analysis has been applied to both a research objective and to 
practical problem solving in formulation development. 
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CHAPTER SIX 
THE EVALUATION OF CAPTOPRIL MICROCAPSULES MANUFACTURED 
USING AN OIL IN OIL SOLVENT EVAPORATION TECHNIQUE 
 
6.1. INTRODUCTION 
Microencapsulation is a technique used to manufacture tiny packaged materials that are 
referred to as microcapsules. Microcapsules are minute heterogeneous containers that are 
normally spherical if enclosing a fluid or are roughly the shape of a particle if manufactured 
to contain a solid (395).  This technique has been used in a diverse range of fields and there 
has been widespread interest in microencapsulation technologies. The first industrial product 
manufactured using microencapsulation was introduced by Green and Schleicher in the 1950s 
(395-396) to produce dye containing pressure-sensitive microcapsules for the manufacture of 
carbonless copying paper (395, 397). The microcapsules were manufactured by complex 
coacervation of gelatin and gum Arabic (395, 396). Carbonless copy paper is still produced 
commercially and is one of the most significant products developed that utilizes 
microencapsulation technology. The technologies developed for carbonless copy paper have 
led to the development of a variety of microcapsule products. Since the 1950s, many products 
of this type have appeared on the market, for pharmaceutical, cosmetic, agricultural chemical, 
food additive, coating, printing ink, adhesive, catalyst and dye applications (395, 398-400) 
and various others are under development  (395, 401-403). The main reasons for the use of 
microencapsulation technologies are shown in Table 6.1. 
 
The term “capsule” is used when an encapsulated substance, referred to as the core, active 
agent, fill material, internal phase, nucleus or payload, is surrounded by a membrane referred 
to as an encapsulant, carrier, coating, membrane, shell or wall. The term “sphere” or just 
“particle” is used when the core material is dispersed or dissolved in a carrier substance. 
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Table 6.1. Reasons for microencapsulation of API (404) 
1. Controlled release of drugs,  
2. Protection of encapsulated materials against oxidation or 
deactivation due to    reaction in the environment,  
3. Masking of odour and/or taste,  
4. Isolation of materials from undesirable phenomena,  
5. Easy handling of powder-like materials 
 
Particles or capsules between 1 and 5000 µm are called microparticles or microcapsules. 
Those below 1 µm are usually referred to as nanocapsules or nanoparticles, whereas those 
above 5000 µm in size are called macrocapsules or coated particles. Microcapsules are 
usually spherical, but they may also be irregular in shape and the differences between 
microparticles and some typical geometries are illustrated in Figure 6.1(405).  
 
 
 
a. Multinuclear microcapsule                                                         b.     Continuous core/shell microcapsule 
Figure 6.1. Schematic diagram of two types of microcapsules 
 
When taken orally, microcapsules spread uniformly in the gastrointestinal tract, thereby 
avoiding exposure of the mucosal tissues to high concentrations of API and ensuring more 
reproducible drug absorption. The risk of dose dumping is also lower than with single-unit 
dosage forms (406, 407).  
The application and potential for use of microencapsulation is shown by the large number of 
methods that have been reported (404-408). The most important methods that have been 
described have been classified in a variety of ways (408). An appropriate classification, based 
on of the method of manufacture (409) is shown in Table 6.2. 
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Table 6.2. Main methods of microencapsulation 
1. Phase separation 
2. Interfacial and/or in situ polymerization, 
3. Spray drying and spray congealing, 
4. Solvent evaporation 
5. Coating. 
 
The solvent evaporation approach was used as the preferred method of encapsulation of CPT 
for these studies as it requires ambient temperatures and mild emulsification techniques.  
 
6.1.1. Solvent evaporation  
The solvent evaporation process entails dissolving a polymer in a suitable water-immiscible 
solvent, and dispersing or dissolving the API in that polymer solution. The resultant solution 
or dispersion is then emulsified to form an aqueous continuous phase in which discrete 
droplets can be observed. For the microcapsules to form, the organic solvent must diffuse into 
the aqueous phase and then evaporate at the water/air interface. As the solvent evaporates the 
microcapsules harden and free-flowing microspheres can be harvested after filtration and 
drying.  
 
The solvent evaporation method has been used extensively to manufacture microspheres 
(410-412). Several variables can influence the properties of microcapsules.  These include 
solubility of the API, internal morphology, solvent type, diffusion rate, temperature, polymer 
composition, viscosity and drug loading (413-414). The effectiveness of the solvent 
evaporation method producing microspheres is dependent on the successful entrapment of an 
API within the particles. This process has been observed to be highly successful for drugs 
that are either insoluble or poorly soluble in aqueous media which is usually the continuous 
phase in these manufacturing procedures (415-416). 
 
Recent advances in the solvent evaporation technique have allowed successful entrapment of 
highly water-soluble drugs (417-419) and other thiol-containing drugs (420). Consequently 
the microencapsulation of CPT, a freely soluble drug, was attempted. 
 
Various methods can be used to manufacture microcapsules by solvent evaporation (421-
424). Efficient drug encapsulation is dependent on the hydrophilicity or hydrophobicity of the 
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API to be encapsualted (424). For insoluble or poorly water-soluble drugs the oil-in-water 
(o/w) method is frequently used. This method is the simplest and other methods are derived 
by modification of this approach. The method comprises of four major steps, summarized in 
Table 6.3: 
  
Table 6.3. Steps used in the microencapsulation process (424)    
1. Dissolution of the hydrophobic drug in an organic solvent containing the polymer, 
2. Emulsification of the dispersed phase, in an aqueous continuous phase, 
3. Extraction of the solvent from the dispersed phase by the continuous phase, solvent 
evaporation, transformation of droplets of dispersed phase into solid particles, and,  
4. Recovery and drying of microspheres to eliminate residual solvent  
 
The conventional o/w solvent evaporation techniques cannot be used for water-soluble drugs 
as they result in low loading efficiency due to partitioning of the drug into the continuous 
phase (426). To reduce drug partitioning into the continuous phase and to enhance drug 
loading, o/o solvent evaporation methods have been proposed (427). 
 
Four alternate methods are available, which make it possible to encapsulate hydrophilic drugs 
(428). The methods are presented in Table 6.4.  
 
Table 6.4. Alternate methods to encapsulate hydrophilic drugs (428)    
1. A w/o/w double emulsion method in which an aqueous solution of hydrophilic drug is 
emulsified with an organic phase (w/o) emulsion that is dispersed in a second aqueous solution 
forming a second emulsion or w/o/w double emulsion, 
2. An o/w co-solvent method that is used when a drug is not soluble in the main organic solvent 
a co-solvent is necessary to dissolve the drug, 
3. An o/w dispersion method in which the drug is dispersed as a solid powder in a solution of 
polymer and organic solvent, 
4. An o/o non-aqueous solvent evaporation method in which the aqueous phase is replaced by an 
oil such as mineral oil for example. 
 
O’ Donnell and McGinity (429) studied the main factors influencing the properties of 
microcapsules. These are summarized in Figure 6.2. 
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The dispersed phase contains the polymer and the encapsulation solvent. The polymer must 
be biodegradable or biocompatible and the choice of polymer is dependent on the desired 
drug release rate. If one polymer cannot produce the appropriate drug release profile a 
combination of polymers can be used.  
 
For the successful application of solvent evaporation, a suitable solvent to dissolve /disperse 
the polymer must meet the criteria shown in Table 6.5: 
 
 
Dispersed phase 
• Polymer  
• Solvent  
• Drug 
 
Continuous phase 
• Surfactant 
• antifoam 
• Viscosity of dispersed phase 
• Volume fraction of dispered 
phase to continous phase 
• Quantity of drug in dispered 
phase 
• Concentration of surfactant 
• Geometry of reactor 
• Agitation rate 
• Temperature 
• pressure 
• Average size 
• Size distribution 
• Surface 
morphology 
• Inner structure 
• Drug 
encapsulation 
• efficiency 
Properties of 
microcapsules 
Parameters 
Properties of materials 
Operating conditions 
Figure 6.2. Schematic representation of the factors influencing the properties of microcapsules (adapted from (429)) 
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Table 6.5. Criteria used to select solvents for microencapsulation (429) 
1. Solvent must dissolve the polymer, 
2. Solvent must be poorly soluble/miscible with the continuous phase, 
3. Solvent must have high volatility and low boiling point,  
4. Solvent must not be toxic. 
 
In certain cases, other excipients such as cosolvent and porosity generators are added to the 
dispersed phase (429-432). A porosity generator, (porosigen or porogen), is used to create 
pores within microspheres to increase the degradation rate(s) of polymers and improve or 
modulate drug release rates (433).  
 
The continuous phase is the second phase in a solvent evaporation process and is larger in 
volume than the dispersed phase and usually also contains a surfactant. Liquid paraffin is 
normally used as the continuous phase in an o/o solvent evaporation procedure. The 
surfactant used in this work was span 80. Span 80 is a tensioactive agent that enhances the 
stabilization of an emulsion by reducing the surface tension of a continuous phase and 
avoiding coalescence and agglomeration of dispersed droplets.  
 
In addition to the use of a surfactant an antifoaming agent may be added so that when 
manufacturing procedures involving aggressive agitation are used, foaming does not interfere 
with the formation of microspheres. After the physico-chemical properties of materials, 
agitation is one of the most important parameters that can be used for controlling the size of 
microcapsules ultimately produced. Many other factors, linked in some way to agitation, also 
influence the size of microspheres. These include the geometry and diameter of the reactor 
and the number and position of impellers (429, 434-435).  
 
It has been observed that encapsulation efficiencies  increase to a maximum, as the quantity 
of API used increases, and then decrease  as further drug is added (429, 434) 
 
The rate of solvent evaporation can be accelerated by increasing the temperature of the 
continuous phase (429, 436, 437), but there are several drawbacks to using elevated 
temperatures. These include a decrease in the total mass recovered and decreased 
encapsulation efficiencies resulting in coarse surface morphology (429, 438). Moreover, the 
chosen temperature should not denature the API or reach the boiling point of the solvent used 
in the production process.  
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6.1.2 Aim 
The aim of this work was to prepare CPT microcapsules with a controlled drug release profile 
suitable for oral administration of the compound.  
 
6.2. EXPERIMENTAL 
6.2.1. Materials 
CPT powder was donated by Protea Chemicals (Midrand, South Africa). Citric acid 
monohydrate was purchased from Aspen Pharmacare (Port Elizabeth, South Africa). 
Hydroxypropyl methylcellulose (Methocel K100M and K15M) were donated by Colocon® 
Ltd (Dartford, Kent, UK). Microcrystalline cellulose (Avicel 101) was purchased from FMC 
(Philadelphia, USA).  Eudragit RS was donated by Rohm Pharma (GmbH, Darmstadt, 
Germany). Span 80 was purchased from Aldrich (Germany). Liquid paraffin was supplied by 
ADC Laboratories (Durban, South Africa).  Acetone AR was purchased from Associated 
Chemical Enterprises (Southdale, South Africa).  n-Hexane was acquired from Burdick and 
Jackson Laboratories (Michigan, USA). Dimethyl polysiloxane was purchased from Sigma-
Aldrich (Kempton Park, South Africa). All chemicals were used without any further 
purification. 
 
6.2.2. Method 
To avoid degradation of CPT all experiments were conducted under ‘safe light’. All 
experimental work was performed on a laboratory scale. RSM in conjunction with a CCD 
was used to establish the number of experiments to be conducted and to interpret the resultant 
data. 
 
6.2.2.1. Experimental design for response surface methodology 
RSM is a rapid technique for deriving a functional relationship between a set of input 
variables and experimental responses. By use of RSM the number of experiments necessary 
for establishing a mathematical trend in the experimental design region is reduced and the 
determination of an optimum level of experimental factors required to produce a specific 
response is readily achieved (224, 225, 230, 439-441).  
RSM was used to investigate the impact of four variables on microcapsule formation. These 
variables were Eudragit® RS (X1), Methocel® K15M (X2), Methocel® K100M (X3) and 
homogenization speed (X4). The variation and level and composition of the variables were 
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designed using a CCD approach. The variables and their concentration ranges are listed in 
Table 6.6. 
The variables were coded to facilitate multiple regression analysis. Thirty experimental 
settings were generated with 4 factors at 3 levels using the principals of RSM with the aid of 
Design Expert 7.1 software. The quadratic polynomial regression model that was assumed for 
predicting Y1 (percent yield), Y2 (microcapsule size), Y3 (encapsulation efficiency), Y4 
(percent drug release) and the Y5 (Hausner ratio) variables are listed as the Y fitted depicted in 
Equation 6.1. 
                           Y = ( )εβ +ok  + ∑
=
+
4
1i
ikixβ ∑ ∑∑
= = +=
+
4
1
3
1
4
1
2
i i ij
jikijikji xxx ββ
      Equation 6.1       
 
 
 where,  Y is a response viz., Y1, Y2, Y3, Y4 and Y5.  ( )εβ +ko
,
kiβ , kjiβ and kijβ  are the 
constant(s) of the  coefficients of intercept, linear, quadratic and interaction terms, 
respectively. ix and jx are uncoded independent variables of concentration of Eudragit® RS, 
Methocel® K100M, Methocel® K15M and homogenizing speed.  
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Table 6.6. Coded levels for independent variables used in experimental design 
Factor Coded Xi Coded level   ∆a 
 
  -1 0 +1  
Eudragit RS (g) X1 1.5 2.0 2.5 0.5 
K100M (g) X2 0.25 0.50 0.75 0.25 
K15M (g) X3 0.25 0.50 0.75 0.25 
Homogenizing speed (rpm, x 1000) X4 1.0 1.5 2.0 0.5 
 
6.2.2.2. Manufacture of microcapsules 
To produce microcapsules the emulsification and solvent evaporation technique used was 
based on the method reported by Khamanga et al (442).  The representative formulations 
used to manufacture microspheres are listed in Table 6.7 and a schematic representation of 
the manufacturing procedure is shown in Figure 6.3. In all the 30 formulations, 0.75 g of CPT 
and 0.5 g of MCC were incorporated. MCC was used as a filler and binder in the 
formulations. 
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Table 6.7. Formulations used to manufacture microcapsules 
RUN  Eudragit® RS Methocel® K100M Methocel® K15M  Homogenizing speed  
   g  g  g  rpm (1000)  
1  2.0  0.50  0.50  1.5  
2  2.0  0.75  0.25  1.5  
3  1.5  0.50  0.50  1.0  
4  2.5  0.50  0.50  2.0 
5  2.0  0.50  0.25  2.0  
6  2.0  0.50  0.50  1.5  
7  2.0  0.75  0.75  1.5  
8  1.5  0.50  0.50  1.0  
9  2.0  0.25  0.75  1.5  
10  2.0  0.50  0.50 1.5  
11  1.5  0.75  0.50  1.5  
12  2.0  0.50  0.50  1.5  
13  2.0  0.25  0.50  2.0  
14  2.5  0.25  0.50  1.5  
15  2.0  0.50  0.50  1.5  
16  2.5  0.50  0.75  1.5  
17  1.5  0.50  0.75  1.5  
18  2.0  0.25  0.50  1.0  
19  2.5  0.75  0.50  1.5  
20  2.0  0.50 0.75  1.0  
21  2.0  0.50  0.75  2.0  
22  2.0  0.75  0.50  1.0  
23  2.5  0.50  0.25  1.5  
24  2.0  0.50  0.25  1.0  
25  1.5  0.25  0.50  1.5  
26  2.5  0.50  0.50  1.0  
27  2.0  0.25  0.25  1.5  
28  1.5  0.50  0.25  1.5  
29  2.0  0.75  0.50  2.0  
30  2.0  0.75  0.50  2.0  
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(A) 
Figure 6.3. Basic steps (A and B) of microencapsulation using a solvent evaporation process (adapted from 
442)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            (B) 
Different amounts of polymer and MCC was dispersed in 20 ml of acetone. An accurately 
weighed quantity of CPT was dispersed in this solution. Light liquid paraffin (120 ml) 
containing 1% v/v span 80 and 0.1% v/v dimethyl polysiloxane was then placed in a 400 ml 
beaker and agitated with a three-blade propeller of 50 mm diameter, linked to a homogenizer 
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fitted with a four-blade “butterfly” propeller having a diameter of 50 mm (Virtis Company, 
New York, USA) to produce an homogenous oily phase. The acetone solution was then 
poured into the oily continuous phase. The system was maintained at 20˚ C to ensure 
evaporation of the acetone. Processing variables such as the amount of liquid paraffin and 
volume of acetone solution were maintained constant for all batches produced. After 2 h,     
10 ml of n-hexane (non-solvent) was added to harden the microcapsules and stirring was 
continued for a further 5 h. The hardened microcapsules were collected using a Buchner 
funnel and were washed 2-3 times with 50 ml n-hexane to remove any residual liquid 
paraffin. The microcapsules were then dried at room temperature for 24 h. All batches were 
prepared in triplicate and the dried microspheres were stored in well-closed containers. All 
experiments in which evaluation of microcapsules was undertaken were performed the next 
day. 
 
The yield (443) of microcapsules was calculated using Equation 6.2. 
 
%  ! =  "#$% #& '(#)*+	(	 #,"'%	 - +	#(	'". "#$%  -  X 100                             Equation 6.2 
 
6.2.2.3. Determination of the mean particle size 
Particle size distribution was performed using a sieve stack. The nest of sieves was vibrated 
at 200 rpm for at least 15 minutes, or until no change in the weight of each fraction was 
observed. The amount of particles retained on each sieve was weighed and the cumulative 
mass retained on each sieve was calculated. The particle size distribution for all formulations 
was determined and the mean particle size of the microcapsules calculated. 
 
6.2.2.4. Flowability 
The importance of the flowability of a powder in the production of pharmaceutical dosage 
forms is well-documented (50). Numerous methods for measuring powder flow have been 
developed and are largely based on an empirical understanding of the flow process.  
 
6.2.2.4.1. Angle of repose 
The stationary angle of repose (θ) for each batch was determined by placing 5 g of the 
microcapsules in a funnel (with orifice and base diameters of 1.0 and 5 .0 cm, respectively). 
The tip of the orifice of the funnel was set at a fixed height (30 cm) from the horizontal 
Page | 135 
 
surface and the microcapsules were allowed to flow only under the force of gravity. The 
angle of repose (445) was calculated using Equation 6.3. 
                                                      /01 2 = +(                                                   Equation 6.3 
where 
   h = height of the pile of microcapsules, and  
               r = the radius of the base of the cone. 
All measurements were performed in triplicate and an average for three determinations was 
reported. 
 
6.2.2.4.2. Bulk and tapped bulk density  
The bulk and tapped bulk density of the microparticles were calculated using the initial and 
final volumes for a fixed mass of the microcapsules before and after tapping. Tapping was 
carried out by hand. The weighed microcapsules were carefully poured into a measuring 
cylinder and the initial volume was recorded. The cylinder was then tapped for 5 minutes, or 
until no measurable change in the final volume was observed. The cylinder was lightly 
tapped to dislodge residual powders from the wall of the measuring cylinder. Each sample 
was poured slowly and gently into a 10 ml measuring cylinder and tapped for 100, 200, 300, 
400, 500, 600, 700, 800, 900 and 1000 times. The percent compressibility of the 
microcapsules was expressed using Carr’s index (CI) (446) as shown in Equation 6.4. This 
equation describes the relationship between the degree of volume reduction of the powder 
column and the pressure applied to the powder.  
                                               34  56789:6;<=>6789 ? @ 100                                                Equation 6.4 
                              34
                                                
Where 34           = Carr’s compressibility index, "*          tapped density, and ,$.C        = bulk density. 
 
6.2.2.4.3.  Hausner ratio 
The Hausner ratio is the ratio of the tapped density and bulk density (447) and was calculated 
using Equation 6.5:  
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                                                   DE = 67899FG6;<=>                                                             Equation 6.5 
 where                      "**	   = tapped density                         ,$.C    = bulk density 
  
6.2.2.4.4.  Kawakita analysis 
Microcapsules have also been analyzed using Athy-Heckel, Kawakita and Cooper-Eaten 
analysis (448). The Kawakita equation is shown in Equation 6.6. 
                                                                
%H  = %" + I",                                        Equation 6.6 
Where 
    n = is the tap number,  
    C = is degree of volume reduction of the microcapsules and is a constant, 
   
I" = constant, is the total degree of volume reduction at the limit of tapping and is 
termed compactibility 
    
I, = constant, related to cohesion and termed cohesiveness.  
The plot of  %H
 
versus n is linear and the compactibility, I" and cohesivity,   I, are obtained from 
the slope, I" and the intercept, I",  of the plot of the modified Kawakita and Ludde equation 
(449).  The data were analysed using an equation developed by Kuno (450) and that is shown 
in Equation 6.7: 
                                                 Ln (ρf -ρn) = -kn + Ln (ρf - ρo)                              Equation 6.7 
where,  ρf, ρn  and ρo are the apparent densities at equilibrium, nth tapped and initial state, 
respectively and k is a constant. 
It has been reported that the Kawakita constant, a, which quantifies the maximum possible 
volume reduction due to tapping or applied load should equal CI (449). Thus, the application 
of the Kawakita equation has no advantage over the use of Carr’s compressibility index as an 
indicator of possible volume reduction. 
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6.2.2.5. Encapsulation efficiency (EE) 
The microcapsules were crushed and powdered using a mortar and pestle. Approximately 100 
mg of the crushed microcapsules was accurately weighed and dissolved in 100 ml of 
phosphate buffer (pH 3.0) with sonication for 20 minutes. The solution was then filtered 
through a 0.45 µm membrane filter (Millipore). A 2 ml aliquot was withdrawn from this 
solution and diluted to 50 ml with buffer and analysed using a validated HPLC method to 
determine the CPT content of microcapsules. The % EE (451) was calculated using      
Equation 6.8. 
 
                              % JJ =  (	". .#"	 ($- +	#(	'". .#"	 ($- X 100                                   Equation 6.8 
 
6.2.2.6. Scanning electron microscopy (SEM) 
The shape and surface morphology of the microcapsules was investigated using SEM 
(Tescan, VEGA LMU, Czechoslovakia Republic). The microcapsules were mounted onto a 
double-sized carbon stub that was placed onto a sample disc carrier (3 mm height, 10 mm 
diameter) and were coated with gold under vacuum (0.25 Torr) with a sputter coater (Balzers 
Union Ltd, Balzers, Lichtenstein). The samples were imaged using a 20 kV electron beam. 
 
6.2.2.7. Drug release studies 
The percent drug released was the response selected as in vitro dissolution testing is the most 
important quality control test for drug products and has the potential to highlight possible 
bioavailability issues (452-453).  
Several dissolution apparatus have been described (454-458). The rotating basket (USP 
Apparatus 1) and the paddle (USP Apparatus 2) devices are simple, robust and adequately 
standardized. They are used worldwide and well understood (457). 
However due to the single container nature of the basket and paddle apparatus, experimental 
difficulties may arise when  a change in pH is required or a change in sink conditions or any 
other test medium parameter occurs during a specific experiment (457). 
The reciprocating cylinder or USP apparatus 3 (Bio-Dis®) has been described  (457) and has 
had a relatively short history since its proposal in the 1990s for use as a dissolution test 
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apparatus by Borst et al (458) for drug release testing of extended-release products and as an 
alternative to USP Apparatus 1 and  2.  
A VanKel® Bio-Dis® dissolution apparatus (VanKel® Industries, New Jersey, USA) was used 
for dissolution testing of microcapsules manufactured in these studies. A model VK 750D 
digitally controlled water circulation / heater (VanKel® Industries, New Jersey, USA) was 
used to maintain the temperature of the dissolution media at 37±0.5°C. Drug loaded 
microcapsules were tested in 250 ml of phosphate buffers of different pH. The dissolution 
test was conducted at a 20 dpm rate. Drug release was determined using a validated HPLC 
method. Samples were collected at predetermined time intervals. A summary of the 
dissolution test conditions is listed in Table 6.8. 
Furthermore, the dissolution behaviour of CPT microcapsules was assessed using a fully 
automated Hanson Research SR 8 PLUS (Chartsworth, CA, USA) dissolution apparatus 
fitted with an Autoplus™ Multifill™ and Maximizer Syringe Fraction Collector, 
respectively. The release studies were carried out at 37±0.5 °C using USP Apparatus 1 fitted 
with 8 USP baskets (40-mesh) rotated at 100 rpm. All dosage forms were placed in the 
baskets that were then lowered into 900 ml of degassed phosphate buffer (Table 6.8). The 
percent drug released from the microcapsules after a 12 h test was determined. Samples (2 
ml) were withdrawn and replaced with 2 ml of fresh medium that has automatically been 
filtered through a 0.45 µm Durapore® membrane HVLP filters (Millipore Corporation, 
Ireland). Samples were collected at predetermined time intervals after 1, 2, 6, 8, 10, and 12 
hours. A summary of the dissolution test conditions for this study is depicted in Table 6.8. 
Results for USP Apparatus 1 are not shown in this report. 
 
The response and formulation variables for all model formulations were analysed using 
Design-Expert® software. Statistical analysis including stepwise linear regression and 
response surface analysis were conduced. The significant terms (p < 0.05) were chosen for 
use in establishing the final equations. The best fit mathematical model                                
was selected based on the comparisons of several statistical parameters including the 
coefficient of variation (CV), multiple correlation coefficients (R2) and adjusted multiple 
correlation coefficient (adjusted R2).  
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Table 6.8. Summary of general dissolution conditions for basket and reciprocating cylinder dissolution test methods. 
Parameter     USP Apparatus 1     USP Apparatus 3 
Dissolution medium         Buffers (pH 1.6, 7.4)     Buffers (pH 1.6, 3.4, 4.6, 6.8) 
Temperature     37.0 ± 0.5°C       37.0 ± 0.5°C 
Initial volume     900 ml       250 ml 
Basket / dip speed    100 rpm      20 dpm  
Screen size     -          405 µm top /177 µm bottom 
Filter size     0.45 µm      0.45 µm 
Volume drawn     2 ml       2 ml 
Dissolution time    1h in pH 1.2 and 11h in pH 7.4         1 h  in pH 1.6 and 3.4 and 5 h in pH 4.6, 6.8 
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6.3. RESULTS AND DISCUSSION 
All experiments were performed in a randomized fashion, resulting in thirty simplified 
experimental data sets being generated in order to minimize the effects of uncontrolled 
factors that may introduce bias on the observed response. A classical second-degree model 
with a cubic experimental domain was postulated for all responses. The coefficients for the 
second-order polynomial model were estimated and quadratic equations were generated.  
 
The amount of Eudragit®, Methocel® K15M, Methocel® K100M and the speed of 
homogenization were investigated in the ranges of 1.5- 2.5g, 0.25-0.75g, 0.25-0.75g and 
1000-2000 rpm, respectively.  The contour and response surface plots for the percent drug 
release (Y4) are shown in Figures 6.4 to 6.15 and plots for the other responses (Y1, Y2, Y3 and 
Y5) are not reported. Percent drug released (Y4) was the chosen response to report. The 
regression coefficients calculated for percent drug release are shown in Table 6.9. 
 
Modeling was performed using Design Expert® (Version 7.01) with a backward, stepwise 
linear regression technique. Significant terms (p < 0.05) were selected in order to define the 
final equations. The mathematical relationships that were generated for the responses Y1, Y2, 
Y3, Y4 and Y5 are expressed as Equations 6.9 to 6.13. 
 
In addition contour plots (Figures 6.4 to 6.9) and three dimensional graphs (Figures 6.10 to 
6.15) were generated for each pair-wise combination of the four factors investigated while 
keeping the other two at the centre point level.   
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Table 6.9. ANOVA Table for Response Surface Quadratic Model for percent drug release  
Source Sum of Squares Df Mean Square F-value p-value      Prob > F  
BLOCK 0.035 1 0.035    
Model 2699.91 14 192.85 4.44 0.033 significant 
LINEAR       
 X1-Eudragit RS 63.57 1 63.57 0.14 0.7100  
 X2-Methocel K15M 127.69 1 127.69 3.29 0.0359 significant 
 X3-Methocel K100M 1123.46 1 1123.46 3.55 0.0132 significant 
 X4-Homogenizng speed 44.93 1 44.93 0.10 0.7544  
QUADRATIC       
X1X2 56.25 1 56.25 0.13 0.7264  
X1X3 576.00 1 576.00 1.31 0.2724  
X1X4 7.98 1 7.98 0.018 0.8949  
X2X3 306.25 1 306.25 0.690 0.4188  
X2X4 25.00 1 25.00 5.757 0.0102  
X3X4 342.25 1 342.25 0.78 0.3934  
INTERACTION       
X12 433.72 1 433.72 6.98 0.0383 significant 
X22 56.85 1 56.85 0.13 0.7250  
X32 31.94 1 31.94 0.072 0.7918  
X42 8.75 1 8.75 0.020 0.8900  
Residual 6177.96 14 441.28    
Lack of Fit 4324.66 9 480.52 1.30 0.4065  
Pure Error 1853.30 5 370.66    
Cor Total 8877.86 28     
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Table 6.9. continued. 
Std. Dev. 6.97 
Mean 85.10 
C.V. % 8.19 
PRESS 3490.94 
R2 0.8471 
Adj R2 0.7325 
Pred R2 -1.8412 
Adeq Precision 46.680 
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The equation for the percent yield (Y1) is shown in Equation 6.9;  
 
Y1 =  96.57 - 9.92X1 +1.47X2 +49.20 X3 -15.72 X4 +12.00X1X2-16.00X1X3+18.75 X1X4  - 56.00 X2X3 +50.00 X2X4  -16.00 X3X4 -3.30X1
2
 
-67.20X2
2
  
+30.80X3
2 
-13.80 X4
2
 
 
Percent Yield =  96.57 - 9.92 Eudragit RS +1.47 X15M +49.20 X100M -15.72 homogenizing speed +12.00 Eudragit RS*X15M-16.00 Eudragit RS * 
X100M+18.75 Eudragit RS * homogenising speed
 
- 56.00 X15M* X100M +50.00 X15M * homogenisng speed -16.00 X100M* homogenisng speed          
-3.30 (Eudragit RS)2 -67.20 (X15M)2 +30.80 (X100M)2 -13.80 (homogenisng speed)2 
                                                                                                                                                                                                     
                                                                                                                                                                                                              Equation 6.9 
 
The equation for particle size distribution (Y2) is shown in Equation 6.10. 
 
Y2 =  425.69 – 227.08X1 +43.89X2 +173.89 X3 -248.75 X4 +0.00X1X2-100.00X1X3+147.50 X1X4  - 80.00 X2X3 -80.00 X2X4  +0.00.00 X3X4 +23.61X1
2
 
+267.78X2
2
  +47.78X3
2 
-21.39 X4
2 
 
Particle size distribution =  425.69 – 227.08 Eudragit RS +43.89 X15M +173.89 X100M -248.75 homogenizing speed +0.00 Eudragit RS*X15M -100.00 
Eudragit RS * X100M +147.50 75 Eudragit RS * homogenising speed
 
-  180.00 X15M* X100M -80.00 X15M * homogenisng speed +0.00.00 X100M* 
homogenisng speed +23.61(Eudragit RS)2 +267.78(X15M)2  +47.78(X100M)2 -21.39 (homogenisng speed)2 
 
                                                                                                                                                                                                            Equation 6.10 
 
 
 
 
 
 
 
Page | 144 
 
 
 
The equation for encapsulation efficiency (Y3) factor is shown in Equation 6.11: 
 
Y3 =  89.22+ 22.60X1 – 128.66X2 -23.51 X3 -16.57X4 +22.98X1X2+33.02X1X3-13.68 X1X4 -26.68X2X3 +47.18X2X4  -26.04X3X4 -7.74X1
2
 +24.18X2
2
  
+17.8X3
2 
+11.91 X4
2 
 
Encapsulation efficiency =  89.22+ 22.60 Eudragit RS – 128.66  X15M -23.51 X100M -16.57 homogenizing speed +22.98 Eudragit RS*X15M +33.02 
Eudragit RS * X100M -13.68 Eudragit RS * homogenising speed
 
-26.68 X15M* X100M +47.18 X15M * homogenisng speed -26.04 X100M* 
homogenisng speed -7.74 (Eudragit RS)2 +24.18 (X15M)2   +17.8 (X100M)2 +11.91 (homogenisng speed)2 
                                                                                                                                                                                                            
                                                                                                                                                                                                            Equation 6.11 
    
The equation for drug release (Y4) factor is shown in Equation 6.12: 
 
  Y4 =  -42.49 – 57.04X1 +141.90 X2 +420.90 X3 +43.74 X4 – 30.00X1X2 - 96.00 X1X3 -6.62 X1X4  - 140.00 X2X3 +20.00 X2X4 -74.00 X3X4 + 34.15 
X1
2
 
-47.90 X2
2
 
- 35.90 X3
2 
-4.85 X4
2
 
 
Drug release =  -42.49 – 57.04 Eudragit RS +141.90 X15M + 420.90 X100M +43.74 homogenizing speed – 6.62 Eudragit RS*X15M - 96.00 Eudragit RS 
* X100M- 6.62 Eudragit RS * homogenising speed
 
– 140.00 X15M* X100M +20.00 X15M * homogenisng speed -74.00 X100M* homogenisng speed + 
34.15 (Eudragit RS)2 -47.90 (X15M)2  -35.90 (X100M)2 -4.85 (homogenisng speed)2 
 
                                                                                                                                                                                                            Equation 6.12 
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The equation for microcapsule flow (Y5) factor is shown in Equation 6.13: 
 
Y5 =  2.67-0.56X1 +0.09X2 -2.86X3 -0.27X4 -0.14X1X2+0.58X1X3+0.18 X1X4 +0.88X2X3 -0.58X2X4  +0.36X3X4 +0.017X1
2
 +0.54X2
2
  +0.84X3
2 
-0.028 X4
2
 
 
Powder flow=  2.67- 0.56 Eudragit RS +0.09 X15M -2.86 X100M -0.27 homogenizing speed -0.14 Eudragit RS*X15M +0.58 Eudragit RS * X100M 
+0.18 Eudragit RS * homogenising speed
 
+0.88 X15M* X100M -0.58 X15M * homogenisng speed +0.36 X100M* homogenisng speed     
+0.017(Eudragit RS)2+0.54 (X15M)2 +0.84(X100M)2  -0.028 (homogenisng speed)2 
 
                                                                                                                                                                                                            Equation 6.13 
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By way of example, as can be seen in Equation 6.12, (percent drug release) the polynomial 
expression contains the coefficient for the intercept, first order main effects, interaction terms 
and higher order effects. The sign and magnitude of the main effects signify the relative 
influence of each factor on the response or drug release in this case. The values obtained for 
the main effects of each factor shown in Equation 6.12 reveal that X1, X4, X1X2, X1X3, X1X4, 
X2X3, X3X4, X22, X32, and X42 have a negative effect on drug release. X2, X3, X2X4 and X12 
individually have rather more pronounced effect on Y4. X2X4 showed the least synergistic 
effect. 
 
ANOVA method was used to estimate the significance of the model using Design Expert 
Software (Table 6.9). At a 5% level of significance the model is considered significant if the 
significance probability or p-value is less than 0.05 (459). It is evident in Table 6.9 that for all 
responses, the cross-product contributions were negative except for X2X4. The model F-value 
of 0.033 implies that the model is significant and also shows that there is a 0.30%                 
(p > 0.003) chance that the model F-value could have been due to noise. The R2 value is close 
to 1 and denotes a high degree of correlation between the observed and predicted values. The 
coefficient of variation (CV) indicates the degree of precision with which the experiments 
were performed and the reliability of an experiment is indicated by a low value for the CV.  
A CV of 6.19 was calculated for the experiments performed in these studies thereby 
indicating the data are highly reliable. The p-value denotes the significance of the coefficient 
and is also important in understanding the pattern of mutual interactions between the 
variables under investigation. The p-value suggests that of   the four variables studied, X1 and 
X2 show the maximum synergistic effect on Y4. These effects were determined by plotting 
the response surface curves. The shapes of the curves reveal moderate interactions between 
the variables under investigation. 
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Figure 6.4. Contour plots showing the effect of Eudragit® RS and Methocel® K15M on drug release  
where A = x- axis and B = y-axis 
 
Figure 6.5. Contour plots showing the effects of Eudragit® RS and Methocel® K100M on drug release
 
where A = x- axis and C = y-axis 
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Figure 6.6. Contour plots showing the effects of Eudragit® RS and homogenizing speed on drug release 
 
where A = x- axis and D = y-axis 
 
 
Figure 6.7. Contour plots showing the effects of Methocel® K15M and Methocel® K100M on drug release 
 
where B = x- axis and C = y-axis 
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Figure 6.8. Contour plots showing the effects of Methocel® K15M and homogenizing speed on drug release 
 
where B = x- axis and D = y-axis 
 
Figure 6.9. Contour plots showing the effects of Methocel® K100M and homogenizing speed on drug release 
 
where C = x- axis and D = y-axis 
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Figure 6.10. Response surface graph showing the effect of Eudragit® RS and Methocel® K15M on drug release. 
 
Figure 6.11. Response surface graph showing the effect of Eudragit® RS and Methocel® K100M on drug 
release. 
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Figure 6.12. Response surface graph showing the effect of Eudragit® RS and homogenizing speed on drug 
release. 
 
 
Figure 6.13. Response surface graph showing the effect of Methocel® K15M and Methocel® K100M on drug 
release. 
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Figure 6.14. Response surface graph showing the effect of Methocel® K15M and homogenizing speed on drug 
release. 
 
 
Figure 6.15. Response surface graph representing the interaction between Methocel® K100M and 
Homogenizing speed 
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In most cases the coefficients of the different factors reveal synergistic effects for all factors 
in responses Y1, Y2 Y3 and Y4. It is obvious that Methocel® K15M (X2) and K100M (X3) had 
the greatest impact on drug release. This is due to the HPMC matrix that retains its viscosity 
and gel layer intact thereby increasing the diffusional pathlength in the particles. 
 
As can be seen (Figures 6.4 to 6.9) drug release rates vary in a non-linear fashion between the 
associated variables. The pattern generated is ‘horse-shoe’ in shape and the resultant 
responses are relatively complex and difficult to interpret since there are different phases and 
they all show dissimilar patterns. The plot showing in Figure 6.8 reveals that drug release 
varies in a linear fashion as the amount of Methocel® K15M
 
is increased. As the 
homogenizing speed was decreased, there is an optimum concentration where an increase in 
concentration results in a radial pattern. The radial pattern indicates that the homogenizing 
speed has a negative effect on drug release. In contrast the results observed for Methocel® 
K100M (Figure 6.9) indicate that there is no clear relationship between homogenizing speed 
and polymer type on drug release. These results are somewhat unexpected as the only 
difference is in the viscosity of the polymers. This may have influenced the manufacture of 
the microcapsules.  
 
6.3.1. Particle size distribution 
On the basis of sieve-analysis data presented in Table 6.10 it can be concluded that there was 
a difference in the average particle size of microcapsules for all manufactured batches. On the 
basis of published data the formation of smaller microspheres at higher stirring rates (429, 
434, 437, 438) was expected and it was presumed that, by lowering the stirring rate the 
average particle size would increase in comparison to the average particle size of 
microcapsules manufactured at high stirring speeds. The use of high stirring speeds 
maintained over a long period would produce uniform microcapsules. As the stirring rate 
decreased, the droplet size of the dispersed phase increased resulting in the production of 
larger microcapsules. If the stirring speed was changed at the time when solidification of the 
droplets has commenced, the influence on the average particle size was not likely to be great. 
If the microcapsules were completely formed, changes of stirring speed would have had no 
influence on the size of microcapsules. A change in agitation speed prior to evaporation of 
the acetone would probably lead to the formation of microspheres of the same size as those 
prepared using constant stirring speeds. However since solvent diffusion into the outer 
emulsion phase and its evaporation starts immediately this effect was not observed. 
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The microcapsules had diameters ranging between 30 and 200 µm, and the mean diameter 
was directly influenced by the manufacturing parameters used (homogenizing speed and 
polymer concentration). Furthermore larger particles were obtained at higher polymer/drug 
ratios. Increasing the polymer load leads to the production of a more viscous solution and 
when the solution is poured into the aqueous phase, larger droplets and thus larger 
microcapsules are formed (460-463).  
 
6.3.2. Microencapsulation 
Microcapsules were manufactured using Eudragit® and Methocel® polymers. During the 
evaporation process, the dispersed phase became more and more viscous and even at low 
agitation speeds the dispersed droplets could not fuse together.  
 
When the solution of solvent was poured into the continuous phase whilst stirring, finely 
dispersed droplets formed immediately and a semi-transparent emulsion was observed. With 
the diffusion of acetone out of the droplets into the continuous phase, the drug and the 
polymer coprecipitate within the droplets and a schematic representation of droplet formation 
is shown in Figure 6.16. The formation of microcapsules can be described in the following 
manner. Initially quasiemulsion droplets are formed, after which the organic solvent diffuses 
out of the droplets followed by solidification of the droplets. During formation of the droplets 
microcapsules agglomerate to form an irregular mass and adhere to the propeller or the vessel 
wall. To avoid agglomeration, span 80 was added to the liquid paraffin during the 
manufacturing process.  The use of the emulgent results in a decrease in viscosity of the 
continuous phase that prevents conglutination of the emulsified droplets. In addition the 
presence of span accelerates the solidification of droplets.  
 
6.3.3. Encapsulation efficiency 
Relatively high encapsulation efficiencies of between 60 to 80% were achieved and the data 
are summarized in Table 6.10.  The EE was expected to be relatively high as CPT is insoluble 
in liquid paraffin. In all cases the EE efficiency was lower than 90% perhaps due to the fact 
that the presence of span 80 increased the miscibility of acetone with the light liquid paraffin 
and which may have increased the extraction of CPT into this phase. The volume of the 
processing medium was kept constant as an increase in volume of the processing medium 
would have caused the emulsion droplets to move freely in the medium, thereby reducing 
collision-induced aggregation and yielding small and uniform microspheres that are 
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associated with higher extraction coefficients and lower encapsulation efficiencies. Although 
stirring rate may affect drug content significantly (464), no significant differences were 
observed for the batches manufactured in these studies. Consequently it was not possible to 
determine microsphere formation time with respect to stirring speed on the basis of 
encapsulation efficiency. Theoretically, the use of high homogenizing speeds would result in 
the production of smaller emulsion droplets, facilitating drug loss from the microcapsules 
before they harden and resulting in a low EE. The assumption that drug diffusion into the 
processing medium may occur was supported by SEM analysis which revealed the presence 
of drug particles on the surface(s) of the microcapsules.  
 
The microencapsulation efficiency was found to dependent on the initial polymer loads and 
the high EE values summarized in Table 6.10 justify the use of an o/o emulsification 
technique for the manufacture of microcapsules of the water-soluble CPT. The increase in EE 
with increase in polymer concentrations is probably due to better encapsulation of the drug at 
these levels and a decrease in the amount of CPT on the surface of the capsules. The increase 
in CPT encapsulation observed when span 80 was used can be ascribed to the emulsifying 
effect of the surfactant, which ensures that CPT is finely dispersed and embedded in the 
polymer matrix prior to encapsulation.  
 
Furthermore, this can also be explained by the hydrophilicity of CPT. CPT is unlikely to have 
an affinity for the organic solvent phase used and the decrease could most likely have been 
the result of CPT having partitioned into the continuous phase. The encapsulation of a drug is 
therefore highly dependent on the solubility of the drug in the solvent and continuous phase.     
 
6.3.4. Flowability 
The physical properties of the microcapsules that were produced are listed in Tables 6.10 
(Hausner ratio) and Table 6.11. The angles of repose for almost all microcapsules were in the 
range of 18 to 40˚, thus indicating good flowability for some batches and poor flow for 
others. This would result in microcapsules from other batches being poorly packed into hard 
capsules. The angle of repose is affected by the particle size distribution and usually increases 
with a decrease in particle size. Lower Hausner ratio values (≤ 1.25) in most of the batches 
indicate good flow except for CPT-005, 014, 016 and CPT-022 which had Hausner ratio 
values of 1.93, 1.61, 1.34 and 1.42, repectively. These values indicate that the ‘particles’ that 
were formed from these batches were adhering to each other and that would result in poor 
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flow. Similar results were observed when using Carr’s Index, with lower values associated 
with low cohesiveness and greater fluidity properties.     
  
The denser the microcapsules and the higher their bulk density, the easier they will be to 
tablet. The percent compressibility calculated from density data generated in these studies 
showed a compressibility of less than 30%.  The low compressibility further supports the fair 
to excellent flow properties of these microcapsules. This would be important for filling into 
two-piece hard capsules, or for use in directly compressible blends for tabletting. 
 
A reduction in the bulk densities of some microcapsules indicates a greater porosity in the 
microcapsules. The microcapsules were easily packed by tapping, and this phenomenon can 
be described using Kawakita and Ludde’s equation (449). The apparent packing velocity 
produced by tapping, represented by parameter b was acceptable, since the microcapsules 
packed closely without tapping because of this excellent flowability and packability. Good 
flowability and packability may be attributed to their sphericity and particle size. These 
results further suggest that the microcapsules may be suitable for capsule filling and that such 
capsules would exhibit a high degree of mass uniformity.   
 
In order to achieve uniformity for capsule fill mass, the fill materials must flow readily and 
pack smoothly. The flowability of the microcapsules was also assessed using CI. 
Microcapsules of similar size but non-uniform in shape can have markedly different flow 
properties owing to differences in the interparticle contact areas. It is also important to note 
that the flow properties of microcapsules will decrease as the shapes of microcapsules 
become more irregular.  
 
As shown in Table 6.11, the small values for parameters a and b generated from fitting data 
to Kawakita and Ludde’s equation indicate the high packability of the microcapsules. The 
values of parameter K in Kuno’s equation indicate that the microcapsules from some batches 
will flow and pack smoothly during filling of two-piece capsules, thereby ensuring mass and 
dose uniformity.  
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Table 6.10. Response data generated for each experiment 
RUN  X1  X2  X3  X4  Y1  Y2  Y3  Y4  Y5  
   g  g  g  rpm (1000)  %  nm  %  %     
1  2.0  0.5  0.50  1.5  87  100  57.66  64  1.23  
2  2.0  0.75  0.25  1.5  83  200  58.64  40  1.17  
3  1.5  0.50  0.50  1.0  93  200  58.25  50  1.27  
4  2.5  0.50  0.50  2.0  87  100  56.87  75  1.17  
5  2.0  0.50  0.25  2.0  88  50  69.92  89  1.93  
6  2.0  0.50  0.50  1.5  92  50  69.07  94  0.87  
7  2.0  0.75  0.75  1.5  78  100  57.76  50  1.20 
8  1.5  0.50  0.50  1.0.  76  50  62.55  91  1.28  
9  2.0  0.25  0.75  1.5  87  20  71.52  90  1.18  
10  2.0  0.50  0.50  1.5  90  50  69.98  88  1.16  
11  1.5  0.75  0.50  1.5  76  100  59.79  95  1.18  
12  2.0  0.50  0.50  1.5  79  100  60.95  63  1.25  
13  2.0  0.25  0.50  2.0  69  50  59.57  58  1.16  
14  2.5  0.25  0.50  1.5  87  100  66.83  88  1.61  
15  2.0  0.50  0.50  1.5  89  50  62.2  60  1.28  
16  2.5  0.50  0.75  1.5  84  50  69.92  83  1.34  
17  1.5  0.50  0.75  1.5  92  50  60.85  97  1.19  
18  2.0  0.25  0.5  1.0  91  80  65.53  88  1.16  
19  2.5  0.75  0.50  1.5  90  150  68.45  93  1.13  
20  2.0  0.50  0.75  1.0  89  100  77.98  87  1.25  
21  2.0  0.50  0.75  2.0 83  50  69.47  49  1.25  
22  2.0  0.75  0.50  1.0  84  100  66.65  84  1.42  
23  2.5  0.50  0.25  1.5  95  100  58.29  95  1.16  
24  2.0  0.50  0.25  1.0  86  100  65.41  90  1.11  
25  1.5  0.25  0.50  1.5  79  50  69.66  75  1.09  
26  2.5  0.50  0.50  1.0  74  100  60.45  67  1.23  
27  2.0  0.25  0.25  1.5  78  75  65.73  45  1.17  
28  1.5  0.50  0.25  1.5  95  50  65.73  61  1.10  
29  2.0  0.75  0.50  2.0  87  30  84.28  64  1.13  
30  2.0  0.75  0.50  2.0   67  30  84.28  65  1.13  
X1 = Eudragit RS     Y1 = percent yield     Y5 = Hausner ratio 
X2 = Methocel K100M    Y2 = microcapsule size 
X3 = Methocel K15M    Y3 = encapsulation efficiency  
X4 = Homogenizing speed    Y4 =  percent released
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Table 6.11. Packability and flowability parameters for CPT microcapsules 
Formulation a b K Angle of repose (θ) Carr’s Index 
CPT-001 0.42   (r =0.998) 0.53 0.025   (r =0.998) 24 32 
CPT-002 0.39   (r =0.989) 0.02 0.006   (r =0.987) 23 26 
CPT-003 0.45   (r =0.991) 0.08 0.015   (r =0.997) 41 46 
CPT-004 0.42   (r =0.999) 0.20 0.014   (r =0.963) 37 43 
CPT-005 0.27   (r =0.994) 0.04 0.016   (r =0.990) 40 28 
CPT-006 0.14   (r =0.998) 0.15 0.018   (r =0.971) 12 16 
CPT-007 0.24   (r =0.999) 0.27 0.022   (r =0.897) 23 17 
CPT-008 0.24   (r =0.996) 0.02 0.014   (r =0.996) 30 32 
CPT-009 0.24   (r =0.997) 0.27 0.014   (r =0.991) 18 22 
CPT-010 0.11   (r =0.993) 0.26 0.004   (r =0.939) 22 14 
CPT-011 0.30   (r =0.997) 0.02 0.007   (r =0.999) 27 18 
CPT-012 0.33   (r =0.998) 0.02 0.007   (r =0.967) 22 17 
CPT-013 0.22   (r =0.997) 0.02 0.010   (r =0.949) 24 20 
CPT-014 0.63   (r =0.999) 0.08 0.019   (r =0.958) 32 35 
CPT-015 0.36   (r =0.951) 0.01 0.017   (r =0.998) 22 24 
CPT-016 0.23   (r =0.999) 0.03 0.014   (r =0.999) 20 22 
CPT-017 0.30   (r =0.997) 0.02 0.023   (r =0.898) 21 30 
CPT-018 0.16   (r =0.995) 0.02 0.018   (r =0.912) 15 16 
CPT-017 0.30   (r =0.997) 0.02 0.023   (r =0.898) 21 30 
CPT-018 0.16   (r =0.995) 0.02 0.018   (r =0.912) 15 16 
CPT-019 0.40   (r =0.911) 0.03 0.001   (r =0.968) 8 30 
CPT-020 0.28   (r =0.977) 0.26 0.013   (r =0.957) 19 30 
CPT-021 0.28   (r =0.996) 0.01 0.011   (r =0.932) 21 26 
CPT-022 0.36   (r =0.981) 0.05 0.014   (r =0.978) 35 36 
CPT-023 0.20   (r =0.998) 0.01 0.020   (r =0.996) 24 20 
CPT-024 0.25   (r =0.999) 0.02 0.011   (r =0.960) 28 24 
CPT-025 0.39   (r =0.997) 0.09 0.014   (r =0.867) 29 30 
CPT-026 0.10   (r =0.867) 0.01 0.013   (r =0.999) 20 20 
CPT-027 0.44   (r =0.999)  0.26 0.019   (r =0.998) 8 18 
CPT-028 0.29   (r =0.998) 0.04 0.011   (r =0.976) 21 28 
CPT-029 0.33   (r =0.987) 0.26 0.013   (r =0.987) 20 30 
CPT-030 0.33   (r =0.999) 0.03 0.110   (r =0.993) 33 27 
a,b
   Parameter from  Equation 6.6          
 
k Parameter from  Equation 6.7
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Figure 6.16a. Schematic representation of a solvent diffusion and evaporation  
 
 
 
 
 
 
 
Figure 6.16b. Schematic representation of a mass transfer model for a single drop of polymer and solvent 
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The results for microcapsule yield, drug loading and encapsulation efficiency are shown in 
Table 6.10 for all batches. A solidification rate may have reduced the partitioning of CPT into 
the external phase of the emulsion resulting in high encapsulation efficiencies. Losses for the 
CPT may be due to drug partly going into the external phase prior to drop formation.  It 
would be ideal for the drug not to diffuse out, but this is not always possible, some of the 
drug will diffuse out, resulting in reduced EE percent.  
 
6.3.5.  Scanning Electron Microscopy 
 Typical SEM micrographs of selected microcapsules are shown in Figures 6.17-6.25. It is 
evident that microcapsules are not similar in shape. All micrographs taken for all batches of 
microcapsules manufactured in this research are presented in Appendix One with 
corresponding dissolution profiles. 
 
The SEM photomicrographs indicate that most of the microcapsules were discrete, spherical 
and uniform in shape and that some have porous surfaces. At high magnification it is evident 
that the microcapsules have rough surfaces free of CPT, suggesting that the drug had been 
efficiently encapsulated by the polymeric matrix. This may be due in part to the fact that the 
drug is thoroughly wetted, finely dispersed and enveloped within the polymer matrix prior to 
encapsulation. In addition, the data from drug loading determinations confirm this was the 
case as CPT concentrations were high in these microcapsules. However, this was not so for 
batches CPT-006 and CPT-025 (Figures 6.18, 6.22) where CPT ‘particles’ could be seen on 
the surfaces of the microcapsules. The small microcapsules produced in batch CPT-022 are 
shown in Figure 6.25. It is clear that the small microcapsules adhere to one another and form 
‘grape-like’ clusters. These microcapsules were also not visually appealing and were not free-
flowing and discrete as those of other batches. These results are supported by the angle of 
repose and CI data for these batches and these are summarized in Table 6.11. Batches that 
failed the ‘geometry’ test could not be used any further.   
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Figure 6.17. SEM of a microcapsule from batch 
CPT-002                          
Figure 6.18. SEM of a microcapsule from batch 
CPT-006    
 
Figure 6.19. SEM of a microcapsule from batch 
CPT-009                         
Figure 6.20. SEM of a microcapsule from batch 
CPT-015  
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Figure 6.21. SEM of a microcapsule from batch 
CPT-020                          
Figure 6.22. SEM of a microcapsule from batch 
CPT-025  
 
Figure 6.23. SEM of a microcapsule from batch 
CPT-030                       
Figure 6.24. SEM of a microcapsule from batch 
CPT-029 
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Figure 6.25. SEM of a microcapsule from batch CPT-022           
 
6.3.6.  In vitro drug release 
Typical drug release profiles of selected microcapsules (those selected for SEM studies) are 
shown in Figure 6.26-6.34. All other drug release profiles are shown in Appendix One and 
the batch production records are shown in Appendix Two. The drug release profiles were 
constructed using Korsmeyer-Peppas equation as it provides a good tool for modeling of drug 
release. Only selected results using USP Apparatus 3 were shown in these studies as USP 
Apparatus 3 offers the advantages of mimicking in vivo conditions.    
 
It was expected that drug release from microcapsules would be rapid when tested in          
USP Apparatus 3 (§ 6.2.2.7). Higher agitation rates when using USP Apparatus 3 effectively 
reduce the stagnant layer that forms around microcapsules during dissolution. However, rapid 
drug release was not observed for all batches: some microcapsules took longer to dissolve 
than those from other batches. The retardant effect on CPT release observed for some batches 
can be attributed to the formation of a diffusional barrier between the drug within the 
microcapsules and the dissolution medium. The results show that the release rate of CPT 
from the microcapsules could be modulated by adjusting the ratios of polymer/drug in the 
formulation and the speed of homogenizing during manufacture.  
 
As can be seen in Figures 6.27-6.32, decreasing the concentration of polymer content resulted 
in a marked increase in drug release rates. In addition to the effect of polymer content this 
phenomenon may be attributed to the hardening sequence used to manufacture the 
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microcapsules. During the formation of the microcapsules, the low viscosity of the dispersed 
phase delayed polymer precipitation and solidification of the dispersed droplets. More water 
could therefore diffuse into the droplets prior to solidification, thus forming water pockets 
and pores in the walls of the microcapsules. The more porous the capsule wall, the easier it 
was for dissolution medium to penetrate the capsule and consequently the dissolution of CPT 
from the microcapsules was more rapid. This phenomenon has also been reported by Pygall 
et al (465). Moreover, the size of the microcapsules decreased significantly with decreasing 
polymer/drug ratio. This also contributed to the faster release of drug at lower polymer 
concentrations, which could have been a surface area effect.  
 
In the majority of cases the microcapsules showed a burst release followed by more constant 
release. In this study, burst release was considered to be any profile that would show 30% 
release in the first hour of dissolution. This burst release phenomenon was primarily 
noticeable for CPT release shown in Figures 6.26, 6.27, 6.28, 6.29, 6.30, 6.31, 6.32, 6.33 and 
6.34. The release profiles can be explained by the heterogeneous distribution of the drug 
within the matrix, as observed in some of the batches when using SEM. The profiles indicate 
that burst release was dominant in these microcapsules. 
 
The drug released is shown in Table 6.10 and in most cases, the initial burst effect contributes 
approximately 40% of the release that was observed in the first 1h. The low polymer levels 
used in these formulations resulted in more drug remaining at the surface of the 
microcapsules producing the initial rapid release. A burst release was not evident in other 
formulations possibly due to the high polymer content resulting in better encapsulation of 
CPT within the microcapsules. The higher release rates are also associated with smaller size 
fractions of particles. When using SEM, drug crystals could be observed at or near the 
surfaces of the microcapsules. These surface crystals dissolve quickly and probably account 
for the observed rapid initial release. Almost all microcapsule batches produced in this study 
showed this behaviour to the same or similar extents for almost all microcapsule sizes 
produced.  
 
During testing a point is reached when dissolution of solid drug particles results in the 
formation of continuous pores or channels within the matrix. Under these circumstances, drug 
release will follow a path of least resistance and drug will diffuse through the channels to the 
Page | 165 
 
bulk dissolution medium. Therefore, as the drug leaches out from the polymer, the matrix 
becomes more porous and faster drug release rates are observed.   
 
The initial burst effect from HPMC matrices is a common occurrence in the release of    
water- soluble drugs (456, 465). Where drug release is retarded it may, in part, be due to the 
solid bridges that are formed between drug-drug and drug-excipient particles during 
processing. In addition, the internal pressure generated due to swelling and relaxation of the 
matrix might cause micro rupturing of the particles during dissolution.  
 
Most of the drug profiles can be described as having two stages. Initially there occurs a burst 
effect, corresponding to the rapid dissolution and release of CPT from the surfaces of the 
microcapsules, prior to formation of a gel membrane at the surface. Secondly, the release rate 
decreases continuously until the end of the process. This phenomenon can be explained by an 
increase in diffusion pathlength for the drug, which is typical of diffusion-controlled release 
mechanisms. Following the formation of a gel, drug release is controlled by drug diffusion 
across the gel layer. The burst effect is also dependent on the amount of drug present at the 
surface of the microcapsules and the size and the shape of the pores generated within the 
microcapsule structure during dissolution testing.  
 
A reason for the occurrence of a burst effect could be the unstable nature of the inner 
emulsion droplets during solvent evaporation, which leads to coalescence and may have 
forced drug particles to migrate to the surface of the microcapsules. 
 
It should be noted that despite the cracks that can be clearly observed in some microcapsules, 
no burst could be detected later on. The hypothesis is that following crack formation and 
exposure of new surfaces to the dissolution medium tight and cohesive gel layers are rapidly 
formed and are able to maintain and control drug release. In this way the gel layer is able to 
‘heal’ or plug the crack, thereby protecting the internal drug reservoir.  
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Figure 6.26.  Cumulative percent CPT released for batch CPT-002 (mean ± SD, n = 3) 
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Figure 6.27. Cumulative percent CPT released for batch CPT-006 (mean ± SD, n = 3) 
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Figure 6.28. Cumulative percent CPT released for batch CPT-009 (mean ± SD, n = 3) 
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Figure 6.29. Cumulative % drug released for CPT-015 (mean ± SD, n = 3) 
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Figure 6.30. Cumulative % drug released for CPT-020 (mean ± SD, n = 3) 
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Figure 6.31. Cumulative % drug released for CPT-025 (mean ± SD, n = 3) 
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Figure 6.32. Cumulative % drug released for CPT-029 (mean ± SD, n = 3) 
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Figure 6.33. Cumulative % drug released for CPT-030 (mean ±SD, n = 3) 
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Figure 6.34. Cumulative percent CPT released for batch CPT-008 (mean ± SD, n = 3) 
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6.4. CONCLUSION 
The controlled release of CPT observed in this study indicates that hydrophilic matrix 
microcapsules of CPT manufactured using Eudragit® and Methocel®, has the potential to be 
used as a twice-a-day oral sustained release drug delivery system. The polymers, solvents and 
diluents all play a role in the formation of quality microcapsules. Moreover, optimization of 
microencapsulation conditions for CPT using RSM has been demonstrated. Input factors such 
as Eudragit® (X1), Methocel® K15M (X2) and Methocel® K100M (X3) content and 
homogenizing speed (X4) had an effect on the release of CPT from the microcapsules. 
Optimization was performed using a CCD approach to yield microcapsules releasing more 
than 85% CPT in 12 h. The polynomial equation generated explained the quadratic and 
interaction effects of the input variables on the ultimate response observed. RSM is an 
appropriate approach as response surface methodology permits the estimation of parameters 
of a quadratic model, and it can assist in detecting the poor fit of a model. The approach 
presented in this study provides a useful guideline for the optimization of microcapsule 
manufacture for other water-soluble drugs.  
 
However, the successful development of these delivery systems requires careful 
consideration of a number of factors that can influence the performance of a formulation, 
including the physical and chemical properties of the API and excipients. Experimental 
design is a preferred strategy, especially with complex formulations. In particular, this multi-
varied strategy of experimental design allows for the simultaneous investigation of the effects 
of a number of variables in addition to their actual significance on a response. Furthermore 
the possible interrelationship between variables can be readily established since maximum 
information is generated with the smallest number of experiments.  
The absence of pores in other microcapsules is of major importance to this study in order to 
help explain the drug release mechanism, since CPT diffusion occurs through water filled 
cavities and is much faster than if diffusion were to take place through dense polymer 
networks. The poor loading efficiency and rapid drug release observed during the early stages 
of testing are some of the challenges encountered when microcapsules containing a freely 
water-soluble drug are manufactured by this method of encapsulation. 
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The angle of repose for the CPT microcapsules ranged between 18-40°, which indicates that 
some microcapsules had poor flow properties. The results were confirmed by the CI and 
Hausner ratio. 
 
The addition of span 80 lowered the surface tension of the continuous phase and in turn 
decreased the sizes of microcapsules. When the homogenizing speed was increased more air 
was entrapped and foam was produced. An anti-foaming agent ensured that air bubbles were 
rapidly dissipated.  
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CHAPTER 7 
MATHEMATICAL MODELING OF CAPTOPRIL RELEASE FROM 
MICROCAPSULES 
7.1. INTRODUCTION 
 In vitro dissolution is one of the most important elements of drug product development. 
Several models can be used to describe drug dissolution profiles where f (t) is a function of     
t (time) that is related to the amount of drug dissolved from a pharmaceutical dosage form. 
The quantitative interpretation of values generated in dissolution studies is facilitated by the 
use of generic equations that mathematically translate dissolution curves as a function of 
certain parameters related to the dosage forms being tested. In some cases the equations can 
be deduced by theoretical analysis of processes that a dosage form is subject to. A            
water-soluble drug incorporated into a hydrophilic matrix is released mainly by a        
diffusion-controlled process whereas for a poorly water-soluble compound the principal 
mechanism of release is a function of erosion of the matrix (466). 
 
There have been many attempts to model the process of solvent penetration and subsequent 
solute release in and from polymeric matrices and there have been many valuable 
contributions to the understanding of the mechanisms driving these processes (467-472). 
However the majority of these models are either too general or require extensive knowledge 
of system parameters and complex differential expressions and they have not been used 
successfully for the development of optimized pharmaceutical formulations (467). 
 
Swelling controlled-release technologies, based on hydrophilic polymer(s), for drug delivery 
have been extensively investigated (473-477). The release mechanism from these systems is 
primarily governed by hydration and gradual transition of a glassy core to a rubbery phase 
and gel layer formation as swelling progresses. Exposure of these systems to an aqueous 
environment, over prolonged period, results in dynamic changes in the appearance and nature 
of the dosage form. Initially the thickness of the gel layer increases as the swelling process 
dominates, after which synchronisation occurs during which time the thickness of the gel 
layer remains constant as swelling and erosion of the polymer occurs at the same rate.  
Eventually erosion predominates as the polymer dissolves and the gel layer thickness is 
reduced (478). The dynamics of these processes are primarily dependent on properties of the 
polymers used to manufacture the dosage form (479), the solubility (480) and loading dose of 
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the drug (481) and the characteristics of other formulation components (482). Furthermore it 
is known that penetration of water or biological fluids into the polymeric matrix creates 
boundaries or fronts and the movement(s) of the fronts influence the thermodynamic states 
associated with various phases of the behaviour of the polymer following hydration (483-
485). 
 
Hydrophilic matrices are widely used since they exhibit biopharmaceutical and 
pharmacokinetics advantages over conventional dosage forms as precise modulation of drug 
release as a result of hydration of the constituent polymer(s) can be achieved (486-487). 
Furthermore a degree of flexibility is possible in achieving a desired drug release profile and 
in general the polymers have FDA acceptability (486-487).  Although there is a wide choice 
of possible matrix-forming polymeric materials, the use of HPMC predominates since it is 
easy to achieve a desired release profiles when using the material (486). Kim and Fassihi 
(488) have shown that zero-order drug release from optimized ratios of specific polymeric 
combinations is easily and readily achievable using HPMC (473). 
 
 Model-dependent methods were used to evaluate the dissolution or release profiles of the 
thirty formulations manufactured in these studies.  Although mathematical models have been 
extensively used to characterize dissolution profiles, these methods are complicated and 
require caution when interpreting fitted data than when evaluating information generated 
using model-independent methods of analysis (489).  
 
The in vitro release profiles of CPT microcapsules manufactured using solvent evaporation 
were generated as described in § 6.2.2.2. The applicability and reliability of several kinetic 
and mathematical models, and the canonical and Lagrange criterion (241), were evaluated for 
their ability to describe drug release from these systems.  
 
A CCD approach (Chapter 6) was used in a multivariate experimental design to establish the 
number and formulae that were to be manufactured in order to optimize the formulation and 
manufacture of CPT microcapsules as the CCD is more efficient in mapping space. In view 
of the fact that CCD was used to optimize experimental variables, it was important that the 
coordinates of a stationary point of the response surfaces generated were estimated and 
interrogated. The fitted response surfaces were analyzed, in part, as described in Chapter 6. In 
this Chapter the modeling of percent drug release and optimization of (Y4) was undertaken 
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using canonical, mathematical and Lagrange methods. Optimization of the formulations was 
done by selecting the formulations (§ 6.2.2.2) based on the criteria of attaining the maximum 
value for percent drug released. This would be done by finding the conditions under which 
certain processes attain optimal results. Canonical and Lagrange methods were therefore used 
to determine the levels of the design parameters at which the response (Y4, percent drug 
released) reaches optimum. The optimum could either be a maximum or a minimum or a 
function of the design parameters.  
 
The model generated in Chapter 6 for Y4 was used in Lagrange and Canonical analysis, 
which allowed a compromise among various responses and helped search for a combination 
of factor levels that jointly optimize the selected response.  
 
In most cases it is difficult to understand and evaluate the shape of a fitted response surface 
by visual inspection of the contour or surface response plots. Furthermore, when many 
independent variables are used in a model it is difficult to evaluate the shape of a surface by 
interrogating the algebraic expression of a polynomial. Canonical analysis may be necessary 
to facilitate interpretation of the data. Such analysis requires the original experimental 
variables, viz., xi, to be mathematically transformed into new variables viz., zi, in order for the 
response surface, to be expressed only in quadratic terms (490-492). It is therefore easier to 
evaluate the transformed terms. 
 
7.1.1.  Canonical analysis 
Canonical analysis (493) is a method of rewriting a fitted second-degree equation in a form in 
which it can be better understood. This is accomplished by the rotation of axes that removal 
of all cross-product terms. In general this simplification is termed the A canonical form. If 
desired this transformation may also be accompanied by a change of origin to remove first 
order terms, in which case a B canonical form is generated (494). The response, Y4 
representing drug release was considered as a function of four variables viz, concentration of 
Eudragit® RS, Methocel® K15M, Methocel® K100M and homogenizing speed.  
 
When using canonical analysis (495) mathematical expressions and analysis involve 
changing the origin of a plot of a response surface plot from its original coordinates to the 
stationary point of a response surface, after which the axes are rotated until they correspond 
to the principal axes of the contour plot. By use of the new coordinate system, second order 
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model equations are simplified and the geometrical nature of the data becomes apparent. The 
algebraic signs of a canonical equation coefficient(s) provide information relating to the 
nature of the stationary point. If all values are negative the stationary point is in fact a 
maximum and if all are positive the stationary point is a minimum. If the signs are mixed the 
point is a saddle. 
 
In mathematics, a saddle point is a point in a domain of a function of two variables which is a 
stationary point but not a local extremum. In general the surface, at such a point, resembles a 
saddle that curves up in one direction and down in another and is in fact similar to a riding 
saddle or a mountain pass (496). 
 
7.1.2.  Lagrange’s criteria 
Lagrange’s criteria are derived from a mathematical procedure used to determine the nature 
of a stationary point of a function (497). In combination with canonical analysis, Lagrange’s 
criteria provide additional information about the nature of the response surface(s). 
 
7.1.2.1. Lagrange’s criterion for four variable functions 
The second order model for four variables (X1, X2, X3 and X4) is shown in Equation 7.1.  
 
Y = Y1 =  W+ aX1 + bX2 + cX3 + dX4 + eX1X2+ fX1X3 
+ gX1X4 + hX2X3 + iX2X4  + jX3X4 + kX1
2
 + lX2
2
  + mX3
2 
+  nX4
2
 
                                                                                                                                     Equation 7.1 
 
where  
Y =  the experimental response to be optimised,  
W = a constant term,  
a, b, c and d  = coefficients of the linear terms,  
e, f, g, h, i and j  = coefficients of interaction between the four factors, and 
 k, l, m and n = coefficients of the quadratic terms.  
 
If the quadratic function in a Lagrange function shows one stationary point, (X10, X20, X30, 
X40), four situations are possible. Initial information about the geometrical nature of the 
surface can be derived from the signs and magnitudes of the quadratic coefficients in the 
polynomial function. If all coefficients are negative the function can show a maximum and if 
positive the function can show a minimum. Should the coefficients be described with a 
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mixture of positive and negative signs the stationary point is a saddle point with a relative 
maximum for the variables with a negative term and with a relative minimum for the 
variables with a positive coefficient. Nevertheless it is always necessary to verify these 
conclusions by applying the Lagrange criteria which will give values for Hessian 
determinants (498). 
 
The Hessian, H, is a real and symmetric matrix. Therefore, H can be diagonalized by an 
orthogonal change of basis of the configuration space. The new basis vectors are called 
Eigenvectors and the entries on a diagonal version of H are called Eigenvalues. This 
Eigenvector basis, the shape of a graph of a quadratic term becomes obvious. Directions 
along Eigenvectors with negative Eigenvalues have a downward curvature and those with 
positive Eigenvalues have an upward curvature (499). It is important to remember that 
eigenvectors are located in a configuration space and therefore each eigenvector represents a 
particular perturbation of a response surface. 
 
7.1.3. Mathematical Modeling 
According to Costa and Lobo (466) drug release models with major applicability and which 
can best describe drug release phenomena must be used to define drug release mechanism. 
This helps to analyze and explain mathematically the processes that occur when a drug is 
released from a dosage form. In this study, several mathematical models were used to 
elucidate the mechanism of release from the batches of microcapsules that were 
manufactured ‘in-house’.   
 
7.2. METHODS   
7.2.1. Model Fitting 
7.2.1.1. Canonical analysis 
The stationary point of the fitted response surfaces were computed using an Online Matrix 
Calculator (Blue Bit) powered by the Net matrix Library (500). The characterization of the 
response surfaces was performed on the Y4 polynomial equation to transform the fitted model 
to a new coordinate system with the origin at x0. The polynomial equation generated using 
RSM in Chapter 6 (§ 6.3) is shown in Equation 7.2.  
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Y4 =  -42.49 – 57.04X1 +141.90 X2 +420.90 X3 +43.74 X4 – 30.00X1X2 - 96.00 X1X3 -6.62 X1X4  - 
140.00 X2X3 +20.00 X2X4 -74.00 X3X4 + 34.15 X1
2
-47.90 X2
2
- 35.90 X3
2 
-4.85 X4
2
 
 
        Equation 7.2 
The fitted model showing the response for Y4 written in matrix language is shown in 
Equation 7.3. 
 
                                                     Ŷ = bo + x’b + x’Bx                                          Equation 7.3 
 
where  
bo = the constant term,  
x =the vector of the experimental variables, x’ (x1, x2, x3, x4)  
x’ = the vector transpose 
b = the vector of the linear coefficients, b’ (b1,b2, b3, b4) 
B = the Hessian matrix 
 
Eigenvalues derived from the symmetrical matrix, B are represented by λ1, λ2, λ3 and λ4, and 
m1, m2, m3 and m4 are the corresponding Eigenvectors. All Eigenvalues and Eigenvectors 
satisfy the mathematical expression shown in Equation 7.3 and these are related concepts in 
the field of mathematics known as linear algebra (501).  
 
                                                                    B mi = mi λi,                                     Equation 7.4. 
 
where i = 1, 2, 3, and 4 indicate the number of factors in a model. 
 
Since B is a symmetric and real matrix, all Eigenvalues are real. These Eigenvalues are the 
coefficients of the canonical model. Eigen value problems are among the most important 
challenges in connection with matrix analyses. An Eigen value of a square matrix is a scalar 
quantity that is usually represented by the Greek letter λ, and an Eigenvector is a non-zero 
vector and therefore cannot be a zero vector.  
 
7.2.1.2. Lagrange’s Criterion 
In this study, Lagrange’s criterion was used (502,503) was to determine the critical point of 
the second order equation based on the calculation of the Hessian determination of the 
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response, Y4. The Hessian determinant of a matrix is represented by delta, ∆. Since there are 
four variables in this study, the four expressions for a 4 X 4 matrix are represented by ΔI, Δ, Δ  and Δ , respectively (504). The mathematical representations of ΔI, Δ, Δ  and Δare shown in Equations 7.5 - 7.8. ΔI = 
MNO 
 
Δ = P

MNO
     
MNON

MN
NO   
MN

 Q 
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Where,               ΔI  JZ[0/\1 7.5              Δ  JZ[0/\1 7.6              Δ  JZ[0/\1 7.7              Δ  JZ[0/\1 7.8 
 
 
7.2.1.3. Mathematical Modeling  
The fitting of dissolution data of all formulations, CPT-001 - CPT-030 was performed using 
GraphPad Prism Software Version 4.0 (GraphPad Prism Software, San Diego, CA, USA). 
The software is used to estimate the parameters of a nonlinear function that provide the 
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closest fit between experimental observations and the non-linear function. The mathematical 
equations for the models used to describe the dissolution curves for CPT formulations are 
summarized in Table 7.1. The data that was fitted was generated in Chpater 6 using USP 
Apparatus 3 (§6.2.2.7) The best-fit solution was identified by evaluating the coefficient of 
determination (R2), and sum of squares of residuals (SSR) where the highest R2 value and 
smallest SSR values indicate the best fit (505-510).  
 
In order to investigate the mechanism of drug release from microcapsules, the drug release 
data were analysed using several mathematical expressions (511). Table 7.1 shows the 
equations used to determine the appropriate models used to study the release. 
 
Table 7.1. Mathematical representation of the models used to fit CPT release from microcapsules 
Model Equation References 
Zero-order Qt = Qo + Kot (512, 513) 
First-order Ln Qt = Ln Qo – K1t (514, 515) 
Higuchi Qt = Qo + KHt1/2 (516, 517) 
Makoid–Banakar Qt = KMB tne(−ct) (518) 
Kopcha Qt = At1/2 + Bt (519) 
Korsmeyer–Peppas Qt = KKP tn (520-522) 
 
 
Page | 181 
 
7.3. RESULTS AND DISCUSSION 
7.3.1. Canonical analysis 
Canonical analysis of the response surface and equations makes it possible to deduce information about the surface plots without need for 
graphical representation. In matrix terms an equation is represented by Equation 7.3; 
 
Ŷ = bo + x’b + x’Bx 
 
In matrix form the expression is then shown in Equation 7.9. 
 
Ŷ= -42.49 + (bI,b, b,b) P –  57.04 141.90 420.90    43.74 Q + (bI,b, b, b) P
34.15  h15   h48     h3.32h15h48  h47.90h70 h70            10 – 35.90     h37h3.32   10 h0.109  h4.85Q i 
bIbbbj 
 
Ŷ = Equation 7.9 
 
 
The Eigen values of B and the corresponding orthogonal Eigenvectors are: 
 kI  = -127.68 k = 70.00 k = 27.91 k = -24.74 
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Eigenvectors  
 
               lI  m h0.27h0.64h0.70h0.16n                            l  m 
 h0.66 h0.31    0.61 h0.31n                                      l  m 
 h0.69  0.45 h0.26   0.51 n                                                 l  m 
  0.12h0.54  0.27  0.79 n  
 
M in matrix form will be represented by lI, l, l    and l. 
 
M   ih0.27  h0.66     h0.69       0.12h0.64h0.70   h0.31   0.61       0.45          0.54  h0.26          0.27h0.16   h0.31      0.51          0.79j 
Λ is a diagonal matrix and is represented by kI, k, k and k. 
 
Λ    ihopq. rs     0.000   0.000    0.0000.0000.000  qt. tt   0.000    0.000    0.000  pq. uo  0.0000.000    0.000    0.000   hpv. qvj 
 
and  
Θ = M’b 
where M’, is the inverse of M. 
BM = M Λ 
Where Λ, is a diagonal matrix and  
M’ = M-1  
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which gives                                              M’BM = Λ 
 
Now by making use of the fact that          MM’ = I,  
Equation 7.3 which is given by 
                                                           Ŷ = bo + x’b + x’Bx                                  Equation 7.3 
 
 
can be represented by Equation 7.10 
                      Ŷ = bo + (x’M)(M’b) + (x’M)M’BM(M’x)                                    Equation 7.10 
 If we write  
 X = M’x  
and                                                               Θ = M’b 
or equivalent                                                 x = MX  
and                                                                b = MΘ   
 
This can be rewritten as Equation 7.11. 
                                                          Ŷ = bo + X’Θ + X’ΛX                                Equation 7.11 
 
Θ = M’b = Ph0.057  h1.542   h0.260      1.152h0.559 – 0.838  h0.7351.080  0.817       0.308  h0.569    h0.4170.310  h1.298   0.636         1.889 Q P 
–  57.04 141.90 420.90    43.74 Q   
 
Θ  m  h274.60  284.94h56.68  148.45 n  
 
where the coordinates of the stationary point in relation to the rotated axes are such that  
Xis = 
:wpxy 
 
X1s = 0.43 
X2s = 2.04 
X3s = 1.02 
X4s = 3.00 
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The canonical form is therefore represented by Equation 7.12 
 
Y4 = -42.49 -274.60 X1 + 284.94 X2 – 56.68 X3 + 148.45 X4 
+127.68 X12 + 70.00 X22 +27.91 X32 -24.74X42 
                                                                                                                              Equation 7.12 
where  
X1 = -0.057 bI -0.559 b – 0.838 b + 0.310 b 
X2 = -1.542 bI – 0.735 b + 1.080 b -1.298 b 
X3 = -0.260 bI + 0.817 b – 0.569 b + 0.636 b 
X4 = -0.310 bI – 1.298 b + 0.636 b + 1.889 b  
 
The important considerations in this canonical form are: 
 
i) The sign(s) and relative magnitude(s) of the Eigen values 
ii) The magnitude of the coordinates Xis  of the stationary point 
iii) The nature of the transformation X = M’x 
 
The negative and positive signs associated with the Eigenvalues indicate that the fitted 
response value i.e. 84% at the centre of the fitted surface is located at a saddle point. The 
coefficients of the Eigenvector associated with the smallest Eigenvalue are 0.12, -0.54, 0.27 
and 0.79, suggesting that for the x4 direction, which is the direction of the greatest elongation 
of the response surface, the homogenizing speed and other factors all have the same effect. 
Upon ‘trading of’ various response variables and comprehensive evaluation of feasibility 
search and exhaustive grid search, the formulation composition with polymer concentration 
of Eudragit® RS  (0.43 g), Methocel®  K100M (2.04 g), Methocel®  K15M (1.05 g) and 
Homogenizing speed of 3000 rpm was found to fulfil the maximum requirement of an 
optimized formulation because of optimized % released. The optimized batch was prepared 
accordingly and dissolution and SEM analysis were carried out using USP Apparatus 3 as 
shown in Table 6.8 in § 6.2.2.7.  
 
The A canonical form can thus be represented by Equation 7.13.  
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Ŷ = -42.49 + 60.836  X1+ 48.867X2 + 124.919X3 + 18.491X4 + 140.02X12 - 
48.28X22+ 24.83X32 +6.23X42                                                                 Equation 7.13 
where, 
  X1 = 0.392x1 + 0.330 x2 +  0.845x3 h0.153x4 
X2 = 0.593x1 + 0.438x2 h0.523x3 h0.427x4 
X3 = 0.663x1 – 0.731x2 z 0.007x3 z 0.162x4 
X4 = 0.235x1 + 0.406x2 h0.109x3 z 0.876x4 
For the response, Y4, the Eigen values that are the coefficients of the quadratic terms, X12, 
X22, X32 and X42 have different signs and therefore mean that the stationary point is also a 
saddle point. 
 
7.3.2. Lagrange’s Criterion 
These matrices are used to solve large-scale optimization problems with Newton-type 
methods since they are the coefficient of the quadratic term of a local Taylor expansion of a 
function (523).  The Lagrange criterion was used to solve a formulation problem. A saddle 
point can be recognized by a contour that appears to intersect itself. 
 
The application of Lagrange's criteria to the models helped locate the critical point of the 
second order equation and was based on the Hessian determinant of Y4. 
   ΔI = 69.00        Δ = -7510.20           Δ = -736674.84              Δ = 99513387.45 
 
Information about the geometric nature of the response surface was derived from the signs of 
the Hessian determinants. These indicate that a saddle point exists in the response surfaces 
showing the percent drug release versus time and formulation variable. 
 
Both Lagrange and Canonical analysis have been used in the study. The saddle point 
indicates that one has to reliably analyze data because this is a dynamic system. This means 
that the formulation problem does not depend on a single variable performance over the 
design space.   
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7.3.3. Mathematical Modeling 
Drug release rate is a fundamental parameter of any pharmaceutical dosage form.  
Quantitative analysis of the values generated in dissolution testing is easier when 
mathematical formulae are used to express the resultant dissolution data as a function of some 
of the characteristics of a dosage form. The dissolution of drugs from dosage forms has been 
described by kinetic models in which the amount of dissolved drug (M) is monitored as a 
function of time (t) and can be simplified as M = f (t).  
 
The curvilinear nature of the cumulative percentage drug released versus time plots suggest 
that drug release from the microcapsules does not follow zero-order kinetics.  The data are 
summarized in Table 7.2. This observation is supported by the low correlation coefficients 
obtained in all cases where the dissolution data were fitted to a zero-order model. The in vitro 
dissolution studies confirmed the drug release was governed by Higuchi kinetics and data 
also fitted the Kopcha matrix model adequately. However, the mathematical expression that 
best describes drug release from these microcapsules was fund to be the Makoid–Banakar 
model in which the resultant R2 values were greater than 0.98. The Korsmeyer–Peppas 
release exponent, n, is approximately 0.3, confirming that diffusion is a controlling factor for 
drug release. This finding was supported by evaluation of the ratios of the exponents A/B 
derived from the Kopcha model which were greater than 1 in all cases. The Kopcha model 
can also be used to quantify the relative contributions of diffusion and polymer relaxation to 
drug release.  The data in Table 7.2 clearly show that the value of A is far greater than that for 
B, suggesting that drug release from the microcapsules is primarily controlled by a   Fickian 
diffusion process.  
 
The results of curve-fitting studies reveal as noted, that CPT release from the microcapsules 
could be described by the Makoid-Banakar, Korsmeyer-Peppas, Kopcha and Higuchi models. 
These coefficients of determination (R2) were higher than 0.900 for all analyses and the 
corresponding SSR values were lower than for the other models used. The formulations with 
low levels of rate-controlling polymers exhibited a higher burst release which can be ascribed 
to the dissolution of the CPT from the surface of the microcapsules.  Furthermore the balance 
that exists between swelling and the gelling characteristics of the microcapsules is vital to 
ensure and maintain the desired release rates for CPT.  
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Table7.2. Results of model fitting of release profiles 
MODEL         FORMULATION 
 CPT-001 CPT-002 CPT-003 CPT-004 CPT-005 CPT-006 CPT-007 CPT-008 CPT-009 CPT-010 
Zero-order           
R2 0.179 0.254 0.174 0.221 0.274 0.465 0.023 0.389 0.533 0.380 
k0 7.047 4.606 5.683 7.843 9.560 9.733 5.976 9.806 9.404 9.240 
SSR 6844 4198 6027 8801 11422 9190 5968 10387 7640 9238 
First -order           
R2 0.612 0.486 0.507 0.612 0.636 0.695 0.540 0.672 0.723 0.692 
k1 28.10 20.63 24.99 29.94 37.03 35.18 25.40 36.53 32.92 34.10 
SSR 3238 1720 2526 4389 5718 5226 2678 5562 4531 4583 
Higuchi           
R2 0.852 0.673 0.717 0.767 0.895 0.954 0.785 0.934 0.968 0.914 
kH 21.34 14.20 17.48 23.59 28.86 29.08 18.29 29.42 27.97 27.68 
SSR 1232 1093 1448 2626 1638 778.7 1249 1122 515.5 1280 
Makoid-Banakar           
R2 0.983 0.991 0.996 0.875 0.994 0.998 0.993 0.997 0.996 0.982 
kMB 33.43 26.56 31.62 36.57 42.88 38.54 31.08 40.98 35.44 39.08 
n 0.263 0.165 0.184 0.266 0.291 0.352 0.219 0.326 0.376 0.317 
c <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SSR 136.4 28.47 19.91 1410 93.39 33.48 39.88 41.28 51.90 256.7 
Kopcha           
R2 0.852 0.673 0.717 0.767 0.895 0.954 0.785 0.934 0.968 0.914 
A 21.34 14.20 17.48 23.59 28.86 29.16 18.29 29.42 27.97 27.68 
B <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SSR 1232 1093 1448 2626 1638 779.3 1249 1122 515.5 1280 
Korsmeyer-Peppas           
R2 0.980 0.991 0.996 0.955 0.991 0.998 0.993 0.999 0.998 0.994 
KKP 33.85 26.61 31.66 44.49 43.94 39.45 31.07 42.33 37.06 42.83 
n 0.252 0.165 0.184 0.0173 0.263 0.327 0.219 0.281 0.325 0.222 
SSR 130.6 28.45 19.90 228.7 60.25 9.489 39.88 6.021 8.193 44.95 
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Table7.2. Continued. 
MODEL         FORMULATION 
 CPT-011 CPT-012 CPT-013 CPT-014 CPT-015 CPT-016 CPT-017 CPT-018 CPT-019 CPT-020 
Zero-order           
R2 0.327 0.096 0.166 0.423 0.086 0.637 0.404 0.595 0.369 0.301 
k0 10.26 6.801 6.429 9.338 6.803 8.570 10.88 9.072 9.909 9.092 
SSR 12382 6852 5750 8934 7029 5199 13102 6423 10858 9896 
First -order           
R2 0.647 0.595 0.610 0.693 0.571 0.754 0.632 0.733 0.667 0.660 
k1 39.14 27.71 25.72 34.17 28.08 28.46 40.85 30.80 37.19 34.68 
SSR 6479 3065 2685 4759 3295 3526 8086 4232 5728 4805 
Higuchi           
R2 0.915 0.829 0.855 0.934 0.829 0.985 0.934 0.977 0.929 0.891 
kH 30.89 20.68 19.49 27.93 20.72 25.30 32.69 26.87 29.76 27.35 
SSR 1561 1296 996.8 1011 1309 208.2 1437 362.2 1224 1532 
Makoid-Banakar           
R2 0.995 0.994 0.992 0.989 0.992 0.995 0.995 0.992 0.998 0.984 
kMB 44.54 33.67 30.72 38.33 33.61 29.30 41.35 32.15 41.99 40.55 
n 0.308 0.241 0.260 0.334 0.244 0.424 0.521 0.406 0.319 0.292 
c <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SSR 81.90 41.11 50.78 159.9 55.55 69.42 108.5 117.6 32.00 226.9 
Kopcha           
R2 0.915 0.829 0.855 0.934 0.829 0.985 0.931 0.977 0.929 0.891 
A 30.89 20.68 19.49 27.93 20.72 25.30 33.48 26.87 29.84 27.35 
B <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SSR 1561 1296 996.8 1011 1309 208.2 1498 362.2 1224 1532 
Korsmeyer-Peppas           
R2 0.996 0.994 0.992 0.992 0.992 0.995 0.998 0.989 0.998 0.989 
KKP 45.27 33.75 30.72 40.59 33.60 30.54 41.37 33.29 43.37 43.45 
n 0.275 0.241 0.260 0.269 0.244 0.380 0.398 0.368 0.272 0.213 
SSR 28.06 41.05 50.78 58.96 55.55 32.92 13.93 78.02 8.300 85.20 
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MODEL         FORMULATION 
 CPT-011 CPT-012 CPT-013 CPT-014 CPT-015 CPT-016 CPT-017 CPT-018 CPT-019 CPT-020 
Zero-order           
R2 0.058 0.428 0.292 0.215 0.316 0.383 0.1856 0.239 0.319 0.303 
k0 5.513 8.585 10.14 9.850 8.449 7.576 4.994 6.570 6.669 6.765 
SSR 4722 7465 12519 12955 8744 9094 4003 5555 7234 5474 
First -order           
R2 0.566 0.705 0.647 0.613 0.617 0.558 0.564 0.634 0.557 0.658 
k1 22.91 31.15 38.97 39.03 32.64 31.68 20.83 25.69 28.09 25.83 
SSR 2177 3849 6240 6393 4901 4178 1776 2669 3195 2686 
Higuchi           
R2 0.818 0.935 0.903 0.881 0.910 0.815 0.796 0.881 0.794 0.897 
kH 16.81 25.67 30.58 29.84 0.758 0.937 0.647 0.661 0.864 0.636 
SSR 909.2 839.2 1703 1953 1140 1741 830.0 865.5 1479 802.2 
Makoid-Banakar           
R2 0.993 0.990 0.997 0.998 0.993 0.997 0.990 0.993 0.997 0.989 
kMB 27.62 35.03 45.10 45.39 35.04 38.05 25.58 30.15 34.45 29.96 
n 0.237 0.336 0.295 0.287 0.432 0.251 0.225 0.279 0.221 0.296 
c <0.001 <0.001 <0.001 <0.001 0.024 0.004 <0.001 <0.001 <0.001 <0.001 
SSR 33.65 119.1 51.63 28.21 83.42 21.41 38.63 48.70 17.58 85.54 
Kopcha           
R2 0.818 0.935 0.903 0.881 0.910 0.815 0.796 0.881 0.794 0.897 
A 16.81 25.67 30.70 29.98 25.61 23.13 15.24 19.85 20.38 20.36 
B <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SSR 909.2 839.2 1705 1955 1142 1741 830.0 865.5 1479 802.2 
Korsmeyer-Peppas           
R2 0.993 0.997 0.998 0.998 0.992 0.998 0.990 0.993 0.997 0.989 
KKP 27.63 37.57 45.67 45.14 34.89 38.00 25.62 30.22 34.50 30.07 
n 0.237 0.270 0.291 0.294 0.353 0.240 0.225 0.278 0.221 0.295 
SSR 33.65 15.36 11.51 12.01 57.16 15.06 38.62 48.62 17.57 85.39 
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The mean (n=3) dissolution profiles for CPT formulations, CPT-001 – CPT-030 are shown in 
Appendix One. CPT release was rapid except for formulations CPT-010 to CPT-020 where 
complete release was observed at 12 hours.  
 
The commonly used Makoid-Banakar, Korsmeyer-Peppas and Kopcha models are simple and 
robust kinetic models that adequately describe the release of CPT from the microcapsules. 
The Makoid-Banakar model fitted the presented data (Table 7.2) better than the other models 
tested when based on SSR and R2 values. When the parameter, c of the Makoid–Banakar 
model is equal to zero, the model is reduced to become Korsmeyer–Peppas power law           
(e-0t = 1).  The results are in agreement with what has been observed by Costa and Lobo (511) 
and Khamanga et al (442). 
 
The most important aspect to consider when developing new pharmaceutical products or 
evaluating drug release mechanisms is the suitability and predictive ability and accuracy of 
any model chosen to describe the release process. The presence of a highly water-soluble 
drug in an HPMC matrix can generate an osmotic gradient which may result in a greater rate 
of polymer swelling and increase in gel thickness with a corresponding initial increase 
followed by a drastic decrease in the rate of drug release (65).  
 
The canonical results reveal that the sign(s) of the Eigenvalues are both negative and positive 
suggesting that the stationary point is a saddle point. The Lagrange criteria data confirm that 
the stationary point is a saddle point as the signs of the Hessian determinants were also 
mixed. 
 
It should be noted that the value of R2 alone, is not an exact measure of a model’s accuracy, 
but is a measure of the reduction in the variability of a response generated by use of 
additional variables in a model. However a large value for R2 does not necessarily imply that 
the regression model used is a good model. The addition of another variable to a model in this 
study, as shown in Table 7.2 increased the value for R2, irrespective of whether the additional 
variable is statistically significant. The variables are n and c as shown in the Makoid-Banakar 
model. 
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7.4. CONCLUSIONS 
Drug delivery systems manufactured using matrix polymers have been assessed and the 
release mechanisms were found to be affected by factors such as the degree of polymer 
swelling. The selection of an appropriate model for the analysis of drug release provided 
insight to the underlying mass transport mechanism of release from the delivery technologies. 
The value of the release exponent, n, was < 0.45 indicating that CPT release was not 
controlled only by diffusion. Fitting of data to the Kopcha model supported the evidence   
that CPT release involved a combination of a diffusion-controlled and a chain relaxation/ 
swelling mechanism for most formulations.  
  
What has emerged from this investigation is that considerable attention must be  focused on 
understanding mathematical models as these provide useful guidance and insight into drug 
release and transport mechanisms from sustained- release technologies. Canonical and 
Lagrange methods make it possible to determine the equations and the roles played by 
experimental variables in drug release studies. In this case the results have considered the 
shape of the stationary point of the surface plots. Information relating to the geometric nature 
of the response surfaces was derived from the sign and magnitudes of the quadratic 
coefficients in the polynomial functions.  
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CHAPTER 8 
CONCLUSIONS  
 
ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal 
disease. They alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic 
properties of AII and the vasodilatory and natriuretic properties of bradykinin and alter the 
metabolism of a number of other vasoactive substances. CPT has a relatively short 
elimination half-life in plasma and is a drug of choice in antihypertensive therapy due to its 
effectiveness and low toxicity. It is usually prescribed to patients who are chronically ill and 
require long-term use for its therapeutic benefits. Development of a once daily CPT oral 
formulation would be a significant advantage for patient compliance, accompanied by 
minimization of drug side effects as a result of reduction of drug blood concentration 
fluctuations in long term therapy. 
 
Impurities in API are highly undesirable and in some cases can prove to be harmful to the 
patient. The ICH Q7 is a guidance for API manufacturers, and it is mentioned in the guidance 
that impurities be maintained below set limits. Thus it was pertinent to characterize the API 
in order to develop a suitable dosage form knowing full well that it had no impurities. A 
comprehensive study was undertaken using NMR spectroscopy. The 1H, 13C NMR,       
DEPT-135, COSY, HMBC and HSQC experiments were carried out at precessional 
frequencies of 400 MHz and in CDCl3 at 25 °C temperature on a Varian- 400 FT NMR 
spectrometer to confirm the structure of CPT. 
 
CPT is characterized by lack of a strong chromophore, and therefore is not able to absorb at 
the more useful UV-Vis region of the spectrum. One of the difficulties of determining CPT 
by UV-HPLC in dosage form is the use of a derivatizing procedure. Using ICH guidelines an 
HPLC-ECD method was developed and validated. The method was successfully applied for 
the determination of CPT in commercial and developed formulations. The method was found 
to be linear over the concentration range 2.0-60.0 µg/ml. The precision of the method was 
measured at two levels: intra-day and inter-day precision and the % RSD values were less 
than 2%, which were less than the limits set in our laboratory. The method was accurate with 
RSD values less or equal to 2%. The content of CPT in commercial tablets was calculated as 
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an average from five determinations using ECD. Recoveries very close to 100% prove the 
suitability and accuracy of the proposed method.  
 
To certify the quality of pharmaceutical formulation parameters such as interaction between 
the API and excipients to be used in formulation development studies, thermogravimetric and 
spectroscopic analysis were undertaken. The data generated in these studies revealed no 
serious incompatibility between the API and excipients. Based on the results from 
preliminary screening, all excipients except citric acid were selected for formulation 
development. Infrared spectroscopic studies confirmed the possibility of an interaction 
between CPT and citric acid. The DSC data generated for the different binary mixtures 
evaluated indicate that the characteristic endothermic peak of about 105.6 ºC for CPT was 
present in all thermograms. This study demonstrates that DSC and FT-IR techniques can 
reveal potential interactions, whereas TG is not as sensitive to the presence of interactions. 
TG analysis revealed that the thermal degradation of CPT takes place in two major and one 
minor step, and that these occur in different temperature ranges. Each thermal degradation 
stage produced an endothermic peak on the DSC thermogram where the melting transition 
was observed prior to the commencement of decomposition. The theoretical basis of 
DSC/TGA and FT-IR experiments was examined and the overall goal providing practical 
guidelines for compatibility studies of CPT with several excipients was achieved.  
In response to the challenges of formulating a CPT sustained-release dosage form,  
Eudragit®, Methocel® and Avicel® were studied, varying their quantities using RSM. The 
control of CPT release observed in this study indicates that hydrophilic matrix microcapsules 
of CPT manufactured using Eudragit® and Methocel®, can be used as a twice-a-day oral 
sustained release drug delivery system. The polymers, solvents and diluents all play a role in 
the formation of quality microcapsules. Moreover, optimization of microencapsulation 
conditions for CPT using RSM has been demonstrated. Input factors such as Eudragit® (X1), 
Methocel® K100M (X2) and Methocel® K15M (X3) content and homogenizing speed (X4) 
had an effect on the release of CPT from the microcapsules. Optimization was performed 
using a CCD approach to yield microcapsules that released more than 85% CPT in 12 h. The 
polynomial equation generated explained the quadratic and interaction effects of the input 
variables on the ultimate response observed. RSM is an appropriate approach as it allowed 
the estimation of parameters of a quadratic model, and it helped determine model fit. The 
approach presented in this study provides a useful guideline for the optimization of 
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microcapsule manufacture for other water-soluble drugs. The adequacy of the model was 
judged by ANOVA. However, the successful development of these delivery systems required 
careful consideration of a number of factors that influenced the performance of the 
formulations, including the physical and chemical properties of the API and excipients.  
The microcapsules formed were spherical, with a more or less porous membrane. The 
absence of pores in other microcapsules was of major importance to this study in order to 
explain the drug release mechanism, since CPT diffusion occurs through water-filled cavities 
and is much faster than if diffusion were to take place through dense polymer networks. The 
rapid drug release observed during the early stages of testing are some of the challenges 
observed with microcapsules containing a freely water soluble drug such as CPT, are 
manufactured using this method of encapsulation. 
The angle of repose for the CPT microcapsules was measured by the fixed-funnel method and 
ranged between 18-40°. This indicates that some microcapsules had poor flow properties, and 
the results were supported by Carr’s Index and Hausner ratio. The addition of span 80 
lowered the surface tension of the continuous phase and in turn decreased the sizes of 
microcapsules produced. When the stirring speed was increased, more air was entrapped and 
foam was produced. The use of an anti-foaming agent ensured that air bubbles were rapidly 
dissipated.  
 
The technique of microencapsulation by oil-in-oil was used to prepare CPT microcapsules. 
The effects of polymer concentration, homogenizing speed, flow properties, morphology, 
surface properties and release characteristics of the prepared CPT microcapsules were 
examined. To decrease the complexity of the analysis and reduce cost, response surface 
methodology using best polynomial equations was successfully used to quantify the effect of 
the formulation variables and develop an optimized formulation, thereby minimizing the 
number of experimental trials. 
 
There was a burst effect during the first stage of dissolution. SEM results indicated that this 
could be attributed to dissolution of CPT crystals present at the surface or embedded in the 
superficial layer of the matrix. During the preparation of microcapsules, the drug might have 
been trapped near the surface of the microcapsules or might have diffused quickly through 
the porous surface. The release data generated from the in vitro release studies were fitted to 
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various kinetic models such as Zero order, First order, Higuchi, Korsmeyer-Peppas, Kopcha 
and Makoid-Banakar. The release kinetics of CPT from most formulations followed classical 
Fickian diffusion mechanism. SEM photographs showed that diffusion took place through 
pores at the surface of the microcapsules. The Kopcha model diffusion and erosion terms 
showed predominance of diffusion relative to swelling or erosion throughout the entire test 
period. Drug release mechanism was also confirmed by Makoid-Banakar and Korsmeyer-
Peppas models exponents. This further supports diffusion release mechanism in most 
formulations. The models postulate that the total of drug release is a summation of several 
mechanisms: burst release, relaxation induced controlled-release and diffusional release. 
These results suggest the potential application of Eudragit® / Methocel® microcapsules as 
suitable sustained-release drug delivery system for CPT.  
 
Inspection of the 2D contour and 3D response surfaces allowed the determination of the 
geometrical nature of the surfaces and further provided results with regard to the interaction 
of the different variables used in CCD. The wide variation indicated that the factor 
combinations resulted in different drug release rates. Lagrange, canonical and mathematical 
modelling were used to determine the nature of the stationery point of the models. This 
represented the optimal variables or stationary points, which is the region of maximal 
response, by consecutively fitting the model in the experimental space. It is difficult to 
understand the shape of a fitted response by mere inspection of the algebraic polynomial 
when there are many independent variables in the model. Canonical and Lagrange analyses 
facilitated the interpretation of the surface plots after a mathematical transformation of the 
original variables into new variables.  
 
In conclusion, the results show that pre-formulation studies, RSM including mathematical 
modeling, play a vital part in product development and formulation. High degree of prognosis 
obtained for CCD, Lagrange and Canonical analysis corroborates the finding that RSM and 
mathematical modelling are efficient tools in experimental design. Modeling and 
optimization was used to increase the efficiency of the formulation process used in this study 
and to determine the optimum formulation.   
 
Beyond the present work performed with a water soluble drug, this process should be well 
adapted to other water soluble drugs. Future studies will focus on stability studies on the 
optimized formulation as per ICH guidelines. 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-001                                                 (end) 15:00 
Microencapsulation Date 16-August-2009   
    
Material Amount added Production Model 
CPT 0.75g Top load 
balance 
Mettler® Toledo 
Eudragit® RS 2 .00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 22.3 ˚C 
Acetone 20 ml Humidity 66.0 % RH 
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• Smooth, free-flowing spherical microcapsules of different sizes. 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-002                                                 (end) 15:00 
Microencapsulation Date 16-August-2009   
    
 
Material Amount added Production Model 
CPT 0.75g Top load balance Mettler® Toledo 
Eudragit® RS 2 .00 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 22.6 ˚C 
Acetone 20 ml Humidity 68.0 % RH 
 
Dissolution                                   SEM
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• Smooth, spherical, free-flowing microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-003                                                 (end) 15:00 
Microencapsulation Date 11-August-2009   
    
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 24.8 ˚C 
Acetone 20 ml Humidity 67.0 % RH 
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• Spherical, smooth microcapsules which adhere to one another 
 
 
 
 
Page | 253 
 
RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-004                                                 (end) 15:00 
Microencapsulation Date 11-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 23.5 ˚C 
Acetone 20 ml Humidity 68.0 % RH 
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• Surface of microcapsule is smooth but they adhere to one another forming a ‘diploid’ 
 
 
 
 
Page | 254 
 
RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 06:00 
Batch ID CPT-005                                                 (end) 15:00 
Microencapsulation Date 10-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 21.8 ˚C 
Acetone 20 ml Humidity 547 % RH 
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• Small, spherical particles about to form microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-006                                                 (end) 16:00 
Microencapsulation Date 10-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 25.6 ˚C 
Acetone 20 ml Humidity 59.0 % RH 
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• Rough, spherical microcapsule with indentation and deformities 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-007                                                 (end) 15:00 
Microencapsulation Date 9-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.75 g Analysis Model 
Methocel® K15M 0.75 g  SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 25.4 ˚C 
Acetone 20 ml Humidity 65.0 % RH 
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• Spherical microcapsules which adhere to one another and there are white, small particles at the surface  
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 09:00 
Batch ID CPT-008                                                 (end) 17:00 
Microencapsulation Date 9-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.5 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 26.6 ˚C 
Acetone 20 ml Humidity 66.0 % RH 
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• Irregular- shaped particles which looks damp and ‘dough-like’ 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 06:00 
Batch ID CPT-009                                                 (end) 14:00 
Microencapsulation Date 11-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.5 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.2 ˚C 
Acetone 20 ml Humidity 56.0 % RH 
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• Rough, spherical, free-flowing microcapsule and free from coalescence 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-010                                                 (end) 15:00 
Microencapsulation Date 11-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 20.6 ˚C 
Acetone 20 ml Humidity 57.7 % RH 
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0 2 4 6 8 10 12 14
0
20
40
60
80
100
Time (h)
Cu
m
u
la
tiv
e
 
%
 
Dr
u
g 
Re
le
a
se
d
                                  
• Spherical, free-flowing, smooth microcapsule and free from coalescence 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
 
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-011                                                 (end) 16:00 
Microencapsulation Date 08-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 21.5 ˚C 
Acetone 20 ml Humidity 57.7 % RH 
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• Spherical, free-flowing, smooth microcapsule and free from coalescence 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 09:00 
Batch ID CPT-012                                                 (end) 17:00 
Microencapsulation Date 08-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 22.0 ˚C 
Acetone 20 ml Humidity 59.0 % RH 
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• Spherical, free-flowing, smooth microcapsule and free from coalescence 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 06:00 
Batch ID CPT-013                                                 (end) 14:00 
Microencapsulation Date 07-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.25 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 21.5 ˚C 
Acetone 20 ml Humidity 58.0 % RH 
 
Dissolution                                    SEM 
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• Spherical, free-flowing, smooth microcapsule and free from coalescence 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-014                                                 (end) 15:00 
Microencapsulation Date 07-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.25 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 22.5 ˚C 
Acetone 20 ml Humidity 56.8 % RH 
 
Dissolution                                    SEM 
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• Irregular-shaped particles which formed aggregates and drug particles seen at the surface 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-015                                                 (end) 16:00 
Microencapsulation Date 05-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 26.3 ˚C 
Acetone 20 ml Humidity 68.0 % RH 
 
Dissolution                                    SEM 
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• Spherical microcapsule, free-flowing and free from coalescence except for tiny spherical particles 
attaching to the surface 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-016                                                 (end) 17:00 
Microencapsulation Date 05-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.75 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 25.4 ˚C 
Acetone 20 ml Humidity 67.5 % RH 
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• Irregular-shaped microcapsule, not free-flowing 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-017                                                 (end) 15:00 
Microencapsulation Date 04-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.50 g Homogenizer Virtis® 
Methocel® K100M 0.75 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.4 ˚C 
Acetone 20 ml Humidity 52.6 % RH 
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• Spherical, free-flowing microcapsule with small attachments at the surface 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-018                                                 (end) 17:00 
Microencapsulation Date 04-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.25 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.5 ˚C 
Acetone 20 ml Humidity 54.6 % RH 
 
Dissolution                                    SEM
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• Surface of microcapsule irregular but smooth 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-019                                                 (end) 15:00 
Microencapsulation Date 01-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.5 ˚C 
Acetone 20 ml Humidity 53.5 % RH 
 
Dissolution                                    SEM
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• Particles have collapsed surface and are irregular in shape 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-020                                                 (end) 15:00 
Microencapsulation Date 01-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.3 ˚C 
Acetone 20 ml Humidity 54.9 % RH 
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• Spherical, free-flowing microcapsules that were coarse on the surface  
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-021                                                 (end) 15:00 
Microencapsulation Date 02-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.75 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 19.4 ˚C 
Acetone 20 ml Humidity 48.0 % RH 
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• Spherical, free-flowing microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 10:00 
Batch ID CPT-022                                                 (end) 20:00 
Microencapsulation Date 02-August-2009   
    
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 19.3 ˚C 
Acetone 20 ml Humidity 46.0 % RH 
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• ‘Grape-like’ structures, which appear as tiny particles that have formed aggregates 
 
 
 
 
Page | 272 
 
RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-023                                                 (end) 16:00 
Microencapsulation Date 04-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 26.7 ˚C 
Acetone 20 ml Humidity 66.0 % RH 
 
Dissolution                                    SEM
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• Spherical, free-flowing microcapsule 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size  5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-024                                                 (end) 15:00 
Microencapsulation Date 04-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 26.3 ˚C 
Acetone 20 ml Humidity 68.0 % RH 
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• Spherical microcapsule, with depression on the surface 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size  5 g 
Product         Captopril Microencapsulation Time   (start) 08:00 
Batch ID CPT-025                                                 (end) 17:00 
Microencapsulation Date 15-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.25 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 18.8 ˚C 
Acetone 20 ml Humidity 56.0 % RH 
Dissolution                                    SEM
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• Microcapsules appear as roughly spherical with particles protruding from the surface  
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 10:00 
Batch ID CPT-026                                                 (end) 18:00 
Microencapsulation Date 15-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.50 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 19.5 ˚C 
Acetone 20 ml Humidity 58.0 % RH 
 
Dissolution                                    SEM
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• Spherical microcapsule which still has some particles adhering strongly to the surface  
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size  5 g 
Product         Captopril Microencapsulation Time   (start) 11:00 
Batch ID CPT-027                                                 (end) 20:00 
Microencapsulation Date 17-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.25 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 24.7 ˚C 
Acetone 20 ml Humidity 64.0 % RH 
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• Smooth, free-flowing spherical microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 12:00 
Batch ID CPT-028                                                 (end) 22:00 
Microencapsulation Date 16-August-2009   
   
 
 
Material Amount added Production Model 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 1.50 g Homogenizer Virtis® 
Methocel® K100M 0.25 g Analysis Model 
Methocel® K15M 0.50 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 23.3 ˚C 
Acetone 20 ml Humidity 64.0 % RH 
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• Smooth free-flowing spherical microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 07:00 
Batch ID CPT-029                                                 (end) 15:00 
Microencapsulation Date 16-August-2009   
   
 
 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 22.7 ˚C 
Acetone 20 ml Humidity 61.0 % RH 
 
Dissolution                                    SEM
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• Smooth, free-flowing spherical microcapsules 
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RHODES UNIVERSITY 
 FACULTY OF PHARMACY, GRAHAMSTOWN, SOUTH AFRICA 
BATCH SUMMARY  
Formulator Sandile  Khamanga Batch Size 5 g 
Product         Captopril Microencapsulation Time   (start) 10:00 
Batch ID CPT-030                                                 (end) 19:00 
Microencapsulation Date 16-August-2009   
   
 
 
CPT 0.75 g Top load balance Mettler® Toledo 
Eudragit® RS 2.00 g Homogenizer Virtis® 
Methocel® K100M 0.50 g Analysis Model 
Methocel® K15M 0.75 g SEM  Tescan, VEGA LMU 
Avicel® 102 0.50 g Dissolution VanKel® Bio-Dis® dissolution tester 
Liquid paraffin 120 ml Temperature 26.3 ˚C 
Acetone 20 ml Humidity 60.0 % RH 
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• Smooth, spherical microcapsules with tiny particles adhering to the surface 
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APPENDIX TWO 
BATCH PRODUCTION RECORDS FOR CPT-001 
 
Only one solvent evaporation record is included for this study. The records for the other batches, 
CPT-002 – CPT-030 are available on request. 
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RHODES UNIVERSITY, FACULTY OF PHARMACY,  
GRAHAMSTOWN, SOUTH AFRICA 
BATCH PRODUCTION RECORD 
Product name Captopril   
Batch         CPT-001   
Batch Size 5 g   
 
 
MANUFACTURING APPROVALS 
 
Batch record issued by  Date : 
Master record issued by  Date : 
 
 
RHODES UNIVERSITY, FACULTY OF PHARMACY,  
GRAHAMSTOWN, SOUTH AFRICA 
BATCH PRODUCTION RECORD 
 
Product name Captopril   
Batch         CPT-001 
Batch Size 5 g 
 
MASTER FORMULA AND BATCH FORMULA 
Component % m/m (v/m) Amount dispensed Dispensed by Checked 
CPT 0.75g    
Eudragit® RS 2 .00 g    
Methocel® K100M 0.50 g    
Methocel® K15M 0.50 g    
Avicel® 102 0.50 g    
Liquid paraffin 120 ml    
Acetone 20 ml    
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RHODES UNIVERSITY, FACULTY OF PHARMACY,  
GRAHAMSTOWN, SOUTH AFRICA 
BATCH PRODUCTION RECORD 
Product name Captopril    
Batch         CPT-001   
Batch Size 5 g   
 
 
EQUIPMENT VERIFICATION 
Description Type Verified By Confirmed By 
Scale Mettler Model PM 6000   
Homogenizer Virtis   
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RHODES UNIVERSITY, FACULTY OF PHARMACY,  
GRAHAMSTOWN, SOUTH AFRICA 
BATCH PRODUCTION RECORD 
 
Product name Captopril   
Batch         CPT-001   
Batch Size 5 g   
 
 
MANUFACTURING DIRECTIONS 
Step Procedure Time Done By Checked By 
1 Screen separately the following materials 
through a 20# mesh screen 
CPT, Eudragit® RS, Methocel® K100M, 
Methocel® K15M, Avicel® 102 
   
2 Place acetone in a 100 ml beaker and liquid 
paraffin in a 400 ml beaker. Add a drop of span 
80 and dimethyl polysiloxane 
   
3 Place the material in (1) in the beaker containg 
acetone and homogenize at 1500 rpm for 5 
minutes 
   
4 Mix the acetone dispersion with the content in 
the 400 ml beaker 
   
5 Agitate with a three blade stirrer to prepare a 
homogenous oily phase 
   
6 After 2 h n-hexane  was added in drops to 
harden the formed microcapsules and stirring 
continued for a further 5 h 
   
7 Collect microcapsules in a Buchner funnel, 
washed 2 -3 times with n-hexane and dried at 
room temperature overnight. Microcapsules 
transferred to airtight container until ready for 
analysis  
   
8 Mean particle size was determined using a series 
of laboratory sieves, microcapsule flowability 
was determined, encapsulation efficiency and 
dissolution studies were conducted 
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RHODES UNIVERSITY, FACULTY OF PHARMACY,  
GRAHAMSTOWN, SOUTH AFRICA 
BATCH PRODUCTION RECORD 
 
Product name Sandile  Khamanga   
Batch         Captopril   
Batch ID CPT-001   
Batch Size 5 g   
 
                             
 
SIGNATURE AND INITIAL REFERENCE 
Full Name (Print) Signature  Initials  Date 
    
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
